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Part I 
General introduction 

Aims and outline of the Thesis 
Chapter 1 
1. INTRODUCTION 
Patients with end-stage liver disease have a poor overall prognosis with a one-year mortality 
of more than 60% without liver transplantation (1-4). A wide variety of techniques has been 
developed to treat end-stage liver failure, but none has proven to be very effective. Except 
for the molecular adsorbent recirculating system (MARS) (5), none of the liver assist 
techniques like exchange transfusion, plasmapheresis, cross circulation, hemodialysis and 
hemoperfusion have been able to improve patient survival significantly (6-16). 
Extracorporeal liver perfusion using hepatocyte filled bioreactors has been reported to 
produce more promising results (17-21 ). However, the use of hepatoma cells or transgenic 
porcine hepatocytes is not without danger and a clinical trial in the Netherlands was stopped 
awaiting more detailed information regarding the transmission risks of transgenic viruses like 
the porcine endogenous retroviruses (PERVs) (18, 22, 23). 
Therefore liver transplantation still represents the only treatment that offers survival 
benefit in children and adults with end-stage liver disease since the first successful human 
orthotopic liver transplantation was performed by Starzl in 1967 (24). In the early days, liver 
transplantation was a rescue therapy for decompensated liver disease and associated with 
high morbidity and mortality. Since then refinements in surgical technique, peroperative 
monitoring and postoperative immunosuppressive regimens resulted in an increased overall 
survival of patients undergoing liver transplantation. There are now many diseases for which 
orthotopic liver transplantation is petformed and the main indications are given in table 1. 
Table 1. Main indications for orthotopic liver transplantation (25, 26). 
Viral hepatitis 
Cholestatic liver diseases (incl. primary biliary sclerosis and sclerosing cholangitis) 
Post alcoholic liver cirrhosis 
Malignancy (hepatocellular carcinoma, solitary endocrine tumours, endothelioma) 
Acute liver failure (Toxic, viral or auto-immune) 
Cryptogenic liver cirrhosis 
Inborn errors of hepatic metabolism 
Congenital biliary disorders 
Hepatic vein thrombosis (Budd-Chiari syndrome) 
In specialised clinics the one-year patient survival is better than 90% and liver 
transplantation has become a semi-elective procedure (25, 27). However, new challenges 
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were brought by the emerging view that orthotopic whole liver transplantation may not be the 
best solution for all transplant patients (28), high expectations regarding functional outcome 
and patient survival and the scarcity of donor organs (29-31 ). This resulted in discussion 
about the use of auxiliary liver grafts in selected patients, the need for optimisation of clinical 
orthotopic liver transplantation and the use of a partial liver graft instead of whole liver grafts 
(32). 
2. CURRENT PROBLEMS IN AUXILIARY LIVER TRANSPLANTATION 
2.1 Auxiliary partial heterotopic liver transplantation (APHL T) 
Orthotopic liver transplantation (OL T) was in the first two decades after the introduction a 
difficult operation with considerable morbidity, mortality and cost. Auxiliary liver 
transplantation was then introduced by Terpstra et al. as a less invasive procedure for 
patients with end-stage chronic liver disease who could not stand a normal orthotopic liver 
transplantation (33-35). Theoretically, auxiliary liver transplantation has several advantages 
over whole liver transplantation. Transplantation of an organ in the heterotopic position 
evades the surgical trauma of removal of the cirrhotic liver, which is a demanding procedure 
in patients with portal hypertension, abundant venous collaterals and severe clotting 
disorders (36, 37). Without an anhepatic phase, the hemodynamic condition of the patients 
is more stable (38, 39) and the native liver can provide some synthetic and clearing function 
during reperfusion of the donor liver (40). Also, a primary dysfunction of the donor liver does 
not necessarily lead to death or emergency re-transplantation as the remnant function of the 
native liver may enable elective re-transplantation. There is however a serious conceptual 
problem in selecting patients with chronic active hepatitis for this procedure. There is a 
substantial risk of development of hepatocellular carcinoma in the native cirrhotic liver, which 
is left in place (34). Therefore auxiliary heterotopic liver transplantation was abandoned in 
patients with a cirrhotic liver. 
Complete resection of the native liver may also not be indicated in acute liver failure. In 
this situation auxiliary liver transplantation may serve as a bridge to recovery with the 
possibility to withdraw immunosuppressive therapy after regeneration of the native liver. 
Finally, auxiliary liver transplantation was proposed for patients with selected inborn errors of 
hepatic metabolism, in whom only one enzyme or cell membrane receptor is absent and 
have otherwise normal function of the liver (41 ). In those patients auxiliary liver 
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transplantation would provide metabolic correction and preserves the possibility of future 
gene therapy in the native liver. Due to complications associated with the heterotopic 
position of the graft (42), auxiliary liver transplantation never gained wide acceptance. This 
was further enhanced by the strongly improving results of orthotopic liver transplantation 
over the years. Despite its theoretical advantages, clinical auxiliary heterotopic liver 
transplantation was performed in selected cases only. 
2.2 Auxiliary partial orthotopic liver transplantation (APOL T) 
In 1990 a new concept of auxiliary liver transplantation was introduced, in which a partial 
liver graft was placed in the orthotopic position after removal of liver segments 2-4 (43). The 
patient, suffering from an HELLP syndrome (hemolysis, elevated liver enzymes, low 
platelets) and probably hepatitis A, showed recovery of her own liver in six months and 
immunosuppression could be tapered off. Since then auxiliary partial orthotopic liver 
transplantation has been performed successfully for acute liver failure and inborn errors of 
metabolism (44-49). Although many of the complications associated with the heterotopic 
position were solved by the new technique, the need for sharing the portal blood flow 
between liver graft and native liver remains controversial. 
3. CURRENT PROBLEMS IN ORTHOTOPIC LIVER TRANSPLANTATION 
In chapter 3 the development of orthotopic liver transplantation is described in more detail. 
Since its introduction the one-year patient survival improved from approximately 30% to 
better than 80%. Although excellent results can be achieved, there are still some subjects 
that need to be elucidated. 
3.1 Primary graft dysfunction 
Despite the use of specially designed preservation solutions, the donor liver does not 
function well after orthotopic liver transplantation in 5-15% of the patients (50, 51). This 
primary graft dysfunction (PGDF) can resolve or deteriorate into primary non-functioning 
(PNF). The condition is associated with increased need for re-transplantation and mortality 
(52, 53). The initial clinical presentation of PGDF includes serum transaminases over 2500 
U/1, severe coagulopathy and lack of bile production in the first days after transplantation. 
The pathogenesis of PGDF is attributed to cold storage of the liver, which activates 
sinusoidal macrophages (Kupffer cells) and induces preservation injury to endothelial cells 
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with progressive loss of viability (54-59). Subsequent reperfusion causes many reactions 
involving nitric oxide, reactive oxygen species, cytokines and eicosanoids (52, 60-62). 
Leukocyte margination and platelet adherence in the damaged sinusoids may lead to poor 
tissue perfusion and oxygen delivery (63-66). Ultimate result of this ischaemia I reperfusion 
damage is mitochondrial derangement with a loss of ATP synthase activity and reduction of 
ATP levels (67-75). 
Recently, an alternative hypothesis for the cause of mitochondrial dysfunction was 
formulated. Direct inhibition of mitochondrial respiration by nitric oxide and oxygen radicals 
was described in several experimental studies (76-83 ). The main product of this reaction is 
peroxynitrite, which is held responsible for damage to numerous biologic targets. To 
optimise the quality of the graft and reduce the incidence of PGDF, the clinical role of nitric 
oxide and peroxynitrite needs to be elucidated in patients with PGDF. 
3.2 Peroperative coagulopathy 
A second problem that has to be solved is the large amount of blood loss during liver 
transplantation as recent publications indicate that peroperative blood loss still affects 
postoperative outcome (84-86). Surgery in general imposes a situation of hypercoagulability 
through a combination of activation of haemostasis due to tissue damage and release of 
hormones and cytokines, which affect haemostasis (87, 88). In response, fibrinolysis is 
activated by a rise in tissue plasminogen activator activity to maintain the pro- and 
anticoagulant equilibrium. Patients with preceding liver disease however often have 
profound disturbances in the haemostatic system, including a low platelet count, low levels 
of clotting factors and increased levels of fibrinogen degradation products due to 
disseminated intravascular coagulation and subsequent fibrinolysis (89-91 ). During the liver 
transplantation procedure, this accelerated fibrinolysis (hyperfibrinolysis) and coagulopathy 
are recognised complications and massive blood loss remains an important clinical problem. 
In 1989, bleeding complications was the most frequent cause of death during the procedure 
and in the first week after transplantation (92). Refinements of the surgical procedure and 
improved perioperative management have decreased blood loss over the years. Still, 
enhanced fibrinolysis plays an important role in the pathogenesis of peroperative bleeding in 
the anhepatic and reperfusion phase, due to compromised hepatic clearance and release of 
t-PA from the donor liver (40, 93, 94). Once large amounts of t-PA are released in the 
circulation, a2-antiplasmin plays a key-role in scavenging the formed free plasmin (95). 
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When in 1996 solvent/detergent virus-inactivated plasma was introduced in our 
hospital to minimise the risk of viral transmission, suddenly an increase in hypeliibrinolysis 
in patients undergoing OL T was observed with detrimental effects on peroperative 
transfusion requirements. A study was initiated to establish the role of this new plasma in the 
increased incidence of fibrinolysis. 
3.3 Preservation of the recipient vena cava inferior 
The technique of orthotopic liver transplantation is well standardised and results have 
improved significantly over the years. Despite refinements, conventional orthotopic liver 
transplantation requires crossclamping of the inferior vena cava, reducing venous return and 
resulting in decreased cardiac output and systolic blood pressure and increased systemic 
vascular resistance (96-98). These changes are poorly tolerated in hemodynamic unstable 
recipients and may contribute to renal impairment. The introduction of vena-venous bypass 
by Shaw in 1984 (99) improved the results of adult liver transplantation as it corrected 
hemodynamic and renal disturbances and decreased intraoperative blood loss. However, 
the use of a vena-venous bypass is associated with complications including 
thromboembolism, air embolism, hypothermia and wound infection (100-103). Liver 
transplantation with preservation of the recipient vena cava ("piggyback" technique) has 
been proposed as an alternative procedure, allowing normal caval blood flow during the 
an hepatic phase. The use of this piggyback technique was first mentioned by Caine in 1968 
(104) and fully described by Tzakis et al. in 1989 (105). In these first cases the hepatic veins 
were crossclamped and a vena-venous bypass still was used in adult recipients. The 
concept of side clamping of the retrohepatic vena cava, introduced by Belghiti in 1992 (106), 
allowed preservation of caval blood flow during the hepatectomy phase and overcame the 
need for vena-venous bypass. Since then, (modified) piggyback techniques have been 
compared to the conventional orthotopic liver transplantation technique by several authors 
(107-113), reporting reduced operative time, blood loss, transfusion need and 
hospitalisation. So far, in retrospective studies where patients were not matched for other 
variables affecting outcome, no survival benefit has been established. In a prospective, but 
not randomised study, outcome in both groups was excellent and no differences could be 
established (109). We compared therefore our results of a modified piggyback technique to 
a matched historical group of patients transplanted with the conventional technique. 
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3.4 Partial liver transplantation 
With improving results of liver transplantation, more and more patients were referred to a 
transplant centre. This resulted in a steady increase of adults on the waiting list, but the 
death rate on the waiting list increased at an alarming rate, especially for children (29, 30, 
114-116). In chapter 10 an overview is given of the different techniques that were developed 
to solve this problem. The introduction of partial orthotopic liver transplantation resulted in a 
decrease on the paediatric waiting list to almost zero over the years. Refinements of the 
operation opened the gate to right lobe living donor liver transplantation as the demand for 
organs increase every year and the numbers of donors remain constant in western 
countries. There is however serious concern of the well being of the liver donor in terms of 
morbidity and mortality. 
4. AIMS OF THE THESIS 
This thesis is aimed at optimisation of the existing liver transplantation procedures. For most 
candidates for liver transplantation the orthotopic transplantation technique will be 
appropriate. If however the auxiliary transplantation technique is preferred for some selected 
patients, the following questions need to be answered. 
1. How is the portal and arterial blood flow altered after preservation and reperfusion 
of the partial liver graft in the presence of a non-cirrhotic native liver? 
2. Does intervention in the portal blood flow during the transplantation procedure 
change portal and arterial flow patterns? 
3. Which intervention in the portal blood flow improves long-term graft function? 
To optimise graft and patient survival after conventional orthotopic liver transplantation, the 
following questions were addressed: 
4. Is primary graft dysfunction caused by mitochondrial damage due to nitric oxide 
derived radicals during preservation and reperfusion? 
5. Is intra-operative fibrinolysis and subsequent blood loss related to the type of blood 
plasma used during the procedure? 
6. Is the vena cava preserving liver transplantation technique better than the 
conventional transplantation technique? 
7. How do we expand the donor pool for paediatric and adult liver transplantation? 
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5. OUTLINE OF THE THESIS 
Part one of this thesis contains the general introduction to partial and whole liver 
transplantation. Chapter 2 addresses the concept of auxiliary partial liver transplantation. 
Auxiliary partial heterotopic liver transplantation was first introduced as a less invasive 
procedure for patients who could not tolerate a standard orthotopic liver transplantation. 
Later on the technique was proposed for patients with acute liver failure in whom 
regeneration of the native liver was expected, but due to its complications it never gained 
wide acceptance. Since 1990 a new concept of auxiliary partial liver transplantation was 
introduced where the graft is placed in the orthotopic position. 
In chapter 3 the development and current surgical technique of orthotopic liver 
transplantation are discussed. Initially the diseased liver was removed with the vena cava 
and replaced by a whole liver graft. With increasing waiting lists for donor organs, surgical 
techniques were developed to split the donor liver and transplant both partial liver grafts in 
the orthotopic position. 
In part two three studies regarding experimental auxiliary partial liver transplantation are 
presented. In chapter 4 we report the long-term correction of an inborn error of metabolism 
with an auxiliary partial liver graft placed in a heterotopic position. Since the distribution of 
portal blood flow between liver graft and native liver remains controversial in auxiliary liver 
transplantation, the success of metabolic correction was related to four different forms of 
portal inflow. With the introduction of auxiliary partial orthotopic liver transplantation several 
disadvantages of the placement of the graft in heterotopic liver transplantation were 
overcome. 
In chapter 5 we therefore assess the importance of portal flow diversion in an 
experimental model of auxiliary partial liver transplantation in the orthotopic position. The 
portal blood flow was measured with Doppler ultrasonography and changes in portal flow 
distribution were recorded after surgical intervention in the portal blood flow. 
In chapter 6 the metabolic correction following these interventions in portal flow were 
reported. 
Part three contains three studies performed in patients receiving an orthotopic whole liver 
transplantation. In chapter 7 we present the problem of graft dysfunction in the first 7 days 
after liver transplantation. We report our data on mitochondrial dysfunction in patients with 
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primary graft dysfunction and the relation with toxic reaction products of the nitric oxide 
radical. 
In chapter 8 we report an increased incidence of fibrinolysis, the most prominent 
coagulation disorder during orthotopic liver transplantation, after introduction of virus 
inactivated plasma. Consequences of fibrinolysis and treatment options are discussed. 
In chapter 9 we evaluate patient and graft survival between patients transplanted with 
standard liver replacement or a vena cava preserving technique. 
Chapter 10 provides an overview of the development of different techniques for 
splitting of the donor liver in an attempt to alleviate the shortage of donor organs in 
paediatric and adult liver transplantation. 
Chapter 11 summarises the previous studies, bringing the data in perspective and 
provides future perspectives. 
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Introduction 
The concept of transplanting a liver graft side by side to the native liver originated from 
Welch in 1956 (1). The idea is theoretically attractive because the recipient liver is left in situ, 
avoiding the strenuous removal of the cirrhotic liver, which is usually densely attached to the 
diaphragm and abdominal wall due to inflammation and development of large collateral 
vessels. Dissection of the cirrhotic liver is still associated with considerable blood loss during 
liver transplantation, which was the main cause of death during the procedure and in the first 
week after transplantation in the early days (2). As surgical trauma was limited in auxiliary 
liver transplantation, the patients were expected to recover more rapidly than after an 
orthotopic whole liver transplantation. Another advantage of auxiliary liver transplantation is 
the absence of the anhepatic phase during the procedure, which enables some function of 
the native liver in clearance of t-PA and other haemostatic factors during anastomosis and 
reperfusion of the graft (3-5). Without hepatectomy, also the venous return to the right heart 
is preserved, avoiding the need for vena-venous bypass of the blood flow of the splanchnic 
vessels and lower extremities and creating a hemodynamic stable procedure. 
Auxiliary liver transplantation was first introduced as a less invasive procedure for 
patients with end-stage chronic liver disease, who were at high risk of not surviving a 
conventional orthotopic liver transplantation (6-9). However, in patients with chronic active 
hepatitis, the risk of development of hepatocellular carcinoma in the native cirrhotic liver, 
which is left in place has proven to be substantial (7). Therefore auxiliary liver 
transplantation was abandoned in patients with a cirrhotic liver. 
Patients with acute liver failure form another indication in which auxiliary liver 
transplantation is preferable over orthotopic whole liver transplantation (10-13). In these 
patients complete resection of the native liver is not indicated. Auxiliary liver transplantation 
may serve as a bridge to recovery with the possibility to redraw immunosuppressive therapy 
after regeneration of the native liver. Actual 1-year survival after auxiliary partial liver 
transplantation was 61% and of these patients, 65% could be taken off immunosuppressive 
medication (11 ). 
Finally, auxiliary liver transplantation was proposed for patients with selected inborn 
errors of hepatic metabolism, in whom only one enzyme or cell membrane receptor is 
absent and who have otherwise normal function of the liver (table 1) (14-17). In those 
patients, auxiliary liver transplantation provides metabolic correction and preserves the 
possibility of future gene therapy in the native liver. 
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Table 1. Inborn errors of metabolism that possibly can be cured with auxiliary liver 
transplantation. 
Alpha 1 -antitrypsine deficiency 
Crigler-Najjar syndrome 
Urea cycle disorders 
Tyrosinaemia 
Wolman's disease 
Byler's disease 
Glycogen storage diseases 
Familial amyloidotic polyneuropathy 
Protein C deficiency 
Protoporphyria 
Gaucher's disease 
Wilson's disease 
Galactosaemia 
Propionic acidaemia 
Congenital Haemochromatosis 
Familial hypercholestero!aemia 
Haemophilia 
The role of portal flow in auxiliary liver transplantation. 
After an auxiliary partial heterotopic liver transplantation, some functional competition exists 
between the liver graft and the native liver (18, 19). Marchioro first described this functional 
competition in 1965 between two parts of a liver receiving its blood supply partly from the 
vena cava and the other part from the portal vein (20). The important role of adequate portal 
blood flow for survival of a liver graft was early established in both experimental and clinical 
setting (21-24). In the first reports, the nature of the portal blood seemed to be important. 
Various authors have indicated that pancreatic venous blood, with presence of insulin and 
glucagon is needed for graft regeneration. (25-29). Later on, other authors suggested that it 
is not the source of the blood, but rather its quantity that is important (30-35). The direction 
of adequate blood flow through the portal vein of liver graft and host liver is therefore of 
critical importance to auxiliary liver transplantation. In acute liver failure, portal blood flow 
may be a self-regulating mechanism, as in the early phase vascular resistance in the native 
liver is expected to be high due to the complete collapse of the diseased liver. This results in 
a blood flow preferentially towards the graft. In later periods, when the native liver is 
regenerating, a reversal effect may occur due to rejection episodes in the graft, leading to 
preferential blood flow towards the recovered native liver. 
When however an auxiliary transplantation is performed in the presence of normal 
hemodynamic conditions of the recipient, like in inborn errors of hepatic metabolism, the 
distribution of the portal flow remains a major concern. To overcome the problem of 
insufficient portal blood flow, arterialisation of the portal vein was attempted with variable 
outcome (36-39). 
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Auxiliary Partial Heterotopic Liver Transplantation (APHLT) 
The concept of auxiliary liver transplantation was first described by Goodrich and Welch in 
1956 in a dog model (1). Absolon performed the first APHLT in men in 1964, one year after 
the first attempted orthotopic liver transplantation by Starzl (40). The graft comprised a 
whole liver graft and was placed in the upper right quadrant of the abdomen after resection 
of the right kidney. A heterotopic liver transplantation that truly prolonged life was achieved 
in 1972 (41 ). In 1980 the 29-month survival of an adult recipient was reported in Paris (7). In 
the following years many experimental studies were performed to optimise the procedure. 
The placement of a large additional organ in the abdomen precluded in several cases 
wound closure after transplantation (41 ). Forced closure results in increased intra abdominal 
pressure with the risk of kinking or compression of the blood vessels of the graft and 
subsequent portal thrombosis. Removal of one of the kidneys or the spleen has been 
suggested, but has been abandoned today (22, 40). To solve the problem of lack of space in 
the abdominal cavity, different positions of the heterotopic graft have been proposed with 
various transplantation techniques. Besides the most frequently used right hypochondrium 
(Figure 1 ), grafts were placed in the thorax (1 0), left upper abdomen (42) and right lower 
abdomen (1 ). The technique that was developed by Bismuth in Paris placed the graft directly 
under the native liver (figure 2). Also the necessity of unimpaired venous drainage from the 
hepatic veins was demonstrated (43) and a new technique of side to side caval anastomosis 
was developed in the Netherlands (44) (figure 3). The best results were reported with the 
graft draining in the inferior vena cava as close as possible to the diaphragm, as the 
pressure in the vena cava fluctuates with respiration and increases proportionally with the 
distance from the right atrium (45). 
Although satisfactory experimental results have been reported, clinical heterotopic liver 
transplantation was successful in selected patients only. From 1964 until 1980, 47 patients 
had undergone APHL T, but only two of these patients survived more than one year (46). 
While in this period OL T evolved to be the procedure of first choice, the potential 
advantages of APHL T still inspired researchers to study experimental auxiliary models in an 
attempt to overcome the main problems associated with the procedure. 
In the laboratory for experimental surgery of the Erasmus University of Rotterdam, the 
problems associated with the APHL T procedure were extensively reviewed. The optimal 
transplantation technique (47, 48), efficacy (49, 50), intraoperative haemostasis (3, 4, 51-
53), hemodynamic stability (54) and requirements for metabolic correction in case of an 
inborn error of hepatic metabolism were investigated (55, 56). 
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Figure 1. Auxiliary heterotopic liver 
transplantation with a whole graft, Bismuth 
1988. From: Blumgart ed. "Surgery of the 
liver and biliary tract". London, Churchiii-
Livingstone 1988. 
Figure 3. Side-to-side cavo-cavostomy, 
periormed by Ligydakis to optimise 
hepatic outflow. From: J Surg Res 1985; 
38: 246. Academic Press. 
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Figure 2. Auxiliary partial heterotopic liver 
transplantation, Bismuth 1984. 
A) Suprahepatic vena cava inferior. B) 
Anastomosis with Intrahepatic vena cava. C) Graft 
left portal vein. D) Native common portal vein. E) 
Graft hepatic artery. From: Blumgart ed. "Surgery 
of the liver and biliary tract.". London, Churchiii-
Livingstone 1988. 
Figure 4. Auxiliary partial heterotopic liver 
transplantation developped in the Rotterdam 
laboratory for Surgical research. 
HA: hepatic artery. PV: portal vein. SpV: splenic 
vein. VC: vena cava. 
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Figure 5. Auxiliary partial heterotopic technique for 
patients with portal vein thrombosis, Fournier 1990. 1) 
suprahepatic vena ava. 2) cava-renal anastomosis. 3) 
spleno-hepatic arterial anastomosis. 4) spleno-portal 
venous anastomosis. 5) choledocho-jejunostomie. From: 
Fournier. Transplant Proc 1990; 22:1572. 
Figure 6. Liver segmental anatomy, proposed by 
Couninaud in 1957. Segm II +Ill= left liver lobe. 
II, Ill & IV= left hemi liver. V-VIII= right liver lobe. 
V-VIII & IV= right hemi liver. !=caudate lobe. 
from: Blumgart ed. "Surgery of the liver an b!lary 
tract" London, ChurchHI-Livingstone 1994. 
' 
\ 
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Figure 7. Auxiliary partial orthotopic liver 
transplantation according to Gubernatis (1990). 
The biliary tract is not drawn. 
Drawing: de Jonge, 2001 
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A new concept of reduced-size heterotopic liver transplantation was developed with portal 
and arterial inflow, vital to graft survival and biliary tract integrity (57). The graft was placed 
in the right subhepatic space after removal of the left lateral and medial liver segments, 
leaving about 70% of the donor liver. The intrahepatic vena cava of the graft was ligated and 
venous drainage was achieved through anastomosis of the suprahepatic vena cava of the 
graft to the recipient's intrahepatic vena cava, proximal to the renal veins (figure 4). 
The results of these experimental studies initiated a clinical program in Rotterdam 
starting in 1986. Two years later, the favourable outcome in six high-risk patients, rejected 
by another transplant centre, was reported (9). In an open comparative study between OL T 
and APHL T, Metselaar et al. showed similar results in the two groups (58). Blankensteijn 
reviewed the results of APHLT between 1980 and 1990 (59). In that decade 50 APHLTs 
were performed in 48 patients in 11 transplant centres. Overall one-year patient survival was 
55%, but survival in patients transplanted since 1987 was 71%. In two recipients a new 
hepatocellular carcinoma developed in the native liver after transplantation, indicating the 
risk of application of APHL T for cirrhosis due to viral hepatitis (7). 
Experimental studies performed in the last decade showed good results for metabolic 
support in acute liver failure (60-62) and addressed the subject of portal flow distribution 
between graft and native liver in absence of cirrhosis (63-65). 
However, due to persisting complications associated with the heterotopic position of 
the graft, clin'1cal auxiliary heterotopic liver transplantation was rarely performed, despite its 
theoretical advantages (66). In 1990 Fourtanier reported a new technique of APHLT that can 
be used in patients with portal vein thrombosis (67) (figure 5). Since then, some authors 
reported successes with auxiliary heterotopic liver transplantation in individual cases for 
acute liver failure (38, 68-72). Despite these reports, 1-year patient survival after heterotopic 
auxiliary transplantation was only 33% for acute liver failure in a review of the Eurotransplant 
area and primary non-function was more frequent than after orthotopic liver transplantation 
(11 ). Incidental reports of auxiliary heterotopic liver transplantation for Budd-Chiari syndrome 
(73), Alagille syndrome (74) and Protein C deficiency (75) were published in the last 3 years. 
To overcome the problems of space, blood supply and drainage that hampered 
survival, in 1990 a new concept of auxiliary liver transplantation was introduced where a 
partial liver graft was placed in the orthotopic position after removal of liver segments II to IV. 
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Auxiliary partial orthotopic liver transplantation (APOL T) 
The first report of the use of an auxiliary partial orthotopically placed liver graft comes from 
Bismuth in 1985 (76), but the patient died 13 days after the procedure. In 1989 the first 
successful clinical APOL T was performed in Hannover for acute liver failure due to the 
HELLP syndrome (hemolysis, elevated liver enzymes and low platelets) after pregnancy 
(77). 
The donor liver was split by bench surgery to retrieve the left liver lobe (Couinaud 
segments 2-4 (figure 6, (78)). The vena cava inferior was dissected from the liver, except for 
a small part that served as a patch for anastomosis to the recipient left hepatic vein. The 
whole celiac axis including an aortic patch was preserved for the graft. In the patient a 
resection of segments 2 and 4 was performed, preserving portal and arterial blood fiow to 
segment 4. The left hepatic vein was carefully dissected to obtain sufficient length for 
reanastomosing. Hereafter first an end-to-end anastomosis of the hepatic vein was 
performed, without clamping the vena cava inferior or vena-venous bypass. The celiac axis 
of the graft was anastomosed with a patch to the recipient aorta above the native celiac 
trunk. Portal vein reconstruction was performed by end-to-side anastomosis to the common 
portal vein at a sharp angle. The biliary tract was reconstructed with a Roux-en-Y jejunal 
loop (figure 7). After a complicated post-operative course with recurrent gastrointestinal tract 
bleeding, the patient could be discharged from hospital after 3 months and in the following 
year the immunosuppression could be tapered off. 
In this situation no additional precautions were taken to ensure portal inflow in the graft 
as the vascular resistance in the native liver was expected to be much higher and gradual 
atrophy of the graft after native liver regeneration was aimed for. Since its introduction, 
auxiliary partial orthotopic liver transplantation has been mainly used for acute liver failure 
(70, 79-88). In general a 1-year survival comparable to that of orthotopic whole liver 
transplantation for acute liver failure can be achieved Azoulay, 2001 #11 03] and 60% of the 
patients can be taken off immunosuppressive medication (11 ). 
In 1990 APOL T proved also to provide total metabolic correction in a 14-month-old 
patient with ornithine transcarbamylase deficiency (OTCD), a urea cycle defect (89). In this 
case a segment 2/3 graft was placed after resection of the patient's left liver lobe. Portal flow 
reconstruction was achieved by end-to-end anastomosis of the graft left portal vein to the 
preserved vascular pedicle of the resected left lobe. Within 1 week after transplantation a 
normalisation of blood ammonia was seen and normal diet could be taken. Also in this 
particular case no precautions were taken to ensure portal inflow to the graft, as intra-
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operative ultrasound indicated sufficient portal inflow. If, however the vascular resistance in 
the graft increases e.g. due to rejection episodes. the portal flow may be completely divided 
to the patient's own normal liver. This competition for portal blood between the two livers in 
auxiliary transplantation seems difficult to overcome when the patient's liver has only 
metabolic disease and is otherwise unimpaired. 
Since this first report, APOL T procedures for other inborn errors of hepatic metabolism 
have been described in 14 patients with various metabolic disorders: Crigler-Najjar 
syndrome (90-93), OTCD (82, 94-98) and other metabolic diseases (99, 1 00). 
In some of the transplanted patients the portal blood flow towards the native liver was 
artificially obstructed to ensure adequate blood flow towards the graft, so called "banding" 
(90, 91 ). In other cases the host portal vein had to be ligated after initial successful 
transplantation without intervention to guarantee adequate perfusion of the graft after a 
rejection episode (97, 98). For this indication, the complicated hemodynamic situation of the 
liver graft- side by side with the non-cirrhotic native liver- still is a critical issue at the time of 
surgery and of major importance to long-term graft survival. Only few experimental studies 
addressed the problem of portal blood distribution between the native liver and the auxiliary 
graft (29, 101, 1 02) and therefore this problem is further assessed in chapters 5 and 6. 
The technical advances that enabled auxiliary orthotopic liver grafting had also other 
consequences to liver transplantation (89, 1 03). It opened the way for living donor hemi-liver 
transplantation in the situation of acute liver failure (82, 104, 1 05) and metabolic diseases 
(15, 82). There is however great reservation to put a healthy donor at risk and ethical issues 
of donation remain to be solved as long-term donor safety must be established. So far two 
donor deaths are reported with more than 1000 living donor procedures performed, but this 
is probably underreported. For the sake of donor safety in living donor liver transplantation, 
the left lobe is currently being used most often for the graft. However, in countries where 
living donors are the only source of liver grafts (as in Japan where brain death is non 
commonly accepted), restrictions on graft size are a serious obstacle for the expansion of 
indications for adult recipients. To overcome this problem, auxiliary partial orthotopic liver 
transplants was performed on the basis of the concept that the residual native liver would 
support the graft function until the graft had grown enough to function by itself (1 06). From 
1995 until 1998, 20 recipients underwent living donor APOL T, which was indicated because 
a small for size graft (estimated graft/recipient's body weight ratio <0.8%) was harvested. 
Post-operative survival was 65% in these patients with signs of advanced liver failure, such 
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as massive ascites or hepatic coma. Mortality was not related to technical failure, but 
associated with sepsis. 
This indicates that auxiliary partial liver transplantation is not only useful to bridge a 
patient in acute liver failure to recovery or provide metabolic correction in inherited metabolic 
liver diseases, but also can help to expand the indication of living donor liver transplants for 
adult recipients. 
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Chapter 3 
Orthotopic whole liver transplantation (OL T) 
The concept of orthotopic replacement of the liver was first mentioned by Claude S. Welch 
(1 ), although the first reported experiments with canine orthotopic liver transplantation were 
done by Cannon (2) in 1956. None of the animals survived the operation and it took four 
years until the technique was performed successfully by teams in Denver and Boston (3, 4). 
Human orthotopic liver transplantation was first attempted on 1 March 1963, at the 
University of Colorado by Starzl and co-workers (5). This first transplantation and six others 
in Colorado, Boston and Paris were unsuccessful and clinical trials were halted for 3 years. 
In 1967 Starzl performed the first clinical transplantation that extended life, when a child 
lived 1.5 years after transplantation for hepatic malignancy before dying of metastasis (6). 
Operation technique 
Transplantation of the liver is a major operation, often offered to some of the sickest patients 
who are submitted to surgery. The technique of liver transplantation is divided into three 
stages: the hepatectomy phase, the anhepatic phase and the reperfusion phase. 
Hepatectomy is the most difficult part of the procedure because of the presence of portal 
hypertension and severe coagulopathy. Control of haemorrhage during the removal of the 
patient's owns liver can be difficult. Blood loss in the hepatectomy phase is often significant, 
with the need of large amount of packed red blood cell, fresh frozen plasma and 
thrombocyte substitution. After resection and haemostasis, particularly of the right adrenal 
area, the liver graft is anastomosed to the supra and intrahepatic vena cava inferior, portal 
vein and hepatic artery (figure 1 ). Biliary reconstruction may involve an end-to-end 
choledocho-choledochostomy or Roux-en-Y choledocho-jejunostomy with or, currently, 
without t-tube (7-9) (figure 2). After completion of the portal vein anastomosis the liver graft 
is often already reperfused to keep the warm ischaemic period as short as possible. Before 
reperiusion however, the organ is perfused with albumin or another fluid to wash out the 
preservation solution, which contains a high concentration of potassium. 
In the reperiusion phase there are always signs of potassium and acid release with a 
50% reduction in cardiac output, pulmonary hypertension and marked increase in systemic 
vascular resistance (10-13). Also profound haemostatic disturbances with onset of 
hyperfibrinolysis and depletion of clotting factors may be present in this stage of the 
operation (14-17). Adequate surgical haemostasis is promoted by interventions of the 
anaesthetist to achieve normal clot formation. After wound closure over closed sump drains, 
the patient is rewarmed in the intensive care unit where vital functions are supported. 
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Figure 1. Orthotopic whole liver 
transplantation. The supra (A) and 
intrahepatic (B) vena cava inferior, 
portal vein (C), hepatic artery (D) and 
common bile duct (E) are 
anastomosed. From: Forsythe ed. 
"Transplantation Surgery". London, WB 
Saunders, 1995 
Figure 2. Biliary tract reconstruction with end-to-end 
anastomosis or choledocho-jejunostomy and the use 
of aT-drain. From: Busuttil eta!. Ann lnt Med 1986; 
104:377-389. 
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Results 
In the initial phase, one-year patient survival was poor and restricted to approximately 30% 
(8, 18). In the era 1963-1979 immunosuppression was achieved by steroids, azathioprine 
and sometimes anti-thymocyte globulines (ATG). Technical post-operative problems 
included ischaemic injury to the liver graft with poor initial function, anastomotic problems, 
graft vascular injuries, and bile duct problems. Extrahepatic problems were mainly caused 
by too much immunosuppression with bacterial, viral and fungal infections or too little 
immunosuppression with rejection on day 4 or 5 after transplantation. Late problems 
included drug-induced nephrotoxic and cardiotoxic side effects, chronic rejection and 
recurrence of the liver disease. 
In 1980 there was a major step forward with the introduction of Cyclosporine A 
(Novartis) as the main immunosuppressive drug (19). The predictability and reliability with 
which liver transplantation could be carried out improved steadily with the first trials of 
cyclosporine I steroid therapy and since 1980 the majority of liver recipients has survived the 
initial post-operative phase. The most specific survival information was obtained by the 
groups of Starzl (Pittsburgh) and Caine (Cambridge I King's College hospital). One-year 
survival rates increased to 60-75% (20-22). Part of this improved survival was attributed to 
the inclusion of paediatric patients, who had about a 1 0% survival advantage over adult 
recipients, in the liver transplantation programmes. Several other factors played an 
important role in the improvement of survival rates. 
One important technical factor improving patient survival was the introduction of a 
vena-venous bypass by the Pittsburgh group in 1984 for decompression of the blood flow of 
the splanchnic vessels and lower extremities (23). Most of the surgical difficulties were 
centred on the an hepatic phase. Approximately 50% of the patients who died within the first 
year following liver transplantation were lost in the first post-operative month. In addition, 
operative mortality of the first patients treated with cyclosporine still was 9.5% and blood 
loss was the main cause of death in these patients (18). 
Crossclamping of the portal vein and abdominal vena cava inferior causes several 
problems. It leads to impaired venous return to the right heart, portal hypertension and a 
sudden return of the blood frorn obstructed venous beds into the circulation after 
reperfusion. To overcome these problems, a passive vena-venous bypass was tried but 
abandoned after embolic complications (5, 24). A clinical trial with systemic heparinisation 
initiated in 1982 led to increased blood loss and reduced patient survival, but the need for 
some sort of bypass remained evident. An experimental method of bypass without the need 
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for system anticoagulation by heparin coated tubing was successfully developed by the 
Pittsburgh group (25). This enabled early implementation of the bypass (figure 3), greatly 
decreasing the extent of preliminary dissection of the liver. The hepatectomy could then be 
performed with hemodynamic stability and the raw resection surfaces that were created 
during dissection could be systematically closed. All together the technique offered a 10% 
survival benefit in the first 30 days after transplantation to all patient categories (26). 
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Figure 3. Diagram of the vena-venous 
bypass. The venous return of the splanchnic 
and lower extremity vascular beds is 
transferred to the axl!lary vein. 
From: Starzl in "Surgery of the liver and 
biliary tract" Blumgart ed. London, Churchiii-
Livingstone 1988 
Another improvement in graft and patient survival was obtained by the development of 
a special preservation solution to keep the harvested donor liver in good condition during 
cold storage. At the University of Wisconsin, Belzer and co-workers developed in 1989 a 
preservation solution ("UW-solution"), which contained all prerequisites for cell survival and 
energy preservation (27, 28). The introduction of the UW-solution enabled safe storage of 
the donor liver up to 16 hours and changed the liver transplantation from an emergency into 
a semi-elective operation (29). Additionally other preservation solutions were designed with 
equal results (30, 31 ). 
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Further improvements in operation technique and perioperative care included the 
aggressive intra-operative monitoring of the coagulation cascade by thromboelastography 
(TEG), introduced by Kang in 1985 (32). This enabled detection of hyperfibrinolysis, a 
serious coagulation disorder where the blood clot is dissolved by tissue type plasminogen. 
The standard use of anti-fibrinoly1ic medication during the procedure further reduced blood 
loss (33-38). 
The introduction of a transplantation technique, which preserves the vena cava during 
the transplant procedure further reduced transfusion requirements and shortened the warm 
ischaemic period. This "piggyback" technique was first mentioned by Caine in 1968 (39), but 
fully described by Tzakis in 1989 (40). The technique originally uses the hepatic veins of the 
recipient for cava-caval end-to-end anastomosis, obviating the need for cross clamping of 
the vena cava inferior. Initially the vena-venous bypass was used during the procedure, but 
in 1992 Belghitti introduced a modification with side-to-side cavo-cavostomy (41 ), which 
enabled transplantation without bypass (42). 
Parallel advances in immunosuppression were made by the introduction of tacrolimus 
(FK-506, Fujisawa) (43), which is comparable with Cyclosporine (CsA) in efficacy, but 
sometimes can be used in CsA resistant rejection or GsA induced nephrotoxicity. 
Rapamycine (Sirolimus, Wyeth), an inhibitor of the mammalian target of rapamycine 
(mTOR) is another new immunosuppressive agent with promising short-term results (44, 
45). Recently the recombinant human monoclonal CD-25 receptor antagonists Daclizumab 
(Roche) (46) and humanised Basiliximab (Novartis) (47) were engineered to reduce acute 
rejection in the first year after transplantation. At this moment steroid withdrawal and even 
steroid-free immunosuppression regimens are under study. 
These factors together made that orthotopic whole liver transplantation is nowadays a 
safe option for end-stage chronic and acute liver failure. Currently many centres report one-
year survival rates of 90% and about 4500 liver transplantations are performed annually in 
the USA with 16000 patients on the waiting list (48) and about 4000 liver transplantations 
are performed in Europe with 9000 patients waiting on the list (49, 50). 
Orthotopic liver transplantation in Rotterdam 
In the Netherlands, orthotopic liver transplantation was first performed at the University 
hospital in Groningen in 1979. Until 1982 transplantations were only performed in adults 
because survival results did not justify paediatric transplantation. The first experience with 
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liver transplantation in the Rotterdam University hospital was gained in 1986. Since then 
more than 300 orthotopic liver transplantation have been performed. 
Partial orthotopic liver transplantation 
Worldwide shortage of donor livers was the main obstacle for further expansion of liver 
transplant programs during the last decade. During this period the waiting lists for adults 
showed a steady increase all over the world, but the death rate on the waiting list for 
children increased at an alarming rate. To solve this problem several alternative techniques 
of partial liver transplantation were developed. 
The earliest form consisted of a reduction of a whole liver graft to the left lateral 
segment or the left liver lobe, small enough to transplant to a young child. The remaining 
part of the liver was discarded. This method solved part of the great need of liver grafts for 
children but as the remaining part of the liver was lost, the method was in fact detrimental for 
adults on the waiting list. 
Further surgical development resulted in splitting of the liver ex-v;vo into two 
transplantable partial grafts, the left part to a child and the right lobe to an adult. The 
procedure was successfully introduced but the complicated logistics resulted in prolonged 
cold ischaemia times of the grafts. In order to keep the cold ischaemia time as short as 
possible Rogiers developed the in-situ split liver technique in which the liver was split in the 
post-mortem donor (51). Refinement of this operation led to results, superior to the ex-vivo 
method. It opened the gate to living donor liver transplantation. The first successful living 
donor liver transplantation was performed in Australia from a mother to a child who received 
the mother's left liver segment (52). The introduction of living donor transplantation resulted 
in a decrease over the years on the paediatric waiting list to almost zero. As the demand for 
organs increases every year and the numbers of donors are constant in western countries, 
the right lobe living donor liver transplantation for adults was introduced. There is however 
concern of the well being in terms of morbidity and mortality of the living donor. Until now 
there are in the literature two donors who died after living liver donation but the true figure, 
after more than 1000 living donor liver transplantations is expected to be higher judged by 
experts (53, 54). 
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Abstract 
Auxiliary liver transplantation is an attractive alternative for orthotopic liver transplantation in 
patients with certain inborn errors of metabolism of the liver, where complete resection of the 
liver is unnecessary or even contraindicated. As in these diseases portal hypertension is 
mostly absent, finding a balance in portal blood distribution between native liver and graft is 
complicated. Our objective was to investigate requirements for long-term (180 days) graft 
survival in auxiliary partial heterotopic liver transplantation (APHL T) in a dog model. A 
metabolic defect was corrected in 26 Dalmatian dogs with a 60% Beagle heterotopic 
auxiliary liver graft. Grafts were preserved in UW solution (Viaspan, DuPont). Four groups of 
different portal inflow were studied: In the ligation group the portal vein to the host liver was 
ligated. In the split-flow group graft and host liver received separate portal inflow. In the 
banding group the distribution of the portal flow was regulated with an adjustable strapband 
and in the free-flow group the portal blood was allowed to randomly flow to host or graft liver. 
Post-operative the dogs received Cyclosporine in an oral dosage of 10 mg/kg/day. Metabolic 
correction increased in all groups after transplantation from 0.19 ± 0.02 to 0.70 ± 0.05 
(p<0.0001 ), but remained significantly better in the ligation and split-flow groups (graft 
survival 135 ± 27 and 144 ± 31 days). In the banding group metabolic correction decreased 
significantly after 70 days and although the grafts kept some function for 155 ± 14 days, in 
4/6 dogs portal thrombosis was found. In the free-flow group, competition for the portal blood 
lead to reduced correction within 12 days and total loss of function in 96 ± 14 days. Graft 
function was also assessed with 99mTechnetium dimethyl-iminodiacetic acid uptake. A good 
linear association between HIDA uptake and metabolic correction was observed (r;;;:Q.74; 
p<0.0005). Grafts that contributed more than 15% to the total uptake of HIDA showed 
biochemical correction. This indicates a critical graft mass of about 15-20% of the 
hepatocyte volume to correct this metabolic defect. Auxiliary partial heterotopic liver 
transplantation can be a valuable alternative treatment for inborn errors of hepatic 
metabolism, if the native liver and the graft receive separate portal blood inflow. 
Introduction 
Orthotopic liver transplantation (OL T) has become the standard therapy for end-stage 
cirrhotic liver disease. Still, children with some life threatening inborn errors of hepatic 
metabolism, in which an enzyme or cell membrane receptor is absent, have an otherwise 
normal function of the liver and complete resection of the liver in OL T is only performed for 
technical reasons (1 ,2). Auxiliary partial heterotopic liver transplantation (APHL T) can be an 
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attractive option as it is a less demanding surgical procedure than OL T and primary graft 
non-function does not lead to an emergency re-transplantation. With partial liver 
transplantation, living-related procedures come into focus, allowing optimal timing and good 
graft quality (3-5). In addition auxiliary transplantation preserves the possibility of future gene 
therapy (6). In spite of these benefits, auxiliary heterotopic liver transplantation never gained 
wide acceptance due to its initially poor results (7) and the success of OL T. In previous 
animal experiments the surgical technique of APHL T and its efficacy to provide temporary 
support in (sub)acute liver failure have been assessed (8,9). In that situation the portal blood 
flow is preferentially toward the graft due to the increased vascular resistance in the native 
liver. In the correction of an inborn error of metabolism however, portal hypertension is 
absent and great attention must be paid to the prevention of portal vein thrombosis due to 
insufficient portal inflow or insufficient venous outflow. In this study we use the metabolic 
defect in the Dalmatian dog as a stand in for a life threatening inborn error and we evaluate 
long-term correction after transplantation of a 60% Beagle liver graft in four groups with 
different portal vascularisation. 
Methods 
Transplantations were performed from 26 Beagles to 26 Dalmatian dogs. The Dalmatian 
dog lacks a normal transport system for uric acid into the hepatocyte, which impedes the 
conversion of uric acid into allantoin and results in significantly depressed allantoin formation 
(1 0). Of this formed allantoin, 94% is excreted in urine by renal clearance (11) and the ratio 
of allantoin I creatinin in urine proved to be nearly constant, allowing correction for daily 
variations in renal function. Pre-transplantation excretion ratio of allantoin was 1.25 ± 0.07 in 
Beagles and 0.19 ± 0.02 in Dalmatian dogs (95% confidence interval: 0.16-0.22). In donors 
total hepatectomy was performed and after in situ perfusion w'1th 1 litre of cold University of 
Wisconsin solution (Viaspan, DuPont), the right lateral and right medial lobe were prepared 
for transplantation by bench surgery. In the recipient the pressure in the common portal vein 
and vena cava was registered simultaneously before transplantation. The graft was placed 
in the right subhepatic region and three vascular anastomoses were made: the suprahepatic 
vena cava of the graft was placed end-to-side with the intrahepatic inferior vena cava of the 
recipient; the hepatic artery was anastomosed to the infrarenal aorta. The portal vein was 
anastomosed end-to-side to the host portal vein and animals were divided in three study 
groups: in the ligation group (n=8) the host portal vein was ligated, the free flow group (n=6) 
had random flow to both livers. In the banding group (n=S) an adjustable strapband round 
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the host portal vein was carefully tightened to decrease the pressure proximal to the banding 
site to 50% of the pre-banding portal pressure. 
In the split flow group (n=4) the graft portal vein was anastomosed to the host superior 
mesenteric vein, which was ligated at its insertion in the portal vein. In this way the flow of 
the mesenteric vein was directed to the graft and the flow of the splenic vein to the host liver. 
Bile drainage was achieved by choledocho-duodenostomy. After reperfusion pressure 
recordings in the graft portal vein and vena cava were performed. Recipients received 
Cyclosporine A (Novartis, Uden, The Netherlands) in an oral dosage of 15 mg/kg/day. 
Changes in uric acid and allantoin levels were measured weekly in plasma and 24 hours 
collected urine samples. Graft function was determined by urinary excretion of allantoin (12). 
Intravenous angiography was performed 14 days after transplantation. At 3, 7, 16 and 24 
weeks after transplantation the liver function of both graft and host liver were quantitated by 
determination of 99MTc labelled dimethyl-iminodiacetic acid (99MTc-HIDA) uptake. Autopsy 
and registration of the wet liver weight were done in all animals. Surviving animals were 
sacrificed 180 days after transplantation. All data are presented as mean ± SEM. 
Differences between groups were detected by analysis of variance (ANOVA} with the 
Bonferroni post hoc test, after testing normality with Shapiro-Wilk statistics. For correlation 
analysis the Spearman rank correlation was calculated. Graft survival was analysed by the 
method of Kaplan-Meier. Loss of graft function was scored when post-transplantation 
allantoin excretion ratio in urine reached the 95% confidence interval of the pre-
transplantation level (mean ± 2 SEM). Differences were considered significant for p<0.05. 
Results 
The harvested grafts were weighed before implantation (231±12 g). After reperfusion the 
portal pressure was significantly increased in the ligation group (11.8 ±0.8 mm Hg; p<0.05 
vs. free-flow and banding). In the free-flow group portal pressure measured 4.2 ± 0.7 mm 
Hg, 6.4 ± 0.3 mm Hg in the banding group and 7.8 ± 3.0 mm Hg in the split-flow group 
(Figure 1 ). The insertion of the graft resulted in a slightly increased central venous pressure; 
vena cava pressure increased from 3.4 ± 0.3 mm Hg to 4.4 ± 0.4 mm Hg (n.s.). None of the 
dogs died during surgery, but late mortality was high. In the ligation group 4/8 dogs died 
from an accident, gastric perforation, arterial thrombosis of the graft and sepsis. In the free-
flow group 4/6 dogs died from severe necrotic grafts with secondary infection (2), bile 
peritonitis and haemorrhagic cystitis. In the banding group 2 dogs died from infected 
haematoma and unknown cause. In the split-flow group 1 dog died from severe rejection at 
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day 98. Graft failure due to hepatic vein thrombosis was not seen. In all 19/26 dogs in which 
an arteriogram could be performed, it showed patency of the graft hepatic artery. 
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Figure 1. Pressure in the graft portal vein before and after transplantation. 
I pre-transplantation; I post-reperfusion. # p<0.05 vs. free-flow and banding group. Increased portal 
pressure after ligation and splitted portal flow. In the banding group the pressure in the host portal vein 
measured 50% of that in the graft portal vein. In the free-flow group the graft functioned as a porto-caval 
shunt with low perfusion pressure in the portal vein. 
In figure 2 the allantoin excretion ratio in urine is shown during follow-up. After 
transplantation excretion of allantoin increased from 0.19 ± 0.02 to 0.70 ± 0.05 in all groups 
(p<0.0001 ). In the ligation and split-flow group metabolic correction remained stable at about 
300% of the pre-transplantation level. Mean graft function lasted 135 ± 27 and 144 ± 31 
days respectively. In the banding group the metabolic correction decreased significantly 
after about 10 weeks from 0.68 ± 0.05 to 0.33 ± 0.06 at week 16 (p=0.01). At autopsy late 
portal thrombosis was seen in 4/6 dogs surviving 180 days. Metabolic correction in the 2 
dogs with patent portal veins was 0.49 compared to 0.19 in the dogs with portal thrombosis 
(p<0.02), but as these animals all survived with their poor functioning grafts, mean graft 
survival still was 155 ± 14 days. In the free-flow group the metabolic correction was 
significantly worse from that in the other groups by day 21 (0.39 vs. 0.81, 0.72 and 0.69; 
p<0.02) and returned to pre-transplantation levels after 3 months; mean graft survival was 
96 ± 14 days. 
In table 1 the wet liver weight of all dogs at autopsy is shown. In the ligation group 
atrophy of the host liver was observed in 1 dog. The grafts in the ligation and split-flow group 
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showed hypertrophy compared with the pre-transplantation graft weight, while grafts in the 
free-flow group showed atrophy. Grafts in the banding group remained their original weight. 
Table 1. Wet liver weights at autopsy. 
Host liver lgl Graft lgl Total lgl 
1. Ligation group 527±83 530±81 t 1057±94 
2. Free-flow 1102±122. 168±44 1269±1 39 
3. Banding 599±100 285±78 884±76 
4. Split-flow 723±168 357±39 1080±1 91 
~P<0.05 versus ligation and banding. tp<Q.05 versus free flow. 
Histology examination showed oedema in the grafts of dogs that died within three days after 
transplantation (N=3). An equal distribution of mild to moderate chronic rejection with mixed 
cellular infiltrate was observed in the ligation, banding and split-flow group. In the free-fiow 
group however, extended (>75%) hepatocellular necrosis and destroyed architecture were 
seen. The wet liver weight of the graft at autopsy correlated significantly with its contribution 
to the total HIDA uptake, as determined in the last scintigraphy before autopsy (N=21, r=O.S-
4; p<0.0005). In figure 3 excretion of allantoin in urine at the time of 99MTc-HIDA scanning is 
plotted against the relative graft contribution to the total HIDA uptake. 72 Scintigraphies 
could be performed in 21 dogs (5 dogs died before the first scan was made). There was a 
significant correlation between proportional correction of the inborn error and the graft 
contribution to the total HIDA uptake (r=0.74; p<0.0005). Grafts that contributed more than 
15% to the total HIDA uptake, had graft function during 49/50 (98%) scans, where grafts that 
contributed less than 15% had graft function during 6/22 scans (27%); p<0.0001, Chi-square 
test. 
Discussion 
Auxiliary liver transplantation seems more and more an attractive option for orthotopic liver 
transplantation in the correction of metabolic diseases (13), but the technical difficulty in this 
specific situation, were the vascular resistance in the host liver is not increased as in acute 
liver failure, is to distribute the portal flow over the host liver and graft. Even the concept of 
auxiliary partial orthotopic liver transplantation (APOL T) does not overcome this problem 
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Figure 2. Excretion of allantoin -corrected for creatinin- in urine. 
Metabolic correction remained stable in the ligation and split-flow group. In the banding group a 
decrease in graft function was seen, where in the free-flow group correction was less marked and 
returned to pre-transplantation levels.--: 95% C.l. of the pre-transplantation al!antoin excretion ratio. 
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Figure 3. Correlation of HIDA-uptake and allantoin excretion in urine. 
72 Scintigraphies were performed in 21 dogs. Graft contribution to the total HIOA-uptake during 
scintigraphy correlated significantly with the urinary allantoin level; r=0.7 4; p<0.0005. 
----: 95% pre-transplantation C. I. of the allantoin excretion ratio. 
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and also in this situation chronic rejection led to decreased portal inflow in the graft (14). In 
this experimental study both ligation of the host portal vein and separate blood flow for host 
liver and graft assured adequate portal flow to the graft and good graft function. However, 
ligation of the host portal vein may interfere with the concept of its life supporting function in 
case of nonfunction of the graft and caused host liver atrophy in 1 dog. In the banding group 
initial good metabolic function decreased in time with increasing vascular resistance due to 
chronic rejection. Unlike the ligation and split-flow group, were chronic rejection did not lead 
to loss of function, the portal flow in this group probably redistributed towards the host liver, 
resulting in decreased portal inflow in the graft and late thrombosis in 4/6 dogs. In the free-
flow group acute competition for the portal blood flow led to rapid loss of function and 
atrophy of the graft as is described before (15, 16). In our study we did not find evidence for 
functional competition between host liver and graft in the split-flow group due to a 
hepatotrophic factor, as was described in literature (17, 18). The host liver, receiving the 
pancreaticoduodenal derived venous blood, did neither show hypertrophy, nor atrophy. The 
weight of the graft, receiving the superior mesenteric derived venous blood, was not different 
from that of the grafts in the ligation group, which received all portal blood. It therefore 
seems that the presence of portal flow, rather than its origin is essential for graft survival. 
Also essential for success in auxiliary liver grafting is to determine the liver mass that 
has to be transplanted for correction of the inborn error. In some metabolic diseases 
probably not more than 1-2% of the total liver volume is required (19). In this study there 
was no absolute correlation (r;Q.74) between HIDA-uptake and allantoin synthesis. Grafts 
that contributed more than 15% to the total uptake of HIDA had good metabolic function, 
probably indicating a critical liver mass of 15-20% of the functional liver weight for this 
specific inborn error. In conclusion, auxiliary liver transplantation remains of interest (20-23) 
and auxiliary partial heterotopic liver transplantation may be a valuable alternative for 
orthotopic liver transplantation for the correction of inborn errors of metabolism. Ligation of 
the host portal vein assures good graft function, but may interfere with the life supporting 
function of the host liver in a primary graft non-function. At this time we have no technical 
solution to find the delicate balance between portal inflow in the host liver and graft as is 
proven by the dysfunction in the free-flow group and the banding group. 
This study confirms the good results (16,24) with separate portal blood flow for host 
liver and graft and therefore we advocate for the split-fiow technique. 
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Abstract 
Background: Auxiliary partial orthotopic liver transplantation (APOL T) has successfully been 
performed in patients with non-cirrhotic metabolic diseases. It remains however unclear if 
intervention in the portal venous inflow is necessary to ensure adequate portal blood flow to 
graft and host liver. In this experimental study we evaluate the hepatic flow during APOL T. 
Methods: left lateral/medial segmental grafts were transplanted from Beagle to Dalmatian 
dogs. Grafts were preserved in UW solution (Viaspan, DuPont) until further use. Resection 
surfaces were sealed with Tissu-coll (Baxter}. Vascular structures were anastomosed end-
to-end. The effect of diversion of the portal flow was studied in three groups: in the ligation 
group (n=3) the host portal vein was tied off, the free flow group (n=6) had random flow to 
both livers. In the banding group (n=11) the host portal vein was banded with an adjustable 
strapband to restore the pre-transplantation flow distribution. Before resection of the left 
segments in the donor, after reperfusion of the graft and after intervention, the portal and 
arterial blood flow was measured with ultrasonography (T206, Transonic systems, USA). 
Results: After reperfusion the blood flow through the common portal vein (CPV) decreased 
from 49 to 36 ml/kg/min (p< 0.03) in all animals. Flow through the left portal vein (LPV) 
decreased from 26 to 5 ml/kg/min (p<0.0001 ). Banding restored the flow in the LPV to 12 
ml/kg/min, while the flow in the free-flow group remained 4 ml/kg/min. In the ligation group 
the total portal flow was forced towards the graft leading to the highest perfusion: 24 
ml/kg/min (p<0.005). Adverse effect of this ligation was the development of portal 
hypertension. 
Conclusions: This experimental study confirms that diversion of the portal flow is necessary 
for adequate graft perfusion in APOL T. Banding can restore the pre-transplantation flow 
distribution, without compromising the flow in the common portal vein. 
Abbreviations 
ALT auxiliary liver transplantation 
APOLT auxiliary partial orthotopic liver transplantation 
CHA common hepatic artery LPV left hepatic vein 
CPV common portal vein OLT orthotopic liver transplantation 
HBFI hepatic blood flow index PI pulsatility index 
LHA left hepatic artery Rl resistance index 
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Introduction 
Auxiliary liver transplantation (AL T) is an attractive alternative for standard orthotopic liver 
transplantation (OL T) in selected patients with diseases that result frorn an inborn error in 
metabolic or synthetic processes mainly involving the liver and in patients with acute liver 
failure. In the latter group, AL T aims at recovery of the native liver and withdrawal of the 
immunosuppressive therapy. In some inborn errors however there is no structural liver 
damage and complete resection of the liver and whole liver replacement is unnecessary or 
even contraindicated. In this situation AL T has potential advantages over OL T. Should 
primary nonfunction occur, this does not necessarily lead to an emergency re-
transplantation. Furthermore, with partial liver transplantation, living-related procedures are 
in focus (1-3). Also in the preserved native liver future gene therapy is still possible (4). 
Although auxiliary partial heterotopic liver transplantation (APHL T) is a less demanding 
procedure than OLT, it has never gained wide acceptance because of initial poor results (5} 
and the success of OL T. Recently auxiliary partial orthotopic liver transplantation (APOL T) 
has successfully been performed in patients with non-cirrhotic metabolic diseases (2, 3, 6-
11). 
A technical problem rising in this situation is the complicated hemodynamical status of 
the liver graft side by side with the non-cirrhotic native liver, without the increased portal 
pressure due to increased vascular resistance (oedema}, as in acute liver failure. The 
hemodynamics of liver transplantation have been studied extensively (12-14), but only few 
studies on the effect of APOL T and hepatic flow patterns have been published ( 15-17). It 
therefore still remains unclear if intervention in the portal venous inflow of the native liver is 
necessary to ensure adequate portal blood flow to both graft and host liver. In this 
experimental study we evaluate the intraoperative systemic hemodynamics and hepatic 
blood flow during APOL T in three groups of portal intervention. 
Materials and Methods 
Auxiliary partial orthotopic transplantations were performed from Beagles to Dalmatian dogs 
(n=20). The Dalmatian dog lacks a normal transport system for uric acid into the hepatocyte, 
impeding the conversion of uric acid into allantoin. This results in significantly depressed 
allantoin formation and excretion and has been used previously to evaluate the concept of 
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correcting an inborn error with heterotopic liver transplantation (18). For auxiliary segmental 
grafts, the left lateral and medial segments of the donor were split in situ to mimic a living 
related liver transplantation. The graft was isolated, immediately perfused with 1 litre cold 
University of Wisconsin solution (Viaspan, DuPont) and stored on melting ice. In the 
acceptor measurements of blood flow in the left and common portal vein and the left and 
common hepatic artery were recorded prior to resection of the left lateral and medial 
segments by perivascular transit-time ultrasonography (T206, Transonic Systems Inc, Ithaca 
NY, USA). After resection the segmental graft was placed in the orthotopic position. The 
donor left hepatic vein, left portal vein and left hepatic artery were anastomosed end to end 
to the preserved vascular pedicles of the acceptor with Ioupe magnification (figure 1 ). 
Figure 1. Adapted from D. Cherqui et al. HPB Surgery 1990; 2:193. Gordon & Breach Publishers, with 
permission. 
Implantation of the left lateral (LL) and medial segments (LM) with end-to-end anastomosis of the left 
hepatic vein (LHV), left portal vein (LPV) and left hepatic artery (LHA). Flow probes in situ for 
measurement of the portal flow in the left and common portal vein (CPV). The left hepatic bile duct 
(LHBD) was anastomosed to a Roux-Y loop. 
The left hepatic bile duct was anastomosed to a Roux-Y loop. After declamping and 
stabilisation of the circulation measurements of the hepatic blood flow were repeated. The 
effect of diversion of the portal flow on the hepatic hemodynamics was studied in three 
groups (figure 2): in the ligation group (n=3) the host portal vein was tied off, directing the 
total portal flow towards the graft. The free flow group (n=6) had random flow to both livers. 
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In the banding group (n=11 ), the host portal vein was banded with a adjustable strapband to 
restore the pre-transplantation flow distribution in terms of percentage between native liver 
and graft segments. 
Free flow (n=6) 
Figure 2. The three study groups. 
Ligation (n=3) Banding (n=11) 
A last series of measurements was performed 60 minutes later. Curve analysis was 
performed on the recorded signal with a personal computer (Burr-Brown AD-converter card) 
with multichannel registration software (MKR, AZR Dijkzigt, the Netherlands). Portal 
pressure was not routinely measured, as it was difficult to control the resulting bleeding. 
Therefore, changes in the vascular resistance between the left lateral liver lobes before 
transplantation and the liver graft after reperfusion were investigated by calculating the 
resistance index (RI), pulsatility index (PI) and hepatic blood flow index (HBFI) (19). 
Rl = (peak systolic velocity- minimum diastolic velocity) I peak systolic velocity, PI = (peak 
systolic velocity- minimum diastolic velocity) I mean systolic velocity and HBFI = (portal vein 
blood flow - hepatic artery blood ftow) I total hepatic blood flow. During transplantation, 
arterial blood pressure, central venous pressure and cardiac output were recorded at 30 
minutes intervals. Liver enzymes in arterial blood samples were determined and compared 
to assess the impact of the different interventions in the portal flow on the liver tissue. 
Recipients received cyclosporin in an oral dosage of 10 mglkg daily. Data are given as 
mean ± SEM. After testing normality with Shapiro-Wilk statistics, analysis of variance was 
performed. Otherwise non-parametrical tests were used. Repetitive measurements were 
analysed with the paired t-test or Kruskai-Wallis test. Differences were considered significant 
for p< 0.05. 
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Results 
The basic characteristics of the different groups are given in table 1. 
Table 1. Basic characteristics of the three intervention groups. 
Ligation Banding Free-flow 
(N=3) (N=11) (N=6) 
Body weight (kg) 20.0 ± 1.5 20.2 ± 0.7 20.0 ± 0.4 
Graft weight (g) 190±16 217 ± 14 201 ± 12 
Removed segments (g) 229 ± 11 227 ± 17 191 ± 13 
Cold ischemia time (min.) 185 ± 24 209 ± 10 184±13 
Warm ischemia time (min.} 70 ± 6 67 ± 4 63 ± 3 
One of the dogs died after surgery from incorrectable blood loss. During the procedure the 
mean arterial blood pressure was 94 ± 4 mm Hg at the onset of surgery, 85 ± 4 mm Hg after 
reperfusion and 80 ± 4 mm Hg one hour after portal flow intervention for all groups together; 
there were no significant differences between groups. Cardiac output measured at the same 
intervals was 3.7 ± 0.2, 3.3 ± 0.2 and 3.2 ± 0.2 1/min. The central venous pressure was 2.6 ± 
0.8, 2.5 ± 0.8 and 1.8 ± 1.0 mm Hg respectively, without significant differences between 
groups. Before transplantation the blood flow through the common portal vein (CPV) was 49 
± 4 ml/kg/min (figure 3), of which 26 ± 3 ml/kg/min (i.e. 52%) went to the lefl portal vein 
(LPV). Directly after reperfusion, but before intervention, the total portal inflow decreased to 
36 ± 3 ml/kg/min (p< 0.03). The flow to the LPV decreased dramatically to 5 ± 1 ml/kg/min: 
only 16% of the flow in the CPV (p<0.0001 ). The effect of artificial diversion of the portal flow 
at 1 hour after intervention is given in figure 4. In the banding group (n=11) the flow in the 
LPV in terms of percentage was restored to 43% (12 ml/kg/min) of the flow in the CPV, while 
the flow in the free-flow group (n=6) remained as low as 20% (4 ml/kg/min) of that in the 
CPV. In the ligation group (n=3) the total portal flow was forced towards the graft leading to 
the highest perfusion: 24 mllkg/min; p<0.005. Adverse effect of the ligation was the 
development of portal hypertension in all three animals with congestion of the small bowel 
and spleen. Portal pressure measurements of 11-14 mm Hg (norma16 mm Hg) (18) proved 
the clinical observation in these animals. In one case the ligature had to be removed not to 
endanger survival. Simultaneously recorded arterial flow patterns showed a flow of 12 ± 1 
mllkg/min in the common hepatic artery (CHA) before transplantation of which 5 ± 0.7 
ml/kg/min went through the left hepatic artery (LHA). After reperlusion this decreased to 8 ± 
1 ml/kg/min (p< 0.01) and 3 ± 0.5 ml/kg/min (p<0.0001) respectively (figure 5). No 
compensatory effect was observed in the arterial inflow after intervention in the portal 
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system (figure 6). The arterial flow towards the graft and native liver was 2 ± 0.5 and 4 ± 1 
ml/kg/min in the free-flow group, 2 ± 0.8 and 6 ± 1 ml/kg/min in the banding group and 2 ± 
0.6 and 5 ± 2 mllkg/min in the ligation group (p=NS). 
The values for the resistance index (RI), pulsatility index (PI) and hepatic blood flow 
index (HBFI) are given in table 2 for the left lateral and medial liver lobes (before 
transplantation) and the graft. After reperfusion decreased portal flow to the graft affects the 
HBFI (p<0.02), while the Rl and PI, which are parameters of arterial resistance, are relatively 
unimpaired. Restoration of the portal blood flow normalised the HBFI in the banding and 
ligation group. 
Table 2. Rl, PI and HBFI of the native liver lobes before resection and of the graft after 
transplantation. 
Resistance 
Index 
Pulsatility 
Index 
Hepatic 
blood flow 
Index 
Before 
Resection 
After 
reperiusion 
0.61 ± 0.04 0.65 ± 0.06 
1.10 ± 0.15 1.60 ± 0.40 
0.66 ± 0.04 0.22 ± 0.15 
(p<0.04) 
1 hour after intervention 
Free-flow 
(N=6) 
0.78 ± 0.08 
1.56 ± 0.30 
0.32 ± 0.29 
Banding 
(N=11) 
0.81 ± 0.07 
2.44 ± 0.87 
0.66±0.10 
Ligation 
(N=3) 
0.63 ± 0.11 
1.06 ± 0.32 
0.82 ± 0.04 
Histopathological examination of biopsies taken at the end of the procedure revealed 
severe damage with swelling, steatosis and moderate to severe necrosis in grafts in the 
free-flow group, consistent with portal hypoperfusion. Grafts in the banding group only 
showed evidence of handling damage with mild steatosis and sporadic necrotic hepatocytes. 
Grafts in the ligation group showed widened hepatic sinusoids and moderate necrosis as 
signs of congestion. In two dogs (1 banding, 1 free-flow) dilation of the sinusoids was seen, 
possibly indicating hepatic outflow problems, but clinical congestion was not seen in these 
dogs. In the dog in the free-flow group metabolic correction of the inborn error decreased 4 
days after transplantation, but a biopsy taken on day 7 after transplantation showed normal 
hepatic architecture. 
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Levels of ASAT, ALAT, alkaline phosphatase and y-GT measured after reperfusion and at 
the end of the procedure showed no differences between the study groups. Transaminases 
increased between reperfusion and the end of surgery from 433 ± 73 to 586 ± 79 U/1 (ASAT) 
and 585 ± 110 to 857 ± 123 U/1 (ALAT) with similar increment in all three groups. 
Discussion 
Auxiliary partial orthotopic liver transplantation is an attractive alternative for orthothopic liver 
transplantation in patients with some metabolic disorders and in patients with acute liver 
failure. In the latter group regeneration of the native liver is to be expected and auxiliary liver 
transplantation can prevent life-long immunosuppressive therapy (20). The theoretically 
attractive concept of heterotopic liver transplantation in this situation never gained wide 
acceptance because it was initially hampered by technical problems and later overcome by 
the success of the OL T. 
In 1990 the first successful clinical APOL T was performed for acute liver failure, in 
which a segment II I Ill graft was placed in the orthotopic position after creating space by 
resection of the corresponding segments in the acceptor (21). In this situation no additional 
precautions are necessary to ensure portal inflow in the graft as the vascular resistance in 
the swollen native liver is expected to be much higher and gradual atrophy of the graft after 
native liver regeneration is aimed for. In 1993 APOLT proved to provide total metabolic 
correction in a patient with Crigler-Najjar syndrome (6) and since then APOLT procedures 
for other inborn errors of hepatic metabolism have been described in 14 patients (2, 3, 7-11). 
It became evident that the complicated hemodynamic situation of the liver graft side by side 
with the non-cirrhotic native liver led in some of these patients to competition for the portal 
inflow between the native liver and graft (3, 6, 9, 11), requiring banding or ligation of the 
native portal vein. 
In this experimental study we investigated the acute portal redistribution in the situation 
of APOL T for metabolic disease, in which portal hypertension is absent. The flow distribution 
in this experiment was studied by direct transit-time ultrasound measurements with 
perivascular adjustment of the probes, assuring accurate measurements (22) and 
preventing technical problems with the angle of insonation (19). In our study the decrease in 
portal flow to the graft after repetfusion was more marked than in the experimental studies of 
Then et al. (17) and Yabe et al. (15), but the values of portal flow towards the graft are 
comparable to the results found by Kaibori et al. (11) in clinical paediatric APOLT. The 
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decrease was found in all animals without signs of acute rejection on histology. Therefore 
this was probably caused by the parenchymal swelling in the portal fields due to 
preservation and handling damage, despite careful dissection technique and standard 
harvesting procedure with short preservation times. The resistance index - a marker for 
arterial obstruction and early reperfusion reaction (23, 24) - did not increase significantly 
and the arterial pulsations did not show a dampened waveform in the pulsatility index, 
indicating good arterial patency (25). Without intervention, portal inflow towards the graft 
remained marginal, whereas ultrasound-guided intervention with an adjustable strapband 
could restore the pre-transplantation flow distribution in terms of percentage, without 
compromising the flow in the common portal vein. Ligation of the portal vein of the native 
liver led to portal hypertension as the total portal flow was forced into a liver graft comprising 
about 40% of the total liver weight. Remarkable was the absence of a reactive increase in 
arterial inflow towards the native liver after cessation of the portal inflow in the ligation group, 
which was described in orthotopic liver transplantation and abdominal surgery (13, 26, 27). 
In conclusion, this experimental study confirms that in the complicated situation of an 
auxiliary partial orthotopic liver graft co-existing with a partial non cirrhotic native liver, 
occlusion of the portal flow towards the native liver is essential for adequate graft perfusion. 
Acute total ligation of the host portal vein may interfere with the life supporting function of the 
native liver in case of a primary graft dysfunction and lead to unacceptable portal 
hypertension in this model. Without intervention the portal fiow is deviated from the graft, 
leading to poor perfusion and severe damage on histology. Partial banding under 
intraoperative transit-time ultrasonography, aimed at restoration of the pre-transplantation 
fiow distribution, leads to adequate graft perfusion, without compromising the total portal 
blood flow. 
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Abstract 
After auxiliary partial orthotopic liver transplantation for inborn errors of metabolism, finding a 
balance in portal blood flow distribution between native liver and graft is complicated. We 
investigated the correction of hypoallantoinuria in the Dalmatian dog with a reduced-size 
Beagle orthotopic auxiliary liver graft, depending on intra-operative intervention in the portal 
flow. 
There were three groups: a ligation group, where the host portal vein was tied off, a free-flow 
group with random flow to both livers and a banding group, were the host portal vein was 
banded with an adjustable strapband. Metabolic correction was initially seen in all groups, 
but ligation led to portal hypertension and early mortality. In the free-flow group, correction 
was lost after 7 days, while banding preserved correction until 6 weeks. We conclude that 
acute ligation can lead to portal hypertension and free-flow leads to hypoperfusion and early 
loss of metabolic correction. Banding divided the portal blood flow between host liver and 
graft and prolonged metabolic correction. 
Abbreviations 
AL T auxiliary liver transplantation 
APOL T auxiliary partial orthotopic liver transplantation 
Cl confidence interval 
NS not significant 
OL T orthotopic liver transplantation 
POD postoperative day 
ROI region of interest 
Introduction 
Auxiliary liver transplantation, in which a (reduced-size) graft is placed in the recipient and 
the diseased liver is lett in place, has potential advantages over standard whole liver 
replacement by orthotopic liver transplantation. In children with some life threatening inborn 
errors of hepatic metabolism, only one enzyme or cell membrane receptor is absent and 
they have an otherwise normal function of the liver. In this case auxiliary liver transplantation 
provides the missing metabolic function, while the native liver supports the total liver 
function. 
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Should primary graft non-function or severe rejection occur, this does not necessarily 
lead to an emergency re-transplantation. (1, 2) Furthermore, with partial liver transplantation, 
future gene therapy is still possible in the preserved native liver (3, 4). The first auxiliary 
transplantation was performed as an auxiliary partial heterotopic liver graft (APHL T) in 1964 
(5), but never gained wide acceptance because of disappointing results. Potential problems 
of APHL T were the lack of space in the abdomen, causing compression on large vessels 
and the disturbance of portal inflow and venous drainage (6). Recently, auxiliary partial 
orthotopic liver transplantation (APOL T), in which a reduced-size graft orthotopically 
replaces the resected liver lobe in the recipient, has successfully been performed in patients 
with non-cirrhotic metabolic diseases (2, 7-12). 
The complicated division of portal blood between the liver graft side by side with the non-
cirrhotic native liver is the critical issue at the time of surgery and of major importance to 
intermediate and long-term graft survival is. Without an increased vascular resistance in the 
native liver due to cirrhosis or collapse, the portal flow is preferentially towards the native 
liver (13). To investigate the requirements for intermediate-term metabolic correction of an 
inborn error of metabolism, a 60% Beagle liver graft was transplanted into the Dalmatian 
dog. Graft function was evaluated by correction of the metabolic defect in three groups with 
different distribution of the portal flow at the time of surgery. 
Materials and Methods 
Auxiliary partial orthotopic liver transplantation was performed from 20 Beagles to 20 
Dalmatian dogs according to the guidelines for animal experiments of the Erasmus 
University. The Dalmatian dog lacks a normal transport system for uric acid into the 
hepatocyte, which impedes the conversion of uric acid into allantoin and results in 
significantly depressed allantoin formation (14). Of this formed allantoin, 94% is excreted in 
urine by renal clearance (15) and the ratio of allantoin I creatinin in urine proved to be nearly 
constant, allowing correction for daily variations in renal function. For auxiliary partial grafts, 
the left lateral and medial segments of the donor were split in situ to mimic a living donor 
liver transplantation. The graft was isolated, immediately perfused with 1 litre of cold 
University of Wisconsin solution (Viaspan, DuPont) and stored on melting ice. 
In the recipient the left lateral and medial segments of the liver were resected and the 
partial graft was placed in the orthotopic position. The donor left hepatic vein, left portal vein 
and left hepatic artery were anastomosed end to end to the preserved vascular pedicles of 
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the recipient, using 5x Ioupe magnification. The hepatic bile duct of the graft was 
anastomosed to a Roux-Y loop. Recipients received a blood transfusion from the liver donor. 
The effect of diversion of the portal flow on post-operative graft function was studied in three 
non-randomised groups. In the ligation group (n=3) the host portal vein was tied off, directing 
the total portal flow towards the graft. The free flow group (n=6) had random flow to both 
livers. In the banding group (n=11 ), the host portal vein was banded with an adjustable strap 
band to restore the pre-transplantation flow pattern in terms of percentage of the total portal 
flow between native liver and graft segments. The distribution of portal flow was monitored 
with simultaneous perivascular transit-time ultrasonography (T206, Transonic Systems lnc, 
Ithaca NY, USA) of the common and left portal vein (13). Recipients received Cyclosporin A 
(Novartis, Arnhem, The Netherlands) in an oral dosage of 15 mg/kg/day, but rejection was 
not monitored. Changes in allantoin levels were measured weekly in urine samples, 
collected over 24 hours. Graft function was determined by urinary excretion of allantoin (16). 
Liver function of both graft and host liver was further quantitated at 4 weeks after 
transplantation by the uptake of 99MTc labelled dimethyl-iminodiacetic acid (99MTc-HIDA, 74 
MBq). Dynamic acquisition was performed with a Pho gamma V camera (Siemens, 
Gammasonics, the Netherlands) equipped with a low energy all-purpose collimator. Regions 
of interest were drawn around the native liver and the graft and the uptake of HIDA between 
4 and 16 minutes after injection, corrected for background activity, was used to calculate the 
relative uptake of the graft. Autopsy and registration of the wet liver weight was performed in 
all animals. Surviving animals were sacrificed 50 days after transplantation. All data are 
presented as mean ± standard error. Differences between pre- and post transplantation 
excretion ratio's were detected by paired t-test analysis. Linear regression was calculated 
with analysis of variance (ANOVA). Graft survival was analysed by the method of Kaplan-
Meier with log rank statistics. Loss of graft function was scored when the excretion ratio of 
allantoin in urine after transplantation reached the 95% confidence interval of the pre-
transplantation level (mean ± 2 standard deviations, i.e. 0.15 - 0.58). Differences were 
considered significant when P was less than 0.05. 
Results 
Pre-transplantation excretion ratio of allantoin I creatinin was 1.75 ± 0.22 in Beagles and 
0.38 ± 0.03 in Dalmatian dogs (95% confidence interval: 0.15-0.58). Operation time was 348 
± 10 minutes, with a mean loss of blood of 1221 ± 192 mi. Cold and warm ischaemia times 
were 198 ± 9 and 67 ± 3 minutes respectively, with no differences between groups. 
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Ligation group: 
Acute ligation of the host portal vein led in our model to unacceptable portal hypertension 
with rupture of the capsule of the graft, congestion of the small bowel and diffuse oozing 
from the splen ic area in al l dogs in this group. Histology sections taken 5 minutes after 
reperfusion of the graft showed oedema and necrosis in the portal area (figure 1 ). Two dogs 
died from intra-abdominal bleeding at post-operative day 3 and 4 with poor graft function. 
Excretion ratio of allantoin I creatinin at the first post-operative day was 0.88 ± 0.20, not 
significantly different from pre-transplantation. In the third experiment again portal 
hypertension occurred during the procedure after total ligation. It was decided to convert into 
banding to release portal hypertension and not endanger survival. Hereafter ligation of the 
host portal vein was no longer performed. 
Free-flow group: 
Figure 1. Histology 
section taken 5 
minutes after 
reperfusion in the 
ligation group, 
showing portal 
oedema and 
necrosis. 
In 7 dogs the portal flow distribution between graft and host liver was not altered during the 
operation. Mortality in this group was high with 517 dogs (71 %) dying before the end of the 
experiment. Mean survival of the dogs was 17 ± 8 days, median 7 days. The allantoin I 
creatinin ratio increased to 1.11 ± 0.14 after transplantation (P<0.001 compared to pre-
transplantation level), but metabolic correction was not longer significantly different from pre-
transplantation levels at day 12 after transplantation (figure 2). Mean graft function lasted 10 
± 4 days with a median of 6 days (figure 3). At autopsy thrombosis of the graft portal vein 
was seen in 3 of the 7 dogs in the free-flow group. 
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Figure 2. Excretion ratio of allantoin I creatinin in urine. 
Metabolic correction lasted unti l sacrifice in the banding group (•). In the free-flow group (e) 
a loss of graft function was seen by day 12, where in the ligation group (.A) no significant 
correction was observed and dogs died of portal hypertension on postoperative day 3 and 4. 
a: p<0 .01 versus pre-transplantation ratio, b: p<0.05 versus pre-transplantation ratio. ---------: 
95% Confidence interval of the pre-transplantation al lantoin excretion ratio. 
Figure 4. In the grafts lasting until sacrifice, a moderate to severe fibrosis and mainly 
lymphocellu lar infiltrate in the portal area was observed 
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Figure 3. Kaplan-Meier curve of graft survivaL Mean graft function lasted 10 ± 4 days 
in the free-flow group(-----, censoring animals 1111) and 37 ± 10 days in the banding 
group (---, censoring animals llll : p<0.05). 
Banding group: 
Intra-operative banding of the host portal vein was performed in 11 dogs. In this group, 8 of 
the 11 dogs died before the end of the experiment (72%). Mean survival was 21 ± 6 days 
with a median of 14 days, not significantly different from the free-flow group. Metabolic 
correction increased to 1.17 ± 0.10 (p<0.001 compared to pre-transplantation levels) and 
sustained until sacrifice (figure 2). Mean graft function lasted 37 ± 10 days (median 17, P< 
0.05 vs. free-flow). At autopsy, portal thrombosis was seen in 4/11 dogs. 
In table 1 the wet liver weight at autopsy is shown. There were no significant 
differences in graft weight between groups. Histopathological examination showed moderate 
to severe hepatocellular necrosis, mostly with signs of sepsis or congestion of the central 
vein, in the grafts of dogs that died within a week after transplantation (n=9). In the grafts 
lasting until sacrifice, a moderate to severe fibrosis and mainly lymphocellular infiltrate in the 
portal area was observed (figure 4). 
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Table 1. Wet liver weights at autopsy. All grafts had increased in weight compared to their 
pre-transplantation weight. Grafts in the free-flow group showed more oedema, but 
differences were not significant between groups. 
Host liver (g) Graft (g) Total (g) 
Free-flow 554 ± 90 402 ± 73 (188%)' 
340 ± 64 (148%)' 
333 ± 108 (180%)' 
955 ± 149 
Banding 566 ±52 906 ± 97 
Ligation 515±139 815 ± 62 
• Increment in graft weight compared to the weight at the time of transplantation. 
In figure 5 the metabolic correction at the time of 99MTc-HIDA scanning is plotted against 
the relative graft contribution to the total HIDA uptake. 11 Scintigraphies could be performed 
in 9 dogs (11 dogs died before the first scan was made). There was a statistically significant 
correlation between proportional correction of the inborn error and the graft contribution to 
the total HIDA uptake (r=0.67; p<0.05). 
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Figure 5. Correlation of HIDA-uptake and allantoin excretion in urine. 
11 Scintigraphies were performed in 9 dogs. Graft contribution to the total HIDA-uptake 
during scintigraphy correlated significantly with the urinary allantoin level; r=0.67; p<0.05. 
---------: 95% pre-transplantation confidence interval of the allantoin excretion ratio. 
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Discussion 
Auxiliary partial orthotopic liver transplantation is an attractive alternative for standard 
orthothopic liver transplantation in patients with specific disorders of hepatic metabolism and 
in patients with acute liver failure. In the latter group the graft can provide temporary life 
support, while regeneration of the native liver is to be expected and thus auxiliary liver 
transplantation can prevent life-long immunosuppressive therapy (17). In 1990 the first 
successful clinical APOLT was performed for acute liver failure, in which a segment II I Ill 
graft was placed in the orthotopic position (18). In this situation no additional precautions 
were necessary to ensure portal inflow in the graft as the vascular resistance in the native 
liver is expected to be much higher and gradual atrophy of the graft after native liver 
regeneration is aimed for. 
In 1993 APOLT proved to provide total metabolic correction in a patient with Crigler-
Najjar syndrome (2) and since then APOL T procedures for other inborn errors of hepatic 
metabolism have been described in 14 patients (7-12, 19). In some of these patients the 
host portal vein was banded during transplantation (2, 10), in other cases the host portal 
vein had to be ligated after initial successful transplantation without intervention to guarantee 
adequate perfusion of the graft (8, 19). The complicated hemodynamic situation of the liver 
graft - side by side with the non-cirrhotic native liver - leading to competition for the portal 
inflow between the native liver and graft is still a critical issue at the time of surgery and of 
major importance to intermediate and long-term graft survival. 
In a previous study we assessed the results of intervention in the portal inflow in a 
model of auxiliary heterotopic liver transplantation (20). In this situation a 60% Beagle graft 
was placed under the native liver and metabolic correction was studied for 180 days. Acute 
ligation of the portal vein led in this model to moderate portal hypertension, but this had no 
clinical consequences and metabolic correction was good. Without intervention in the portal 
flow, metabolic correction was lost after 12 days and mortality was 66% due to sepsis from 
necrotic grafts. Banding of the portal vein to the native liver led to initial good metabolic 
correction, which decreased after 84 days due to late portal thrombosis of the graft. Mortality 
in this group was 25% and chronic rejection (which was not monitored) was found at 
autopsy. 
In the present experimental study the effect of intraoperative intervention in the portal 
flow on graft perfusion was recorded and the effect on postoperative metabolic correction is 
for the first time assessed for APOL T. In the free-flow group, allowing free distribution of 
portal inflow between graft and native liver resulted in early loss of metabolic correction. 
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Hypo-perfusion of the graft led to portal thrombosis and mortality was high due to sepsis 
from necrotic grafts, in accordance with the results of our heterotopic experiment. 
Acute ligation of the host portal vein led in our model to portal hypertension. Two dogs 
died of bleeding from the splenic area and showed congestion of the portal vein in histology 
sections. At autopsy no evidence could be found for stenosis in the hepatic vein 
anastomosis. At the time of surgery, portal inflow in these grafts was forced from 5 ml/kg/min 
without intervention to 24 ml/kg/min after ligation. We assume that a hyperperfusion 
syndrome occurred in which portal inflow exceeded hepatic outflow and this resulted in a 
relative venous outflow obstruction. 
Primary ligation of the native portal vein was clinically performed by Kaibori et al. (19) 
and further assessed in an experimental study by Yabe et al. without problems of portal 
hypertension (21 ). In the study of Yabe, 2/7 dogs died before sacrifice at day 5 from 
unknown causes but histologic findings were not given. An explanation for the difference 
with our own results in the heterotopic experiment may be that in the present study the total 
portal flow was forced into a liver graft comprising about 40% of the total liver weight. 
According to the results of Yabe et al. (8, 21) we found no evidence that ligation of the native 
portal vein had detrimental effects on the native liver supplied by arterial flow only. 
Banding of the host portal vein provided metabolic correction until the end of the 
experiment, although the correction decreased within time. Loss of metabolic function during 
follow-up was accompanied by portal thrombosis 4 of the 11 dogs and can be explained by 
increased vascular resistance in the graft secondary to infection and rejection. Regarding 
the problem of late portal thrombosis, a gradual occlusion of the host portal vein as 
performed by Hirayama et al. (22) may be an attractive solution. This can assure optimal 
graft function without the risk of portal hypertension. In the banding group we found no 
evidence for promoted regeneration of the graft liver and atrophy of the native liver. Although 
all grafts had increased in weight compared to their pre-transplantation weight, there were 
no differences between groups. The interval after transplantation was probably too short for 
hypertrophic changes. Grafts in the free-flow group showed more oedema, which might be 
caused by the shorter interval between transplantation and autopsy in most animals in this 
group. 
Also essential for success in auxiliary liver grafting is the determination of the liver 
mass that has to be transplanted for correction of the inborn error. In some metabolic 
diseases probably not more than 1-2% of the total liver volume is required (23). In our study 
there was no absolute correlation (r=0.67) between HIDA-uptake and allantoin synthesis. 
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Adequate metabolic correction was seen in a graft that contributed 8% to the total uptake of 
HID A, indicating a critical liver mass of about 10% of the functional liver weight for this 
specific inborn error. 
In conclusion, this experimental study shows that an auxiliary partial orthotopic liver 
graft can correct the inborn error of metabolism, but that an adequate portal flow to the graft 
is required for sustained graft function. Acute total ligation of the host portal vein leads to 
portal hypertension with congestion of the parenchyma and early death in our model. 
Without intervention, the portal flow is preferentially to the native liver, leading to poor 
perfusion and early loss of metabolic function of the graft. Partial banding, aimed at 
restoration of the pre-transplantation flow distribution, gives the best metabolic correction. 
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Abstract 
Background. Primary graft dysfunction (PGDF) occurs in 5-15% of the patients after liver 
transplantation. PGDF is attributed to cold storage, warm ischemia and reperfusion, which 
cause damage to the vascular endothelium. Poor tissue perfusion ultimately results in 
mitochondrial dysfunction with loss of ATP. Recently, direct inhibition of mitochondrial 
respiration by reaction products of nitric oxide (NO) was described. In this study the 
expression of the inducible NO synthase (iNOS), the formation of nitrotyrosine and the 
relation with adenine nucleotide levels was assessed in patients with and without PGDF. 
Methods. INOS and nitrotyrosine were determined immunohistochemically, adenine 
nucleotide levels were measured and transition electron microscopy was performed in liver 
biopsies of 8 patients with and 16 patients without PGDF. 
Results. In patients with PGDF, ATP decreased from 6.1 ~mol/gat the end of cold ischemia 
to 3.5 after reperfusion. In control patients, ATP increased from 3.5 at the end of cold 
ischemia to 6.8 ~mol/g after reperfusion (P<0.05). The energy charge was significantly 
higher in the control patients after reperfusion (0.57 versus 0.47, P<0.05). Electron 
microscopy confirmed poor mitochondrial function in patients with PGDF as soon as 1 hour 
after reperfusion. iNOS and nitrotyrosine showed abundant staining, mainly in the 
hepatocellular cytoplasm, without differences between PGDF and control patients . 
Conclusions. Mitochondrial dysfunction in patients with PGDF is present after reperfusion, 
leading to the inhibition of ATP synthesis. Although nitration of cell structures was present 
during preservation and reperfusion, this does not cause mitochondrial dysfunction, as NO 
formation and nitrotyrosine residues also were present in patients with excellent 
postoperative liver function. 
Abbreviations 
AST Aspartate amino transferase 
iNOS Inducible nitric oxide synthase 
HE Hematoxylin/eosin 
HPLC High performance liquid chromatography 
NO Nitric oxide 
OL T Orthotopic liver transplantation 
ONOO" Peroxynitrite 
PGDF Primary graft dysfunction 
TAN Total adenine nucleotides 
TEM Transition electron microscopy 
UW University of Wisconsin 
90 
Mitochondrial nitration and PGDF 
Introduction 
Primary graft dysfunction (PGDF) occurs after liver transplantation in 5-15% of the patients 
(1-3), despite the introduction of special preservation solutions like the University of 
Wisconsin (UW) or histidine-tryptophane-ketoglutarate (HTK) solution (4-6). PGDF is 
defined as a dysfunction of the donor liver in the first week after transplantation with an AST 
level > 2500 U/L and a prothrombine time > 16.5 seconds, in absence of vascular 
complications or acute rejection (7). The pathogenesis of PGDF is attributed to cold storage 
of the liver, which activates sinusoidal macrophages (Kupffer cells) and induces preservation 
injury to endothelial cells with progressive loss of viability (8-13). Subsequent reperfusion 
causes a plethora of reactions involving nitric oxide (NO), reactive oxygen species, 
cytokines and eicosanoids (14-17). Leukocyte margination and platelet adherence in the 
damaged sinusoids may lead to poor tissue perfusion and to poor oxygen delivery to the 
hepatocytes (18-21 ). Ultimate result of this ischemia I reperfusion damage is mitochondrial 
derangement with a loss of ATP synthase activity and reduction of ATP levels (22-30). 
However, recently an alternative hypothesis for the cause of mitochondrial dysfunction 
was proposed. In several experimental studies, a direct inhibition of mitochondrial respiration 
of cytochrome oxidase and complexes I and IV was found by reaction products of NO and 
the superxide radical 02 (31-38). The main product of this reaction is peroxynitrite (ONOO'), 
a potent nitrating and oxidizing agent with a high affinity for thiol (R-SH) structures. 
Peroxynitrite is held responsible for damage to numerous biologic targets by oxidizing thiols 
and removing iron from the iron-sulfur centres (39). Additionally, peroxynitrite can react with 
tyrosine residues to produce nitrotyrosine (40-42), which was shown to increase 900% after 
preservation and reperfusion in an experimental model (43). Ohsima et al. first proposed the 
stable end product nitrotyrosine as an in vivo indicator of nitration (44) as it is almost 
exclusively produced by peroxynitrite (45). 
In this study we investigated the hypothesis that mitochondrial dysfunction in clinical 
PGDF is caused by peroxynitrate. The expression of the inducible NO synthase (iNOS) and 
formation of nitrotyrosine was assessed and related to the adenine nucleotide levels and 
electron microscopic findings in liver biopsies during cold storage and reperiusion in 24 
patients with and without PGDF. 
Materials and Methods 
From October 1998 to June 2000, 68 orthotopic liver transplantations were performed at the 
Erasmus University Medical Center Rotterdam. Liver biopsies were taken routinely from the 
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donor livers in these patients. Biopsies were taken from the left liver lobe at 3 stages during 
the procedure. 1) At the end of the cold ischemia, when the donor liver was taken from the 
ice, 2) at the end of the warm ischemia, when all vascular anastomoses were completed and 
3) one hour after reperfusion of the donor liver. The biopsies were divided into 3 pieces. One 
piece was snap-frozen in liquid nitrogen to perform analysis of the intracellular adenine 
nucleotide content (ATP, ADP and AMP). One piece was fixed in 2% glutaraldehyde to 
perform electron microscopy. A third piece was formaldehyde fixed and used for normal 
hematoxylin/eosin (HE) staining and immunohistochemical staining of inducible nitric oxide 
synthase (iNOS) and nitrotyrosine. 
In 8 cases (12%) postoperative primary graft dysfunction (PGDF) was diagnosed by 
elevation of AST >2500 U/1 and a prothrombin time > 16.5 seconds on the 2nd to 7th post-
operative day. Vascular occlusion or acute rejection were ruled out in these patients. 
Biopsies of these 8 patients were compared with the biopsies of 16 control patients without 
PGDF, transplanted in the same period. 
Analysis of adenine nucleotide content. 
The nucleotide content was measured using the method of Sellevold et al. (46). Briefly, 
biopsies were homogenized by 2-3 minutes of shaking in a liquid nitrogen pre-cooled Teflon 
cup in a mechanical homogenizer (Micro-Dysmembrator, Braun, The Netherlands) with 500 
~I of 4% HCI04. The homogenate was neutralized with KOH (2M) and K,co, (1 M) to pH 6-
6.5. After precipitation, the extract was spun down in an Eppendorff centrifuge for 3 min. at 
1 Ox g. The supernatant was kept on ice until injection of 20 ~I into the HPLC system. The 
pellet was used for determination of the protein content according to the method of Lowry. 
The HPLC system consisted of a Waters model 600E system equipped with a model 484 
UV detector and Millenium integration software package (Waters, Milford, MA, USA). 
Adenosine tri-, di- and mono- phosphates were separated over a C-18 reversed-phase 
column (~Bondapack, 10 3.0 mm, Waters, USA) with a guard column. The mobile phase 
contained 175 mM potassium dihydrogen phosphate, 2.3 mM tetrabutylammonium hydrogen 
sulfate and 2.5% acetonitril. After adjusting the pH to 6.25 with KOH, the solution was 
filtered through a 2~m cellulose filter (Millipore, Bedford, USA) and degassed before use. 
Eluting peaks were detected at 214 nm and quantified against an external standard. The 
total adenine nucleotide content (TAN= ATP + ADP + AMP) and the adenylate energy 
charge (EC = ATP + 1/2 ADP I [ATP + ADP +AMP]) were calculated. The EC denotes the 
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part of energy directly available for energy demanding cell processes without further use of 
metabolic pathways. 
Transition electron microscopy (TEM) 
TEM was performed on about 1 mm3 of liver tissue after immersion fixation overnight in 2% 
glutaraldehyde I 0.1 M cacodylate buffer. After washing with the same buffer, the tissue was 
postfixed for 2 hours in 1% osmium tetroxide. The specimens were dehydrated through a 
graded series of ethanol and propylene oxide and embedded in Epon. Ultra-thin sections 
were stained with uranyl acetate followed by lead citrate. The sections were examined and 
photographed with a JEOL JEM-200CX electron microscope (Jeo! Ltd, Japan). 
Immunohistochemistry and histology 
The major portion of each biopsy was fixed in formalin, embedded in paraffin and part of 
these sections was routinely stained with HE. Specific criteria including cholestasis, severity 
of steatosis, cellular swelling and inflammation were blindly assessed by the pathologist. In 
corresponding sections immunohistochemistry was performed after deparatfinisation, 
dehydration, unmasking with saponin and inactivation of endogenous peroxidase activity 
with H202. Tissue sections were stained for inducible nitric oxide synthase (iNOS) and 
nitrotyrosine. Nitrotyrosine can be formed in the reaction NO + 02.----7 peroxynitrite +tyrosine 
residue----7 nHrotyrosine. To detect protein tyrosine n·ltrosylation, a polyclonal rabbit anf1-iNOS 
antibody (Santa Cruz biotechnology) and monoclonal mouse anti-nitrotyrosine antibody, 
kindly provided by prof. Dr. WA Buurman, University hospital Maastricht, the Netherlands 
(47) were used. Control samples were processed without the second antibody to check for 
aspecific staining. Specificity of nitration was tested by reducing nitrotyrosyl residues by 
anaerobic incubation with sodium di-thionite (48) before staining. 
Statistical analysis. 
Eight patients with PGDF were matched with 16 control patients transplanted in the same 
period, to correct for confounding factors in the transplantation procedure. A 2-to-1 match 
was performed to detect a clinical relevant difference of 25%, with a calculated SE of 15%, 
90% power and a significance level of 2.5% on both s·1des follow"1ng Altman's nomogram for 
sample size (49). Repeated measurement analysis showed within subject independence of 
ATP level from sample time. Statistical analysis was performed with Student's T-test and 
paired T -test after testing normality with the Shapiro-Wilk statistic. If the data were not 
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normally distributed, the Mann-Whitney U-tes! was used. For 2x2 table analysis Fisher's 
exact test was used. A p-value <0.05 was considered statistically significant. 
Results 
Clinical course 
Eight patients with PGDF were compared to 16 control patients, transplanted in the same 
period as the patients in whom PGDF occurred. Characteristics of the transplantation 
procedure are given in table 1. There were no significant differences ibetween the two 
groups, except for the duration of the warm ischemic period, which was about 10 minutes 
longer in the control group, p<0.05. As expected by definition, AST and PT levels were much 
higher in the patients with PGDF (figure 1 a and b). Repeated measure analysis showed 
significant within-subject dependence, but differences were statistically significant from 
control patients at day 5 (AST) and at day 4 (PT), p<0.05. Three of the 8 patients with PGDF 
(38%) were scheduled for re-transplantation. Eventually 2 patients received an emergency 
graft in time, the third patient died after 3 days from cerebral edema. Of the 2 re-
transplanted patients, 1 died after 14 days of fungal sepsis and therefore 1-month mortality 
was 25% in the PGDF patients. Of the control patients, 1 patient died after 28 days from 
sepsis, another patient was successfully re-transplanted for hepatic artery thrombosis after 4 
days. 1-Month mortality was 6%. Patients with PGDF had a 6-month graft and patient 
survival of both 63%. In control patients these results were better, but with 75% and 82% 
respectively the differences were not significant. 
Table 1. Characteristics of the patients with PGDF and control patients. 
Control patients (N=16) PGDF (N=8) P-value 
Male I Female 10 I 6 612 N.S. 
Recipient age (yr) 46 ±3 39 ±6 N.S. 
Donor age (yr) 40 ± 3 49 ± 3 N.S. 
Donor- acceptor: 
Sex mismatch 8116 618 N.S. 
Blood group mismatch 4116 118 N.S. 
Cold ischemia time (min) 632 ± 32 621 ±50 N.S. 
Warm ischemia time (min) 79 ± 5 62 ± 7 0.05 
Total ischemia time (min) 711 ± 34 683 ± 49 N.S. 
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Adenine nucleotide metabolism 
In patients with PGDF, the total adenine nucleotide (TAN) content at the end of the cold 
ischemic period was significantly higher than in control patients (33.0 versus 16.8 nmol/ mg 
protein, p<0.05). However, this high TAN content decreased significantly to 13.3 nmol 1 mg 
protein after reperfusion (40%, table 2). The decrease was caused by a loss of ATP (from 
6.1 to 3.5), ADP (from 14.7 to 5.4, p=0.04) and AMP (from 12.2 to 4.5, p<0.01). The TAN 
level in control patients initially decreased to 13.1 nmol I mg protein during the warm 
ischemic period, but tended to increase again to 17.9 nmol/mg after reperfusion. 
The amount of ATP present at the end of the cold ischemic period was also significantly 
higher in patients with PGDF (6.1 versus 3.5 nmollmg, p<0.05), but ATP levels decreased 
during the warm ischemic period and there was no de novo generation of ATP after 
reperfusion (figure 2). In contrast, control patients had low ATP levels at the end of the cold 
ischemic period, but their ATP levels increased after reperfusion, indicating mitochondrial 
recovery. 
Table 2. Adenine nucleotide content in control patients and patients with PGDF during 
preservation and reperfusion. 
ECI EWI Rep+ 60' 
PGDF Control PDGF Control PDGF Control 
AMP 12.2±1.9 8.1±1.7 11.4±2.1 5.7±1.1# 4.5±0.7 5.0±1.2 
ADP 14.7±3.0 5.2±1.1# 10.2±1.2 4.3±0.5' 5.4±1.3 6.1±0.9 
ATP 6.1±1.0 3.5±0.7# 3.9±0.8 3.7±0.4 3.5±0.8 6.8±o.8• 
TAN 33.0±4.9 16.8±2.4# 25.5±3.1 13.1±1.6' 13.3±2.4 17.9±2.2 
EC 0.39±0.03 0.40±0.05 0.37±0.03 046±0 03 045±0.04 0.57±0.04# 
ECI= end cold ischemia, EWI= end warm ischemia, Rep+ 60'= one hour after reperfusion. 
PGDF =primary graft dysfunction. Control= normal function. TAN= total adenine 
nucleotides. EC= energy charge. Values are nmol/mg protein± standard error.#: p-value < 
0.05 versus PGDF. •: p-value < 0.01 versus PGDF. 
One hour after reperfusion, energy restoration was significantly better in control 
patients, indicated by the higher energy charge in these patients (0.57 versus 0.47, p<0.05), 
due to a decrease in AMP (from 8.1 to 5.0 nmollmg) and an increase in ATP (from 3.5 to 6.8 
nmollmg). 
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Figure 1a. Post-operative course of ASTin patients with (D) and without (D) PGDF. 
Differences between patients were statistically significant on day 5 (#: p<0.05). Reference Hne indicates 
definition of PGDF, combined with PT > 16.5 sec. 
Figure 1 b. Post-operative course of pro-thrombine time (PT) in patients with ( 0) and without ( 0) 
PGDF. Differences between patients were statistically significant on day 4 (#: p<0.05). Reference line 
indicates definition of PGDF, combined with AST > 2500 U/1. 
Figure 2. ATP 
content of the 
donor liver at 
the end of cold 
and warm 
preservation 
and after 
reperfusion. 
#: p < 0"05 
versus control. 
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Figure 3. Electron microscopic view of a 
biopsy taken 1 hour after reperfusion in a 
patient with PGDF (7000x). Electron lucent 
hepatocyte with mitochondria showing 
inclusion bodies (A). The rough 
endoplasmic reticulum (B) was generally 
intact and showed only mild swelling. Near 
total depletion of glycogen particles (arrow). 
Figure 5. iNOS expression (brown colour) 
in the cytoso l of hepatocytes of a patient 
with PGDF (400x). 
Mitochondrial nitration and PGDF 
Figure 4. Electron microscopic view of a 
biopsy taken 1 hour after reperfusion in a 
control patient (7000x). Electron dense 
mitochondria showing a bi-layer (A). 
Glycogen is abundant (B) and fat 
vacuolisation is present (C). 
Figure 6. iNOS expression (brown colour) 
in the cytosol of hepatocytes, bile duct 
epithelium and portal vein endothelium of a 
control patient. Note the absence of 
expression in connective tissue in the portal 
triad (400x). 
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Figure 7. Nitrotyrosine production (red 
colour) in a patient with PGDF. Note the 
absence of staining in the connective 
tissue in the portal triad (400x). 
Figure 9. Controle sample of figure 8. The 
second antibody was omitted, with only 
standard HE staining (200x). 
Figure 8. Nitrotyrosine production in a 
control patient (red colour). There are 
no differences with the patients with 
PGDF (400x). 
Figure 10. Controle sample of figure 8. 
Nitrotyrosyl residues were reduced by 
anaerobic incubation with sodium di-
th ion ite. Standard HE staining only 
(200x). 
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Histology and electron microscopy 
Hematoxylin I eosin stained histology sections were essentially normal at the end of the cold 
ischemic period, except for mild hepatocellular swelling. Phagocytosis of extracellular matrix 
material by Kupffer cells was seen in sections, counter stained with periodic acid according 
to Schiff (PAS), after pretreatment with amylase, which indicates activation of Kupffer cells. 
This phenomenon was present in patients in both groups at the end of the cold ischemic 
period, but PAS positive Kupffer cells increased after reperfusion, without differences 
between groups. Nearly all patients showed micro-vesicular steatosis in 0-15% of the 
hepatocytes during the cold and warm ischemic period, without differences between patients 
with or without PGDF. This steatosis could remain present after reperfusion or completely 
resolve, without relation to post-operative function of the donor liver. After reperfusion a mild 
reactive hepatitis was seen, characterized by influx of neutrophils into the peri-portal area . 
Electron microscopy of the biopsies taken 1 hour after reperfusion showed however already 
marked differences between patients with PGDF (figure 3) and control patients (figure 4 ). In 
the former group electron lucent hepatocytes with cytoplasmic fat vacuolization and 
formation of hepatocellular blebs protruding in the sinusoids were seen. The electron lucent 
mitochondria showed the onset of condensation with formation of inclusion bodies which 
indicate protein denaturation and loss of phosphorylating capacity. The rough endoplasmic 
reticulum was generally intact and showed only mild swelling, but there was a near total 
depletion of glycogen particles 
In control patients, the mitochondria were electron dense and sharp lined, even the bi-
layer structure of inner and outer membrane could be recognized. The cytoplasm in these 
patients contained much more glycogen, but fat vacuolization was present as well. Bile 
canalicular microvilli were intact in both groups. 
Immunohistochemistry 
The staining pattern for iN OS and nitrotyrosine showed no differences between the groups: 
iN OS expression was positive during all stages of the transplantation mainly in the cytosol of 
hepatocytes and bile duct epithelium and portal vein endothelium of patients with (figure 5) 
and without PGDF (figure 6). Markedly, Kupffer cells did only show moderate staining, while 
staining of the sinusoidal endothelium was almost absent. The formation of nitrotyrosine was 
located in the cytosol with deposits in the nuclei of hepatocytes and bile duct epithelium. 
Collagen, fibrous tissue and leukocytes in the portal triad were not nitrated. The staining 
pattern did not show differences between patients with (figure 7) and without PDGF (figure 
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8). Control samples without the second antibody (figure 9) and after anaerobic incubation 
with sodium di-thionite (figure 1 0), showed no staining. 
Discussion 
In this study we investigated the energy content in hepatocytes during preservation and 
reperiusion and assessed the role of the nitric oxide derived peroxynitrite radical in 
mitochondrial dysfunction. 
Surprisingly, a higher TAN and ATP content at the end of the cold preservation was 
observed in patients with PGDF. During the warm ischemic period, the TAN content 
remained more or less stable in both groups, although there were discrete differences in 
separate adenosine phosphates. In the control patients, there was some decrease of AMP, 
little decrease in ADP, but no loss of ATP during this period. In the patients with PGDF, ADP 
and ATP showed some decrease, with little changes in AMP. These discrete changes 
became apparent after reperiusion, when the TAN content of the control patients remain 
stable, but decreased significantly in patients with PGDF. Moreover, control patients showed 
ATP regeneration after reperfusion, with significantly better energy charging of the 
hepatocytes, whereas patients with PGDF showed no recovery of ATP. 
The high levels of TAN and ATP content at the end of cold preservation in our study 
are in contrast with the results of others, who described lower or equal TAN and ATP levels 
in PGDF patients, compared to their control patients (23, 24, 29). The values we found in 
our control patients are in accordance with previous reports. However, none of these studies 
did follow the course of the adenine nucleotides content during the warm ischemic period, 
which makes it difficult to interpret the results. 
We hypothesize that the high energy content in our PGDF patients is caused by poor 
perfusion of the donor liver during organ donation. Optimal rapid hypothermic perfusion 
leads to cessation of all metabolic processes and enzymatic activity, but poor perfusion 
gives the donor liver time to induce oxidative phosphorylation, glycogenolysis and glycolysis 
in a salvage attempt to preserve ATP levels for proton pumping and maintenance of 
membrane integrity. Due to glucose administration, the glycogen storage of the donor liver is 
supposed to be filled, which was indeed confirmed by the electron microscopic photographs 
of the control patients, but absent in patients with PGDF. The glycogen metabolism and 
glucose output would have been inhibitory on ATP consumption. Also these cell processes 
are promoted by the presence of stress hormones after brain death, necessity for large 
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quantities of catecholamines in the liver donor and relative starvation, despite glucose 
administration (50-52). 
The induction of oxidative phosphorylation to form ATP and activation of glucose 
output in patients with PGDF also prevents the degradation of high energy phosphates to 
adenosine. This may give another explanation for the association between lower levels of 
TAN and ATP and good postoperative function, as the formed adenosine can not be further 
metabolized by dependence of enzymatic activity during the cold perfusion of the donor 
liver. Adenosine has a strong vasodilative effect, which may be beneficial at reperfusion of 
the donor liver (53) and omission of this substance from preservation solutions has 
deleterious effects (54). The functional impairment of the mitochondria found 1 hour after 
reperfusion as a cause of the decrease of ATP levels in patients with PGDF, was confirmed 
by electron microscopy in the same biopsies. In these patients we found depletion of 
glycogen particles and electron lucency of the mitochondria with inclusion bodies already at 
the end of the cold ischemic period. These results are comparable with the findings of other 
authors (11, 12, 55, 56). 
In the same biopsies, nitrotyrosine was used as an indicator to elucidate the cause of 
mitochondrial dysfunction in PGDF. All hepatocytes and bile duct endothelium stained 
positive. The level of nitration was high already at the end of the cold ischemic period and 
remained at that high level during warm ischemia and after reperfusion. Connective tissue in 
the portal triads did not contain nitrotyrosine. Staining for iNOS revealed hepatocytes as the 
main source of NO, but Kupffer cells and bile duct endothelium showed, to a lower level, 
expression as well. We found that in the livers of all patients nitrotyrosine was present and 
that they did express iNOS already at the end of the cold preservation. Since the necessary 
NO for tyrosine nitration can not be produced by iN OS during cold ischemia, this indicates 
that the cellular proteins of the donor liver have been nitrated before the donation procedure. 
In conclusion, our study shows that PGDF related mitochondrial dysfunction does not 
originate from the cold or warm ischemic period, but probably is caused earlier, during the 
organ donation procedure. Apparently, the high TAN and ATP levels at the end of the cold 
ischemic period can be used as an early marker of primary graft dysfunction. Although 
experimental studies indicated that occurrence of nitration of mitochondria is detrimental, the 
lack of any difference in nitrotyrosine formation between patient with or without PGDF 
makes nitration of mitochondria a unlikely cause of clinical primary graft dysfunction. 
101 
Chapter 7 
Acknowledgements 
The authors wish to thank Mrs. Elly de Wit and Mrs. Regina Kraak-Siee for their skillful 
contribution to the study. 
References 
1. Furukawa H, Todo S, lmventarza 0, Casavllla A, Wu YM, Scotti-Foglieni C, et al. Effect of cold 
ischemia time on the early outcome of human hepatic allografts preserved with UW solution. 
Transplantation 1991 ;51 (5):1 000-4. 
2. Strasberg SM, Howard TK, Molmenti EP, Hertl M. Selecting the donor liver: risk factors for poor 
function after orthotopic liver transplantation [see comments]. Hepatology 1994;20(4 Pt 1):829-38. 
3. Porte RJ, Ploeg RJ, Hansen B, van Boeke! JH, Thorogood J, Persijn GG, et al. Long-term graft 
survival after liver transplantation in the UW era: late effects of cold ischemia and primary 
dysfunction. European Multicentre Study Group. Trans pi lnt 1998;11 (Sup pi 1 ):8164-7. 
4. Belzer FO, Kalayoglu M, D'Aiessandro AM, Pirsch JD, Sollinger HW, Hoffmann R, et al. Organ 
preservation: experience with University of Wisconsin solution and plans for the future. Clinical 
organ preservation with UW solution [letter]. Clin Transplant 1990;4(2):73-7. 
5. Southard JH, van Gulik TM, Ametani MS, Vreugdenhil PK, Lindell SL, Pienaar BL, et al. Important 
components of the UW solution. Transplantation 1990;49(2):251-7. 
6. Hatano E, Kiuchi T, Tanaka A, Shinohara H, Kitai T, Satoh S, et al. Hepatic preservation with 
histidine-tryptophan-ketoglutarate solution in living-related and cadaveric liver transplantation. 
Clin Sci (Colch) 1997;93(1):81-3. 
7. Ploeg RJ, D'Aiessandro AM, Knechtle SJ, Stegall MD, Pirsch JD, Hoffmann RM, et a!. Risk 
factors for primary dysfunction after liver transplantation--a multivariate analysis. Transplantation 
1993;55(4 ):807 -13. 
8. Caldweii-Kenkel JC, Currin RT, Tanaka Y, Thurman RG, Lemasters JJ. Kupffer cell activation 
and endothelial cell damage after storage of rat livers: effects of reperiusion. Hepatology 
1991 ;13(1 ):83-95. 
9. Haba T, Hayashi S, Hachisuka T, Ootsuka S, Tanaka Y, Satou E, et al. Microvascular changes of 
the liver preserved in UW solution. Pathological and immunohistochemical examination. 
Cryobiology 1992;29(3):31 0-22. 
10. PostS, Rentsch M, Gonzalez AP, Palma P, Otto G, Menger MD. Effects of Carolina rinse and 
adenosine rinse on microvascular perfusion and intrahepatic leukocyte-endothelium interaction 
after liver transplantation in the rat. Transplantation 1993;55(5):972-7. 
11. Okouchi Y, Sasaki K, Tamaki T. Ultrastructural changes in hepatocytes, sinusoidal endothelial 
cells and macrophages in hypothermic preservation of the rat liver with University of Wisconsin 
solution. Virchows Arch 1994;424(5):477 -84. 
12. Caries J, Fawaz R, Neaud V, Hamoudi NE, Bernard PH, Balabaud C, et al. Ultrastructure of 
human liver grafts preserved with UW solution. Comparison between patients with low and high 
postoperative transaminases levels. J Submicrosc Cytol Pathol 1994;26(1 ):67-73. 
13. Clavien PA. Sinusoidal endothelial cell injury during hepatic preservation and reperfusion. 
Hepatology 1998;28(2):281-5. 
14. Bremer C, Bradford BU, Hunt KJ, Knecht KT, Connor HD, Mason RP, et al. Role of Kupffer cells 
in the pathogenesis of hepatic reperfusion injury. Am J Physiol 1994;267(4 Pt 1 ):G630-6. 
15. Hisama N, Yamaguchi Y, lshiko T, Miyanari N, lchiguchi 0, Goto M, et al. Kupffer cell production 
of cytokine-induced neutrophil chemoattractant following ischemia/reperfusion injury in rats. 
Hepatology 1996;24(5):1193-8. 
16. Bzeizi Kl, Dawkes R, Dodd NJ, Plevris JN, Hayes PC. Graft dysfunction following liver 
transplantation: role of free radicals. J Hepatol 1997;26(1 ):69-74. 
102 
Mitochondrial nitration and PGDF 
17. Shibuya H, Ohkohchi N, Seya K, Satomi S. Kupffer cells generate superoxide anions and 
modulate reperfusion injury in rat livers after cold preservation. Hepatology 1997;25(2):356-60. 
18. Clavien PA, Harvey PR, Sanabria JR, Cywes R, Levy GA, Strasberg SM. Lymphocyte adherence 
in the reperfused rat liver: mechanisms and effects. Hepatology 1993;17(1 ):131-42. 
19. Arii S, Monden K, Adachi Y, Zhang W, Higashitsuji H, Furutani M, et al. Pathogenic role of 
Kupffer cell activation in the reperfusion injury of cold-preserved liver. Transplantation 
1994;58(1 0):1 072-7. 
20. Lemasters JJ, Peng XX, Bachmann S, Currin RT, Gao W, Thurman RG. Dual role of Kupffer cell 
activation and endothellal cell damage in reperfusion injury to livers stored for transplantation 
surgery. J Gastroenterol Hepatoi1995;10(Supp11):S84-7. 
21. Horie Y, Wolf R, Russell J, Shanley TP, Granger ON. Role of Kupffer cells in gut 
ischemia/reperfusion-induced hepatic microvascular dysfunction in mice. Hepatology 
1997;26(6): 1499-505. 
22. Marubayashi S, Takenaka M, Dohi K, Ezaki H, Kawasaki T. Adenine nucleotide metabolism 
during hepatic ischemia and subsequent blood reflow periods and its relation to organ viability. 
Transplantation 1980;30(4 ):294-6. 
23. Lanir A, Jenkins RL, Caldwell C, Lee RG, Khettry U, Clouse ME. Hepatic transplantation survival: 
correlation with adenine nucleotide level in donor liver. Hepatology 1988;8(3):471-5. 
24. Kamiike W, Burdelski M, Steinhoff G, Ringe B, Lauchart W, Pichlmayr R. Adenine nucleotide 
metabolism and its relation to organ viability in human liver transplantation. Transplantation 
1988;45(1 ):138-43. 
25. Harvey PR, lu S, McKeown CM, Petrunka CN, llson RG, Strasberg SM. Adenine nucleotide 
tissue concentrations and liver allograft viability after cold preservation and warm ischemia. 
Transplantation 1988;45(6):1 016-20. 
26. Higashi H, Takenaka K, Fukuzawa K, Yoshida Y, Sugimachi K. Restoration of ATP contents in 
the transplanted liver closely relates to graft viability in dogs. Eur Surg Res 1989;21(2):76-82. 
27. Hickman R, Rose-lnnes C, Tyler M, Bracher M, Lotz Z, Fourie J. Energy charge as an indication 
of liver viability. A comparison of changes in livers that remained intact with those subjected to 
autografting. Transplantation 1992;53(3):540-5. 
28. Konishi Y, Shaked A, Egawa H, Busuttil RW, Ozawa K. Correlation of hepatic injury, synthetic 
function, and mitochondria energy level in orthotopic liver transplantation. J Surg Res 
1992;52(5):466-71. 
29. Hamamoto I, Takaya S, Todo S, Bronsther 0, Fujita S, Van Gulik TM, et al. Can adenine 
nucleotides predict primary nonfunction of the human liver homograft? Transpl lnt 1994;7(2):89-
95. 
30. Sammut lA, Thorniley MS, Simpkin S, Fuller BJ, Bates TE, Green CJ. Impairment of hepatic 
mitochondrial respiratory function following storage and orthotopic transplantation of rat livers. 
Cryobiology 1998;36(1 ):49-60. 
31. Takehara Y, Nakahara H, lnai Y, Yabuki M, Hamazaki K, Yoshioka T, et al. Oxygen-dependent 
reversible inhibition of mitochondrial respiration by nitric oxide. Cell Struct Funct 1996;21(4):251-
8. 
32. Welter R, Yu L, Yu CA. The effects of nitric oxide on electron transport complexes. Arch Biochem 
Biophys 1996;331(1):9-14. 
33. Balakirev M, Khramtsov W, Zimmer G. Modulation of the mitochondrial permeability transition by 
nitric oxide. Eur J Biochem 1997;246(3):710-8. 
34. Clementi E, Brown GC, Feelisch M, Moncada S. Persistent inhibition of cell resp'1ration by nitric 
oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of 
glutathione. Proc Natl Acad Sci US A 1998;95(13):7631-6. 
35. Alexander B. The role of nitric oxide in hepatic metabolism. Nutrition 1998;14(4):376-90. 
36. Abe K, Hayashi N, Terada H. Effect of endogenous nitric oxide on energy metabolism of rat heart 
mitochondria during ischemia and reperfusion. Free Radle Bioi Med 1999;26(3-4):379-87. 
103 
Chapter 7 
37. Brookes PS, Bolanos JP, Hea\es SJ. The assumption that nitric oxide inhibits mitochondrial ATP 
synthesis is correct. FEBS Lett 1999;446(2-3):261-3. 
38. Brown GC. Nitric oxide and mitochondrial respiration. Biochim Biophys Acta 1999;1411(2-3):351-
369. 
39. Packer MA, Porteous CM, Murphy MP. Superoxide production by mitochondria in the presence of 
nitric oxide forms peroxynitrite. Biochem Mol Bioi \nt 1996;40(3):527-34. 
40. \schiropou\os H, Zhu L, Chen J, Tsai M, Martin JC, Smith CD, et a!. Peroxynitrite-mediated 
tyrosine nitration catalyzed by superoxide dismutase. Arch Biochem Biophys 1992;298(2):431-7. 
41. van der Vliet A, Eiserich JP, O'Nei\\ CA, Ha\\iwe\\ B, Cross CE. Tyrosine modification by reactive 
nitrogen species: a c\oser look. Arch Biochem Biophys 1995;319(2):341-9. 
42. Reiter CD, Teng RJ, Beckman JS. Superoxide reacts with nitric oxide to nitrate tyrosine at 
physiological pH via peroxynitrite. J Bioi Chem 2000;275(42):32460-6. 
43. Skinner KA, Crow JP, Skinner HB, Chandler RT, Thompson JA, Parks DA. Free and protein-
associated nitrotyrosine formation fo\\owing rat liver preservation and transplantation. Arch 
Biochem Biophys 1997;342(2):282-8. 
44. Ohshima H, Friesen M, Brouet \, Bartsch H. Nitrotyrosine as a new marker for endogenous 
nitrosation and nitration of proteins. Food Chem Texico\ 1990;28(9):647-52. 
45. Eiserich JP, Cross CE, Jones AD, Ha\\iwe\\ 8, van der Vliet A. Formation of nitrating and 
chlorinating species by reaction of nitrite with hypochlorous acid. A nove\ mechanism for nitric 
oxide-mediated protein modification. J Bioi Chem 1996;271(32):19199-208. 
46. Se\\evo!d OFM, Jynge P, Aarstad K. High performance liquid chromatography: a rapid isocratic 
method for determination of creatine compounds and adeninenuc\eotides in myocardia\ tissue. J 
Moll Cell Cardiol1986;18:517-527. 
47. ter Steege JC, Koster-Kamphuis L, van Straaten EA, Forget PP, Buurman WA. Nitrotyrosine in 
plasma of celiac disease patients as detected by a new sandwich ELISA. Free Radle Bioi Med 
1993;25(8):953-63. 
48. Riordan JF, Sokolovsky M. Reduction of nitrotyrosy\ residues in proteins. Biochim Biophys Acta 
1971 ;236(1 ): 161-3. 
49. Altman DG. How large a sample? In: Statistics in practice 1982;eds S.M. Gore and D.G. 
A\tman(BMA, London). 
50. Vreugdenhll PK, Marsh DC, Mack VE, Belzer FO, Southard JH. Effect of fasting on hepatocytes 
cold stored in University of Wisconsin solution for 24 hours. Transplantation 1993;56(6):1454-9. 
51. Lamarche L, Yamaguchi N, Peronnet F. Selective hypoglycemia in the liver induces 
adrenomedu\\ary counterregulatory response. Am J Physiol 1996;270(6 Pt 2):R1307 -16. 
52. Ainscow EK, Brand MD. The responses of rat hepatocytes to glucagon and adrenaline. 
Application of quantified elasticity analysis. Eur J Biochem 1999;265(3):1 043-55. 
53. Palombo JD, Pompose\\i JJ, Fechner KD, Blackburn GL, Bistrian BR. Enhanced restoration of 
adenine nucleotides in rat liver following extended preservation in UW solution by provision of 
adenosine during reperfusion. Transplantation 1991 ;51 (4 ):867-73. 
54. Gao WS, Hijioka T, Lindert KA, Caldwe\\-Kenkel JC, Lemasters JJ, Thurman RG. Evidence that 
adenosine is a key component in Carolina rinse responsible for reducing graft failure after 
orthotopic liver transplantation in the rat. Transplantation 1991 ;52(6):992-8. 
55. Kakizoe S, Yanaga K, Starzl TE, Demetris AJ. Evaluation of protocol before transplantation and 
after reperfusion biopsies from human orthotopic liver a\\ografts: Considerations of preservation 
and early immunological injury. Hepatology 1990;11 :932-941. 
56. Colina F, Lopez-Carreira M, Moreno E, Garcia I, Corral MA, Fiano C, eta!. A clinopathologic 
review of 8 liver graft primary nonfunctions. Hepatogastroenterology 1995;42(3):212-21. 
104 
Fibrinolysis during liver transplantation is enhanced 
by using solvent/detergent virus inactivated plasma 
Jeroen de Jonge1, Theo H.N. Groenland2 , Herold J. Metselaar3 , Jan N.M. 
IJzermans 1, Huub H.D.M. van Vliet4 , Loes Visser2 and Hugo W. Tilanus 1. 
Departments of Surgery', Anesthesiology", Hepato-gastroenterology' and Haematology4 , 
Erasmus University Medical Centre Rotterdam. 
Anesthesia & Analgesia (in press) 
Chapters 
Chapter 8 
Abstract 
After introduction of solvent/detergent treated plasma (ESOEP®) in our hospital, an 
increased incidence of hyperfibrinolysis was observed (75% versus 29%, p=0.005) 
compared to the use of fresh frozen plasma (FFP). To clarify this increased incidence, 
intraoperative plasma samples of patients treated with FFP or ESDEP were analysed in a 
retrospective observational study. During the anhepatic phase plasma levels of D-dimer 
(6.58 versus 1.53 ~g/ml, p=0.02) and FOP (60 versus 23 mg/1, p=0.018) were significantly 
higher in patients treated with ESOEP. After reperfusion differences increased to 23.5 
versus 4.7 ~g/ml (0-dimer, p=0.002) and 161 versus 57 mg/1 (FOP, p=0.001 ). The amount of 
plasma received per packed red blood cell concentrate, clotting tests and levels of individual 
clotting factors did not show significant differences between both groups. a2-Antiplasmin 
levels however, were significantly lower in patients receiving ESDEP the anhepatic phase 
(0.37 versus 0.65 IU/ml, p<0.001) and after reperfusion (0.27 versus 0.58 IU/ml, p=0.001 ). 
Analysis of a2-antiplasmin levels in ESOEP itself showed a reduction to 0.28 IU/ml (normal 
> 0.95) due to the solvent/detergent process. Therapeutic consequences for the use of 
ESDEP in orthotopic liver transplantation are discussed in view of an increased incidence of 
hyperfibrinolysis due to reduced levels of a2-antiplasmin in the solvent/detergent treated 
plasma. 
Implications: The use of solvent/detergent virus inactivated plasma is of increasing 
importance in the prevention of HIV and HCV transmission. Since the use of this plasma 
during orthotopic liver transplantation an increased incidence of hyperfibrinolysis was 
observed. Clotting analysis of the patients revealed low a2-antiplasmin concentrations due 
to the solvent/detergent process. 
Introduction 
To minimise the risk of transmission of lipid coated viruses (HBV, HCV, and HIV) in blood 
component substitution therapy, solvent/detergent (SO) treated plasma is used in our 
hospital since 1996. Since its introduction, an increase in hyperfibrinolysis during orthotopic 
liver transplantation (OL T) was observed. Enhanced fibrinolytic activity during OL T has been 
attributed to high levels of tissue-type plasminogen activator (t-PA) (1 ,2) and contributes to 
the serious bleeding complications (3). t-PA Plasma levels peak just after reperfusion as 
result of the absent clearance during the anhepatic phase and the release of t-PA from 
damaged endothelial cells in the donor liver (4). In vitro studies demonstrated some 
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alterations in individual clotting factors due to SD treatment, particularly a loss of factor VIII 
(up to 20%), proteinS (35%) and o:2-antiplasmin (up to 76%) (5,6). 
In the present observational study intraoperative plasma samples of patients treated 
with SD treated plasma or FFP were analysed to find an explanation for the increased 
incidence of hyperfibrinolysis observed with the use of ESDEP during liver transplantation. 
Methods 
From June 1994 to March 1997, 67 patients underwent OL T for end stage cirrhosis, after 
written informed consent was obtained. In 41 patients, complete coagulation follow-up 
during the procedure was present. From June 1994 - December 1995 clotting factors were 
substituted in 21 patients with fresh frozen plasma (FFP, 300 ml, CLB Amsterdam, the 
Netherlands). Since January 1996 SD virus-inactivated plasma (ESDEP®, 200 ml, CLB 
Amsterdam), was used in 20 patients. The ESDEP was prepared from pooled plasma of 
2000 voluntary Dutch blood donors and virus inactivation is realised by treating the pooled 
plasma with 1% tri-(n-butyl)phosphate (TNBP) and 1% Triton-X1 00 (7) by Octapharma 
(Octapharma, Vienna, Austria). 
Anaesthesia was induced with penthotal 3-4 mg/kg, midazolam 0.1 mg/kg and 
sufentanyl 0.5 ~g/kg. Muscle relaxation was achieved with pancuronium 0.1 mg/kg. 
Anaesthesia was maintained with midazolam 0.1 mg/kg/hr and sufentanyl 0.2 ~g/kg/hr and 
pancuronium 25 !Jg/kg. Calcium chloride was given by infusion as required. Inotropic support 
was provided if necessary with dopamine 5-10 !JQ/kg/min and sometimes epinephrine 0.25 
~g/kg/min. Packed red blood cells (PRBC) were transfused to maintain a hematocrit of 25%. 
FFP or ESDEP was infused 10 ml/kg in the pre-an hepatic phase to correct severe 
coagulopathy and then in a ratio of 1 ml/ml PRBC or ml salvaged blood. Platelet count was 
kept above 80x1 09/1 by infusion of platelet suspension. If fibrinogen decreased below 1.0 g/1, 
purified fibrinogen (Haemocomplettan P, CLB, The Netherlands) was given. A venovenous 
bypass with heparin coated tubing (Bioconsole, Biomedicus, Minneapolis, USA) was used 
after trial clamping of the caval vein. A blood cell salvage system (CATS, Fresenius, 
Schweinfurt, Germany) and rapid infusion system (RIS, Haemonetics, Braintree, USA) was 
routinely used. Routine coagulation tests (aPTT, PTT, thrombocyte count, thrombine time 
5E and 1 OE, fibrinogen, TT and NT) were performed on arterial blood collected 5 minutes 
after induction of anaesthesia (but before administration of plasma), 5 minutes after 
hepatectomy, 5 minutes after reperiusion of the donor liver and at the end of the procedure. 
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Fibrinolysis was detected with four-channel thrombelastograph (TEG) recordings 
according to the criteria of Kang et al. (8) standard at sampling times and further when 
clinically indicated. The following values were measured: reaction time (r), coagulation time 
(r+k), maximal amplitude (MA) and clot lysis index (CLI) at 30 and 60 minutes (MA-MAtt/MA 
x 100%). Tranexamic acid (500-1000 mg) was administered when TEG recordings showed 
a CLI (eO) of more than 10% and generalised oozing occurred. After administration of 
tranexamic acid the result was evaluated with new TEG recording and if necessary the 
treatment was repeated with dosages of 10-15 mg/kg/h. To confirm the diagnosis of 
fibrinolysis, 0-dimers were analysed afterward in stored plasma using the Miniquant 
automated agglutination analyser and Miniquant test kit (Biopool Kordia, Leiden, The 
Netherlands). FOP were also analysed in stored plasma using a Latex agglutination reaction 
(Diagnostica Stago Roche, The Netherlands). Clotting factors II, VII, VIII, IX and X levels 
were analysed afterwards by standard clotting assays in stored plasma ( -80'C) on an 
automatic coagulation laboratory (ACL Instrumentation Laboratory, IJsselstein, the 
Netherlands) using human deficient plasma (Biopool Kordia, Leiden, The Netherlands). AT-
Ill and a2-antiplasmin were determined with a chromogenic assay (Dade-Behring, Leusden, 
The Netherlands). 
All data are presented as mean ± SEM. After testing normality with Shapiro-Wilk 
statistics, a Student's t-test or Mann-Whitney U-test was used for data analysis. a2-
Antiplasmin levels had logarithmic transformation before analysis and the changes from 
baseline a2-antiplasmin levels were investigated with repeated measures analysis of 
variance including time period and type of plasma as covariates. For 2x2 table data the Chi-
square test with Yates correction or Fisher's exact test was used. Differences were 
considered significant for P less than 0.05. 
Results 
The characteristics of the FFP and ESDEP treated patient groups are summarised in table 
1. In patients treated with FFP (N=21 ), hyperfibrinolysis was seen in 6 individuals (29%); in 1 
patient during the pre-an hepatic phase, in 1 patient during both pre-anhepatic and anhepatic 
phase, in 1 patient during both anhepatic and reperiusion phase and in 3 after reperiusion. 
In the ESDEP treated group (N=20), hyperfibrinolysis was present in 15 patients (75% vs. 
29%, p=0.005). In 4 patients an episode of hyperfibrinolysis occurred during the pre-
anhepatic phase (20% vs. 10%, NS), in 8 patients during the anhepatic phase (40% vs. 
10%; p=0.03) and in 10 patients after reperfusion (50% vs. 19%; p=0.05). In 7 of these 15 
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patients with hyperfibrinolysis it occurred repeatedly: in 3 patients during both pre-anhepatic 
and anhepatic phase and in 4 patients in the anhepatic and after reperfusion. Clot lysis 
indices after 60 minutes (CLI,o) were 4 vs. 26% (p=0.03) in the anhepatic phase and 4 vs. 
40% (p=0.03) after reperfusion (table 2). The dose of tranexamic acid given in both groups 
to patients with excessive fibrinolysis was well comparable. In the patients treated with FFP, 
a total of 6500 mg of tranexamic acid was administered to 6 patients (29%), mean dose 
1083 mg/patient. In the ESDEP treated group, 12 patients (60%) received a total of 15250 
mg oftranexamic acid, mean dose 1271 mg/patient, p= N.S. 
Table 1. Basic characteristics of patients undergoing orthotopic liver transplantation. 
FFP ESDEP 
(N=21) (N=20) 
Age (yr.) 53 (23-65)' 44 (23-62) 
Male I Female 9/12 15/5 
Indication (N) 
Viral hepatitis cirrhosis 6 6 
Cholestatic liver disease 10 8 
Other cirrhosis 5 6 
Operation time (min) 419(14) 436 (21) 
Blood loss (ml) 12173 (1907) 15191(3155) 
Transfusions 
PRBC (units) 13.1 (1.8) 15.3 (2.9) 
Cell salvage blood (ml) 2481 (655) 2655 (931) 
Plasma (ml) 4271 (616) 5440 (903) 
Fibrinogen (g) 4.7 (0.8) 7.2 (1.6) 
Platelets (units) 19.5 (2.4) 20.0 (3.6) 
Plasma I PRBC (ml) 342 (30) 383 (26) 
Values are mean ± SEM or range. FFP: fresh frozen plasma, ESDEP®: solvent/detergent treated 
plasma. * P< 0.05 vs. ESDEP®. 
Analysis of standard coagulation parameters during the procedure revealed no 
significant differences between patients treated with FFP or ESDEP, except for FVIII after 
induction and the PT in the anhepatic phase (table 3). However, D-dimer and FOP levels 
were significantly higher in the ESDEP treated patients in the anhepatic phase and after 
reperfusion, consistent with the increased fibrinolytic activity recorded on TEG (table 3). 
Also determination of o:2-antiplasmin levels showed significant differences between 
treatment with FFP or ESDEP (figure 1 ). a2-Antiplasmin levels after onset of anaesthesia 
were not statistically different in the FFP and the ESDEP treated group. In patients who 
received FFP, a2-antiplasmin levels remained relatively stable and decreased from 0.76 
IU/ml to 0.65 IU/ml in the anhepatic phase, to 0.58 IU/ml after reperfusion and levelled at 
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0.58 IU/ml at the end of the procedure. The corresponding levels in patients treated with 
ESDEP were 0.64 IU/ml (P=NS), 0.37 IU/ml (P<0.001 ), 0.27 IU/ml (P=0.006) and 0.40 IU/ml 
(p=0.03) respectively. Repeated analysis of variance confirmed that type of plasma was 
responsible for the decrease from baseline value, independent from the time course. 
Table 2. TEG parameters during orthotopic liver transplantation in patients treated with FFP and 
After induction Anhepatic phase After reperiusion 
FFP ESDEP FFP ESDEP FFP ESDEP 
R (mml 21.7 (0.61 23.6 (2.71 15.5 (1.61 16.1 (2.51 24.1 (1.01 29.6 (3.91 
R+K (mml 31.0 (0 91 32.0 (3.01 24.6 (2.1 I 23.3 (3.31 37.5 (1.81 44.3 (5.01 
Ang (degl 50.1 (4.71 42.2 (3.11 43.7 (4.11 52.4 (3.61 41.5 (4.21 33.7 (3.51 
MA (mml 47.7 (2.51 54.5 (3.1 I 40.8 (3.01 48.0 (3.71 32.2 (3.21 35.0 (3.91 
cu,,,, (%1 1.6 (0.41 3.1 (2.11 1.7 (0.5)' 16.8 (7.51 2.0 (0.5)' 31.6 (9.91 
CLI 1, 01 (%1 4.3 (0.81 7.2 (2.21 3.9 (1.1)' 26.2 (9.61 4.2 (1.0)' 39.7 (10.71 
Values are mean± SEM. FFP: fresh frozen plasma, ESDEP®: solvent/detergent treated plasma. 
* P< 0.05 versus ESDEP. 
Table 3. Coagulation parameters during orthotopic liver transplantation. 
After induction An hepatic phase After reperfusion 
FFP ESDEP FFP ESDEP FFP ESDEP 
APTI (s.l 43 (31 46 (31 68 (131 113 (191 157 (181 181 (191 
PT (s.l 17.6 (1.71 15.8 (0.91 15 (0.5)' 24.0 (5.51 17.4 (1.01 24.0 (5.21 
T 10 E (s.l 17 (11 20 (21 19 (21 25 (41 26 (41 33 (61 
Platelets(x10°/ll 103(161 113(171 89(191 75(10) 90(14) 79(9) 
Fibrinogen (g/1) 1.8 (0.1) 2.2 (0.3) 1.5 (0.1) 1.6 (0.2) 1.5 (0.1) 1.4 (0.2) 
Fll (IU/ml) 0.48 (0.05) 0.48 (0.05) 0.47 (0.03) 0.40 (0.04) 0.39 (0.02) 0.37 (0.03) 
FVII (IU/ml) 0.43 (0.05) 0.45 (0.05) 0.41 (0.03) 0.37 (0.04) 0.34 (0.02) 0.35 (0.03) 
FX (IU/ml) 0.56 (0.04) 0.55 (0.04) 0.49 (0.02) 0.44 (0.04) 0.39 (0.02) 0.38 (0.03) 
FVIII (IU/ml) 2.17 (0.25)' 3.41 (0.52) 1.29 (0.21) 1.70 (0.30) 0.80 (0.12) 1.01 (0.24) 
FIX (IU/ml) 0.51 (0.07) 0.58 (0.08) 0.36 (0.05) 0.36 (0.06) 0.22 (0.03) 0.19 (0.04) 
D-dimer (Mgiml 0.46 (0.14) 1.01 (0.40) 1.53 (0.37)' 6.58 (1.98) 4.70 (1.97)# 23.47 (6.56) 
FDP(mg/11 23(5)# 60(16) 57(11)# 161 (24) 
Values are mean± SEM. FFP: fresh frozen plasma, ESDEP®: solvent/detergent treated plasma. 
T 10E= trombine time. * P< 0.05 versus ESDEP, # P<0.01 versus ESDEP. 
Analysis of ESDEP itself revealed normal levels of all clotting factors (>0.81 IU/ml), AT-
Ill (>0.81 IU/ml), protein C (0.80 IU/ml) and plasminogen (0.94 IU/ml). Levels of FVIII (0.71 
IU/ml) and proteinS (0.58 IU/ml) were slightly depressed, but levels of cx2-antiplasmin were 
severely depressed to 0.28 ± 0.02 IU/ml (normal 0.95-1.20 IU/ml) (5). Linear regression 
showed a statistical significant relation between the level of cx2-antiplasmin and the CLI1301 
(P<0.01) and CLI,so) (P<0.01 ), the level of FDP and CLI1301 (P<0.03) and the d-dimer level 
and CLI1,,1 (P<0.01) and CLI 1601 P<0.01 ). 
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Despite the increased fibrinolysis, there was no difference in total blood loss between 
patients receiving FFP or ESDEP, but blood loss was significantly higher in the 21 out of 41 
patients from both groups in whom hyperfibrinolysis occurred (18054 ± 2469 ml vs. 8683 ± 
1339, p<0.001 ). In addition the transfusion requirements for PRBC, platelets, fibrinogen and 
plasma were also higher in patients with hyperfibrinolysis (all p<0.001 ). 
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Figure 1. Intraoperative time course of the a2-antiplasmin levels. Ill Patients with chronic liver disease 
treated with Fresh Frozen Plasma (FFP, N= 21 ). A Patients with chronic liver disease treated with SO 
virus inactivated plasma (ESDEP®, N=20). 
Discussion 
Orthotopic liver transplantation (OL T) has become the standard treatment for end-stage liver 
disease, but the procedure still can be associated with severe disorders of haemostasis (9). 
A key role in the pathogenesis of intraoperative bleeding is played by enhanced 
fibrinolysis during the anhepatic and reperfusion phase (1 0,11 ). To minimise the risk of viral 
transmission, solvent/detergent (SO) virus-inactivated plasma was introduced in 1996 in our 
hospital and thereafter an increase in hyperfibrinolysis in patients undergoing OL T was 
observed. SO treatment of fresh frozen plasma is an effective method to reduce lipid coated 
viruses by> 5 log 10 (12,13), but it has been reported that because of the SO process the 
concentration of FVIII, protein S and u2-antiplasmin is reduced (5,6). u2-Antiplasmin is a 
main physiological inhibitor of t-PA induced fibrinolysis and fibrinogenolysis (14,15) which 
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are held responsible for uncontrollable intraoperative bleeding. Inhibition of this fibrinolysis 
may occur at the level of plasminogen activation by plasminogen activator inhibitor (PAl) or 
at the level of plasmin by o:2-antiplasmin (16). Once large amounts of t-PA are released in 
the circulation of the recipient, o:2-antiplasmin plays a key-role in the scavenging of the 
formed free plasmin. Free plasmin is extreme rapidly inactivated by a2-antiplasmin; the half-
life of free plasmin is estimated to be approximately 0.1 s. Without adequate o:2-antiplasmin 
levels, a small amount of t-PA can start the offset of systemic fibrinolysis (17), as the fibrin 
degradation products can amplify the plasminogen activation (18). 
Although the efficacy of SO plasma in clinical studies in patients with coagulation 
disorders has been established (19,20), the balance between pro- and anti-fibrinolytic 
activity in our patients seems to be disturbed during OL T by SO plasma substitution. In 
patients with chronic liver disease enhanced fibrinolysis occurred about 3 times more in the 
anhepatic phase and after reperiusion in patients who received ESDEP than in patients 
treated with FFP. Determination of a2-antiplasmin concentrations in ESDEP showed 
decreased levels in accordance with the results presented in literature (5,6). In 47% of the 
patients treated with ESOEP hyperfibrinolytic episodes did recur, despite adequate 
treatment of the first hyperfibrinolytic episode, proven by normalisation of the TEG 
recordings. We think that this effect is caused by the large plasma exchanges in liver 
transplantation, which dilute the level of o:2-antiplasmin in the patient to the level of ESOEP 
itself. 
In a recent randomised multi-centre study by Freeman et al. (21) no differences were 
seen in coagulation parameters between patients receiving FFP or SO treated plasma 
during liver transplantation, but a2-antiplasmin levels were not determined in their study. 
Hyperfibrinolytic problems were not mentioned in the article, probably because of standard 
prophylactic use of anti-fibrinolytic drugs in the participating centres in the United Kingdom. 
In our patients with chronic liver disease, a2-antiplasmin levels were relatively high 
(0.70 IU/ml) after induction of anaesthesia, in contrast to the markedly reduced o:2-
antiplasmin levels reported for patients with advanced liver disease (22,23). Low levels of 
o:2-antiplasmin in the anhepatic phase and after reperfusion in the ESOEP treated patients 
compared to the FFP treated patients explains the increase in hyperfibrinolysis seen in the 
former group. At the end of the procedure a2-antiplasmin levels are increasing in the 
patients treated with ESOEP, probably due to increased clearance of t-PA by the donor liver 
and starting synthesis of o:2-antiplasmin. In accordance with the study of Freeman et al., no 
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differences were found in other coagulation parameters, use of blood products or blood loss 
between the FFP and ESDEP treated patients. However, patients from both groups with 
hyperfibrinolysis had significant more bleeding and transfusion requirements than patients 
without hyperfrbrinolysis. 
In summary, the results of this observational study have to be interpreted carefully, 
because potentially other factors could have caused our findings. However, in the time 
considering this study no changes have occurred in our operating or anaesthesiology 
techniques, medical staff or transfusion protocol. Also the increased incidence of 
hyperf1brinolysis was present immediately after switching from fresh frozen plasma to 
ESDEP. Infusion of SO treated plasma in patients needing massive transfusion may lead to 
insufficient levels of cx2-antiplasmin and subsequently to secondary hyperfrbrinolysis. This 
hypeliibrinolysis can not be corrected with infusion of more SO treated plasma, as this would 
dilute the cx2-antiplasmin concentration in the patient to that of ESDEP itself (0.28 lUll). 
Therefore, it should be treated with anti-fibrinolytic medication. The effects of aprotinine on 
antiplasmin activity, hyperfibrinolysis and subsequent blood loss have been reported with 
various outcomes (3, 24-27). Considering the significant higher blood loss in patients with 
hyperfibrinolysis in our study, routine administration of anti-fibrinolytic drugs using SO virus-
inactivated plasma is suggested. 
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Abstract 
Background: The piggyback technique for orthotopic liver transplantation was introduced to 
decrease intraoperative blood loss and postoperative complications. A retrospective analysis 
was undertaken to evaluate the results of the implementation of this technique. 
Methods: 45 patients transplanted since 1999 using a modified piggyback technique were 
compared to 90 controls with a standard anastomosis since 1995. Liver grafts were 
preserved in UW solution (Viaspan, DuPont). All vascular anastomoses with the vena cava 
were made with the vascular stapler (Autosuture, Tyco Health Care). The post-operative 
immunosuppresive regimen consisted of Tacrolimus (FK506, Fujisawa), an IL-2 receptor 
antagonist (Basiliximab, Novartis or Daclizumab, Roche) and a steroid withdrawal scheme. 
The impact on transfusion requirements, postoperative course and patient and graft survival 
was studied. 
Results: Warm ischaemic time and total operation time were shortened significantly in the 
piggyback group: 51 vs. 81 minutes and 5.9 vs. 7.0 hours. Intraoperative blood loss and 
transfusion requirements were significantly decreased in the piggyback group. No 
differences could be identified in incidence of infection (57 and 68%) or relaparotomy for 
bleeding (16 and 10%). Patients in both groups had identical length of stay in the ICU (5 and 
6 days) and in hospital stay (27 and 29 days). At 6 months after transplantation graft survival 
and patient survival were significantly better in the piggyback group (87% and 91%) than in 
the standard group (66% and 73%). 
Conclusion: The introduction of the piggyback technique reduced transfusion requirements 
and increased graft survival and patient survival at 6 months after liver transplantation. 
Introduction 
The results of conventional orthotopic liver transplantation continue to improve because of 
advances in immune suppression therapy, developments in surgical techniques and better 
perioperative monitoring. During the standard procedure with replacement of the recipient 
retrohepatic vena cava inferior, the routine use of a vena-venous bypass (WB) is 
recommended for decompression of the splanchnic and cava inferior system (1 ,2). However, 
the use of a vena-venous bypass is associated with complications including 
thromboembolism, air embolism, hypothermia and wound infection (3-6). Liver 
transplantation with preservation of the recipient vena cava ("piggyback" technique) has 
been proposed as an alternative procedure, allowing normal cava! blood flow during the 
anhepatic stage (7). In a large series of patients the piggyback technique was shown to be a 
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safe procedure with acceptable technical post-operative complications (8,9). Also the 
piggyback technique was reported to decrease the need for red blood cell transfusion and 
administration of platelets and plasma (10-12). Despite these advantages, a beneficial effect 
on graft or patient survival could not be established (10,12,13). In this study we evaluate the 
intraoperative transfusion requirements, postoperative complications and 6-month survival 
after liver transplantation after introduction of the piggyback technique in our hospital. 
Figure 1 a. The middle and left hepatic vein were 
joined into a cuff for anastomosis. This common orifice 
was enlarged by a caudal incision of 7 em. 
Figure 1 b. In the donor liver, the intrahepatic IVC is stapled. 
The dorsal side of the suprahepatic donor IVC is incised 
caudally starting at the confluence of the hepatic veins to 
create a "V shaped" anastomosis. (Compilation of fig 3 and 
4, Cherqui et al. Transplantation 1994; 58: 794). 
Patients and Methods 
Figure 2. End-to-side cava-caval 
anastomosis. (Modification fig 5, 
Cherqui et al. Transplantation 
1994; 58; 795). 
From 1989 to 1999 orthotopic liver transplantation was performed with standard 
replacement of the recipient's inferior vena cava (IVC) with or without WB, according to the 
cardiac index after trial clamping of the IVC. Since March 1999 a modification of the 
"piggyback" technique described by Belghiti (7) and Cherqui (14) was used for caval 
anastomosis. After dissection of the porta hepatis, the diseased liver is mobilised from the 
vena cava with meticulous ligation of all retrohepatic veins originating from segments VI, VII 
and I. A temporary porto-caval shunt was never used. The IVC of the recipient is preserved 
and the orifice of the right hepatic vein is stapled. Hereafter a vascular clamp is applied 
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laterally on the anterior part of the recipient VC and the diseased liver is removed. The 
middle and left hepatic vein are joined into a cuff for anastomosis. This common orifice is 
enlarged by a caudal incision of 7 em in the anterior wall (figure 1a}. In the donor liver, the 
intrahepatic IVC is stapled. The posterior side of the suprahepatic donor IVC is incised 
caudally starting at the suprahepatic cutting surface of the IVC (figure 1b} This way a "V" 
shaped end-to-side cava-caval anastomosis is created (figure 2). 
From March 1999 to July 2000, 50 adult patients received an orthotopic liver 
transplantation using the modified piggyback technique. In the early phase, in two patients 
conversion to conventional liver transplantation with excision of the vena cava was 
necessary because of uncontrollable bleeding from ruptured hepatic veins. The remaining 
48 patients in whom the modified piggyback technique was performed, were matched for 
indication for transplantation. In three patients no appropriate control patients could be found 
because of rare indication. Eventually, 45 patients (21 female, 24 male} were matched for 
indication with 90 control patients. Other variables affecting survival (re-transplantation, 
recipient age over 60 years, donor age over 55 years, cold ischaemia > 12 hours, ABO 
incompatibility and donor/recipient sex mismatching (15}} were analysed to be equally 
distributed. To create a stable control group, minimising the role of a learning effect of the 
surgeons, regression analysis of blood loss and transplantation date was performed. The 90 
control patients (41 female, 49 male} with a standard anastomosis were selected from the 
period 1995-1999, in which the blood loss during transplantation was stable (R=0.06, 
p=0.58}. 
Statistical analysis 
Data are presented as mean with their 95% confidence interval (mean +/- two standard 
errors}, ages as median and range. Differences between the groups were detected with the 
Mann-Whitney test. Patient survival was calculated using the Kaplan-Meier method. 
Differences in 6 month survival between groups were detected using the log rank test. For 
cross table analysis the Fisher's exact test was used. Differences were considered 
significant for p< 0.05. 
Results 
Indication for transplantation was cholestatic liver disease (31%}, viral hepatitis (18%}, acute 
liver failure (18%}, post alcoholic cirrhosis (9%), hepatocellular carcinoma (7%), cryptogenic 
cirrhosis (7%) and other indications (10%, i.e. metabolic diseases, adenoma}. Other patient 
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characteristics are given in table 1. In the conventional group 42 patients (47%) required 
vena-venous bypass after trial clamping of the IVC. Vena-venous bypass was never used in 
the piggyback group. There was no difference in duration of the hepatectomy phase 
between the groups, but warm ischaemia time and total operative time were significantly 
shortened in the piggyback group: 52 (47-58) versus 79 (76-83) minutes, p<0.01 and 5.9 
(5.4-6.3) versus 6.9 (6.5-7.3) hours, p<0.01 respectively. Intra operative blood loss and 
transfusion requirements were significantly decreased in the piggyback group (table 2). 
Table 1. Patient characteristics for recipients of piggyback technique and conventional orthotopic liver 
transplantation. 
Piggyback Conventional p-value 
Donor age 43 (8-68) 38 (13-62) 0.11 
Recipient age 48 (19-68) 48 (17-67) 0.96 
Previous L T x 3/45 8/90 0.75 
Cold iscaemia > 12 hrs 8/45 22/90 0.51 
Donor I recipient 
Sex mismatch 20/45 52/90 0.15 
ABO mismatch 4/45 11/90 0.77 
Postoperative dysfunction 2/45 4/90 1.0 
Post-operative course: 
After transplantation, primary graft non function occurred in 2/45 patients in the piggyback 
group and in 4/90 patients in the standard group (NS). 
Levels of ASAT at the first post-operative day were higher in the piggyback technique group 
than after standard liver transplantation: 782 (135-6214) U/1 versus 680 (115-7127) U/1, 
p=0.43. At the third post-operative day ASAT levels were decreased to 214 (35-3540) U/1 in 
the piggyback group and 178 (9-17300) U/1 in the conventional group, p=0.55. Serum 
creatinine levels were comparable at the third post-operative day in the piggyback group 76 
(42-460) ~mol/1 and in the conventional group: 84 (20-464) ~mol/1, p=0.81. The median 
length of stay in the ICU and in hospital stay was 5 (range 1-119) and 27 (range 13-162) 
days in the piggyback group, patients transplanted with the standard technique were 
discharged after 6 (range 1-101) days from ICU and after 29 (range 14-320) days from 
hospital. No significant differences were found in the number of patients that acquired an 
infection in the first month after transplantation: 29 patients (64%) in the piggyback group 
and 55 patients (61%) in the conventional group. However, in the patients treated with 
conventional liver transplantation more severe infections (septicaemia, deep wound infection 
and pneumonia) occurred in 27 patients (30%) compared to 6 (13%) in the piggyback group, 
p<0.05. Post-operative bleeding requiring laparotomy occurred in 7 patients (16%) after 
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piggyback technique and in 9 patients (10%) in the conventional group, p=0.40. Incidences 
of hepatic artery thrombosis, portal vein thrombosis and vena cava stenosis were 6/45 
(13%), 2/45 (4%) and 1/45 (2%) after piggyback transplantation and 8/90 (9%), 2/90 (2%) 
and 3/90 (3%) after conventional technique. Stenosis of the vena cava was treated with 
balloon angioplasty in 3 patients, one patient with a conventional liver transplantation 
received an intra vascular stent. Actuarial survival rate of the graft at 6 months after 
transplantation was 87% in the piggyback group and 68% (p<0.03) in the standard liver 
transplantation technique group (figure 3). Patient survival rate was 91% in the piggyback 
group and 73% (p<0.02) in the standard liver transplantation group (figure 4). 
Table 2. Intra operative blood loss and transfusion requirements of recipients of piggyback technique 
and standard orthotopic liver transplantation. PBRC: packed red blood cell concentrate. 
Piggyback Conventional 
Blood loss (L) 5.7 (4.6-6.7) 12.4 (10.1-14.8) 
PRBC (U) 7 (6-8) 12 (10-14) 
CeH saver blood (L) 0.6 (0.4-0.9) 2.1 (1.4-2.7) 
Fresh frozen plasma (L) 2.8 (2.2-3.3) 4.9 (4.2-5.7) 
Thrombocyte concentrate (U) 9(7-11) 18(15-21) 
Fibrinogen (g) 1.1 (0.5-1.6) 4.2 (3.2-5.3) 
Graft survival 
1 :r~"- \L__ _________ ---~--
-- I 
,8 ~~ 
---c,__ 
,7 LL 
1.......~~---l...... ______ _ 
,6 
,5 !------:,;:----------~--~---1 
0 30 60 90 120 150 180 
Figure 3. Grafts at risk: 
Piggyback 
Conventional 
122 
40 
68 
38 
63 
38 
61 
days after transplantation 
38 
61 
38 
60 
38 
60 
p.value 
<0.01 
<0.01 
<0.01 
<0.01 
<0.01 
<0.01 
piggyback 
conventional 
Piggyback technique improves patient suNival 
Patient survival 
J 1: 0'-------------------+-§ . '--\ 
0 
.s 
.7 
~l 
~--L,_ 
1._ 
L_ _____ ,_ _______ f--
.5~--~----~----------------------~ 0 30 60 90 120 150 180 
Figure 4. Patients at risk: 
Piggyback 
Conventional 
Discussion 
43 
75 
41 
70 
41 
67 
days after transplantation 
41 
67 
41 
66 
41 
66 
piggyback 
conventional 
Conventional orthotopic liver transplantation requires crossclamping of the inferior vena 
cava, reducing venous return and resulting in decreased cardiac output and systolic blood 
pressure and increased systemic vascular resistance (16-18). These changes are poorly 
tolerated in hemodynamic unstable recipients and may contribute to renal impairment. The 
introduction of veno-venous bypass by Shaw in 1984 (2) improved the results of adult liver 
transplantation as it corrected hemodynamic and renal disturbances and decreased intra 
operative blood loss. The use of the piggyback technique for orthotopic liver transplantation 
in which the retrohepatic vena cava is preserved. was first mentioned by Caine in 1968 (19) 
and fully described by Tzakis et al. in 1989 (20). In these first cases the hepatic veins were 
crossclamped and a vena-venous bypass was used in adult recipients. The concept of side 
clamping of the retrohepatic vena cava. introduced by Belghiti in 1992 (7). allowes 
preservation of caval blood flow during the hepatectomy phase and overcame the need for 
vena-venous bypass, which was associated with complications including hypothermia and 
embolism (5.6). Since then. (modified) piggyback techniques have been compared to the 
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conventional orthotopic liver transplantation technique by several authors (10-13, 21-24), 
reporting reduced operative time, blood loss, transfusion need and hospitalisation. So far no 
survival benefit has been established, but in these retrospective studies patients were not 
matched for other variables affecting outcome. In the prospective, but not randomised study 
by Hosein Shokouk-Amiri et al. (12), outcome in both groups was excellent and no 
differences could be established. 
In the present study we compared our results after introduction of a modified piggyback 
technique to a matched historical group of patients transplanted with the conventional 
technique. This necessitates careful interpretation of the results, as selection or time bias 
may be present. To minimise these effects, control patients were selected from a recent time 
period, in which the surgical team and surgical techniques were not changed in our hospital. 
Donor and recipient characteristics contributing to graft and patient survival according to the 
European Liver Transplantation Registry were analysed and equally distributed in both 
groups. In accordance with most previous studies we found a significant decrease in intra-
operative blood loss and transfusion requirements due to absence of retrocaval dissection 
and caval encirclement. The observed survival benefit of the piggyback technique can not 
easily be explained as we found no differences in postoperative course between both 
groups, except for the incidence of severe infections. The decreased blood loss and blood 
component transfusion may be directly responsible for the improved survival, as these 
factors were proven to increase graft and patient survival (25-27). Finally the reduction of the 
warm ischaemic period with more than 30 minutes may contribute to graft quality and patient 
survival (27-28). In summary, the modified piggyback technique could be used in all patients 
without use of a vena-venous bypass. It reduced the warm ischaemia time, intra-operative 
blood loss and the need for transfusion of blood components. In our series these factors 
seemed to improve patient and graft survival at 6 months after liver transplantation. 
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Abstract 
Since the introduction of the split liver transplantation procedure now 15 years ago a variety 
of partial liver transplantations have been developed. The earliest form consisted of a 
reduction of a whole liver graft to the left lateral segment or the left liver lobe, small enough 
to transplant to a young child. The rest of the liver was discarded. This method solved part of 
the great need of liver grafts for children but as the remaining part of the liver was lost for 
transplantation, the method was in fact detrimental for adults on the waiting list. 
Further surgical development resulted in splitting of the liver ex-vivo into two 
transplantable partial grafts, the left part to a child and the right lobe to an adult. The 
procedure was successfully introduced but the complicated logistics resulted in prolonged 
cold ischaemia times of the grafts. ln order to keep the cold ischaemia time as short as 
possible Rogiers et a/. developed the in-situ split liver technique in which the liver was split 
in the post-mortem donor. Refinement of this operation led to results, which were superior to 
the ex-vivo method. Moreover, it opened the gate to living donor liver transplantation. The 
first successful procedure was performed from a mother to a child who received the mother's 
left liver segment. The introduction resulted in a decrease over the years on the paediatric 
waiting list to almost zero. As the demand for organs increases every year and the numbers 
of donors are constant in western countries, the right lobe living donor liver transplantation 
for adults was introduced. 
Introduction of all forms of partial liver transplantation has relieved the pressure on 
waiting lists, especially for children but also for adults. There is however serious concern of 
the well being in terms of morbidity and mortality of the living donor donation procedure. 
Introduction 
World-wide shortage of donor livers was the main obstacle for further expansion of liver 
transplant programs during the last decade. During this period the waiting lists for adults 
showed a steady increase all over the world but the death rate on the waiting list for children 
increased at an alarming rate. To solve this problem several alternative techniques of partial 
liver transplantation were developed. 
In the first split liver techniques a donor liver was reduced mostly to the left lateral 
segment, the segments 2 and 3 or to the left lobe, the segments 2, 3 and 4. As most 
attention and care was paid to the graft and as all vascular and biliary structures were kept 
to the graft including the vena cava, the right part of the liver could not be used as a liver 
graft. This first important step forward over the years eventually has led to transplantation of 
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living donor transplantation of the right liver lobe to an adult recipient in a high urgent 
situation. 
REDUCED SIZE LIVER TRANSPLANTATION. 
The first reduced size liver transplantation (RSL T) was performed by Bismuth and Houssin 
in 1984 (1 ). They transplanted a left lateral liver segment to a child. In their consecutive 
series of paediatric liver transplantations, morbidity and mortality did not differ from the early 
results of whole liver transplantation at that time in the Paris program. Emond and Broelsch 
reported larger series of RSL T in children and, with the refinement of surgical technique and 
better patient selection, the results gradually improved. Initially RSL T was applied in 
desperate situations only and complications as hepatic artery thrombosis and portal vein 
thrombosis lead to inferior results. With increasing experience patient and graft survival 
approached 70% at one year and these results were comparable to the results of whole liver 
transplantation in children (2,3). Reduced size liver transplantation significantly reduced the 
number of children dying on the waiting list. 
SPLIT LIVER TRANSPLANTATION. 
Post mortem ex vivo SL T 
Reduced size liver transplantation alleviated the mortality on the waiting list for children but 
its introduction was detrimental for the waiting list of adults as only a small part of a whole 
liver was transplanted to a child and the remaining part was discarded. Realising this, further 
attempts were made to preserve both parts for transplantation. This requested a new 
approach and a meticulous dissection technique during preparation on the backtable. 
Already in 1957 the French pathologist Couinaud proposed a new concept of functional 
division of the liver in 8 segments, according to their portal and arterial blood supply and bile 
drainage. It took however until 1988 before this knowledge could be applied by Pichlmayr to 
transplant one donor organ to two recipients (4). The donor liver was divided in such a way 
that the left part, the segments 2 and 3 without the caval vein could be transplanted 
successfully into a child and the right part, the segments 1 ,4,5-8, into an adult. Common bile 
duct and common hepatic artery remained with the left part of the liver and the portal vein 
with the right one. In the recipient of the left part of the liver the vena cava was preserved 
and anastomosed with the left hepatic vein, the other anastomoses were carried out in the 
typical way. In the recipient of the right part of the liver the right hepatic artery was 
anastomosed with the recipient's common hepatic artery using a saphenous interponate. 
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Two separate intrahepatic bile ducts were anastomosed with a Roux-en-Y loop of the 
jejunum. The other anastomoses were carried out in the typical way. Shortly afterwards the 
first emergency split liver transplantation in two patients using one donor was reported. 
Using the same technique as Pichlmayr, Bismuth et al. grafted two patients with 
fulminant hepatitis when only one donor was available. Both recipients recovered from coma 
and regained normal liver function. However, both patients died due to causes not directly 
related to the transplantation, one from multiple organ failure and one from diffuse 
cytomegaly virus infection on the 20th and 45th postoperative day respectively (5). 
Especially in the early phase of this new development the complication rate regarding 
thrombosis of the small hepatic artery was higher than in whole liver transplantation. 
Stevens et at. reviewed the early Chicago experience and concluded that the use of a 
cadaveric left lobe or left lateral segment graft and an aortic arterial anastomosis were less 
prone to hepatic artery thrombosis than right sided grafts and an arterial anastomosis on the 
acceptor hepatic artery or celiac axis (6). Biliary leakage and obstruction were the most 
common complication but were similar in reduced size and full size grafts (7). 
The European experience was reviewed by de Ville de Goyet (8). The European Split 
Liver Registry included the early results of 9 European centres over a 5 year period from 
1988 to 1993. From 50 donor livers, 100 grafts were prepared, 2 grafts were discarded and 
the other 98 were transplanted in 53 children, two times in 2 children and 43 adults.63 grafts 
were transplanted in an emergency situation. Portal vein thrombosis, hepatic artery 
thrombosis, biliary complications and retransplantation rate were 4%, 11.5%, 18.7%, and 
18.7%, respectively. Most of these complications were unrelated to the technique itself. 
Actual 6-month graft survival of elective and urgent orthotopic transplants was 88.9% and 
61.3% in children, and 72.2% and 55.6% in adults. Actual 6-month patient survival for similar 
groupings was 88.9% and 61.1%, and 80% and 67.7%, respectively. These results were 
comparable to the results of whole liver transplantation at the time. 
One of the major drawbacks in partial liver transplantation is the long cold ischaemia 
time due to the logistics around the ex-vivo splitting procedure on the back table which has 
to be performed in the donor hospital or in the transplant centre. The procedure itself takes 2 
to 2.5 hr. in experienced hands and there is a possibility of warming up during the back table 
procedure. There are some reports of early graft dysfunction and post transplant 
complications due to the cutting edge of a right hemi-liver graft, which were attributed solely 
to the partial aspect of the transplantation. To overcome the logistic as well as the functional 
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problems of the ex/vivo procedure Rogiers et a/. developed the in-situ liver splitting 
operation. 
Post mortem in-vivo SL T 
In the in-situ split liver operation the liver is split in the post mortem donor. The procedure is 
demanding especially during a multi organ donation. It has to be performed with the greatest 
surgical skill under constant perfusion of the liver preventing the Pringle manoeuvre in which 
the vascular structures in the hepato-duodenal ligament are clamped in order to prevent 
blood loss but resulting in warm ischaemia. Rogiers reported the first case in 1995 (9) and 
analysed their first in-situ split liver procedures one year later. The 14 split livers resulted in 
14 transplanted patients with a 6 months patient and graft survival of 92.8% and 85.7% 
Biliary complications were absent. Postoperative courses were mostly uneventful and 
characterised by lower peak transaminases compared to the standard techniques (1 0). 
These extremely good early results were superior to the 19 ex-vivo split liver 
transplantations performed during the same time period. It rendered graft reduction alone 
obsolete and opened a donor pool for adults to receive right lobes safely. 
Goss et at. procured 15 in-situ split liver grafts, which resulted in 28 liver transplants. In-situ 
splitting of selected livers from hemodynamically stable post mortem donors was performed 
at the donor hospital without any additional work up or equipment being needed. The 
procedure took an extra 1 to 1,5 hour of donor hospital operating room time and resulted in 
14 left lateral segments, the segments 2 and 3, and in 14 right trisegmental grafts, the 
segments 1 and 4-8. The 1-year actuarial patient and graft survivals were 92% and 86%. 
The 1-year survival of patients who received a left lateral graft was 100% (11 ). 
From the same centre, Ghobrial analysed the predictors of survival after in-vivo split 
liver transplantation. During a 3.5 yr.-period, 55 right and 55 left lateral in vivo split grafts 
were transplanted in 102 paediatric and adult recipients. Overall survival rates were not 
significantly different from those of patients who received a whole organ transplant at the 
same median follow up time. Survival of left lateral segment recipients was 76% versus 80% 
receiving a trisegmental graft. 50 of 102 patients were high-risk urgent recipients and this 
group had a significantly lower survival rate than that of non-urgent patients. Multivariate 
logistic regression analysis identified UNOS status and length of donor hospital stay as 
independent predictors of survival (12). 
After and simultaneously with this pioneering work other groups introduced the ex-vivo 
and the in-situ split liver techniques in their liver transplantation programs and published 
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equal results. This virtually solved the problem of children dying on the waiting list (13-15). 
Moreover, the in-situ split liver technique opened the possibility of living donor liver donation, 
in the beginning the transplantation of left lateral lobes for pedantic transplantation but in a 
later phase, transplantation of right lobes to adults. 
LIVING DONOR LIVER TRANSPLANTATION 
The first successful liver transplantation from a living donor to her son was performed in 
Australia and reported in 1990 (16). The success of the procedure had a major impact on 
liver transplantation especially in countries in which post mortem organ transplantation was 
not available or rarely performed. The first series, of 20 children, was published by the 
Chicago group one year later (17). All children were less than 2 years old or weighed less 
than 15 kg. Volunteer related donors were selected after medical and psychiatric 
evaluations, and the suitability of the donor liver was established by functional and 
radiological criteria. The donor group for the initial 20 LDL T procedures comprised 12 
mothers, 7 fathers and 1 grandmother. In addition one father and one uncle, who was an 
identical twin to the recipients father, who did not qualify for anatomic reasons, were used in 
repeat LDRT. All donors survived and were in normal health 3 and 18 month after donation. 
Nineteen infants received LRT as first grafts and one as a second graft. Four patients 
underwent retransplantation, all for hepatic artery thrombosis. All other complications were 
in the first 3 transplantations during which a full left liver graft was used, including segment 
4. After a median hospital stay of 27 days 17 of the recipients were alive 3 to 8 months after 
LDRT. 
As liver transplantation from brain death donors has not yet been accepted in Asia and 
especially in Japan, the only alternative method at present is transplantation from a living 
donor. One of the first reports comes from Makuuchi et al. who transplanted 16 children with 
mainly biliary atresia using 16 living donated partial livers. These early results were 
unsatisfactory as 5 of these children subsequently died. Much care was taken to ensure the 
safety of the donor. A preoperative banking of the donor's own blood and plasma was 
performed. In addition, selective vascular occlusion minimised blood loss of the donor during 
resection. Using intra-operative Doppler ultrasound, the optimal position of the graft for 
maximal vascularisation could be established. They concluded that living related liver 
transplantation is an acceptable procedure for small children but that post mortem donation 
is absolutely necessary for adult recipients (18). 
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One of the mayor causes of morbidity and mortality in LDL T in small children is 
thrombosis of the hepatic artery and this complication was solved to a great extend by the 
introduction of microvascular surgery into the reconstruction of the hepatic artery. Mori et al. 
from the Tanaka group from Kyoto introduced this modality at an early stage in their 
paediatric living related liver transplantation program. The time required for completion of the 
microvascular anastomosis was not different from that in the Ioupe magnifying assisted 
anastomosis. More important, there were no patients with hepatic artery thrombosis after 
introduction of this technique (19). Between 1989 and 1994 more than 150 living related liver 
transplantations were performed world wide, mostly in the United States and in Japan. The 
first series of living related liver transplantation in Europe came from Hamburg (20). Twenty 
LDL T were performed in children transplanting the left liver lateral segment in the majority of 
cases and with an overall patient survival of 85%. For the 13 patients who underwent 
elective transplantation the survival was 100%. Technical complications included one arterial 
thrombosis necessitating re-transplantation and five bile leaks requiring surgical revision. All 
procurements resulted in excellent graft function. No intraoperative complications occurred, 
and no re-operations were necessary. No heterologous blood transfusion was given. In 2 
patients an incisional hernia developed after wound infection. 
Only a small proportion of the potential living donors-to-be donates eventually. In a 
retrospective analysis of 75 identified potential donors for 38 paediatric candidates with an 
age range from 17 days to 14 years the donor process was evaluated. Twenty three percent 
of potential donors declined evaluation. Of the 75 donors only 10 (13%) were found to be 
acceptable for donation. The leading causes for donor declination were significant medical 
history (23%), ABO incompatibility (23%), and psychosocial history (20%). Of the 38 
recipient candidates, 9 (23%) were offered living-donor liver transplantation. These results 
suggest that, especially in the early phase of LDL T, donor criteria were the limiting factor in 
the application (21 ). When the post operative donor liver function is analysed, donation of a 
left lobe (the segments 2,3 and 4 with the middle hepatic vein) leads to significantly higher 
post-operative liver enzyme levels in the donor than donation of a left lateral segment (the 
segments 2 and 3 without the middle hepatic vein) (22). 
This is important, as donor safety is the most prominent ethical issue in living donor 
transplantation of solid organs. In the literature there are scarce long-term follow-up data 
available about the medical, social and psychological complications of living donors, but 
their long-term well being is all-important and this should be further established. 
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ADULT LIVING DONOR LIVER TRANSPLANTATION 
Since its introduction in 1988 LDLT using the left lateral liver segment has become the 
standard procedure for children with end stage liver disease. In larger children and in adults 
a left sided liver graft will not require the metabolic needs of the recipient as the amount of 
transplanted liver tissue will be less than 40-50% of the original liver. The first successful 
report of a right lobe LDL T was by Yamaoka using the right lobe in a 9-year-old with biliary 
atresia. The decision to use the right lobe was made intraoperatively when the vascular 
anatomy of the left lobe was found incompatible with transplantation (23). Since then large 
experience has been developed in Hong Kong and in Kyoto. 
The shortage of livers for adult transplantation prompted transplant centres to 
investigate right lobe LDL T as left lateral segmentectomies or left lobectomies provided 
insufficient liver mass for an average size adult patient. Wachs et al. described right lobe 
LDL T in two adult patients with chronic liver disease. The first recipient was a 44 year old 
female with end stage liver disease due to hepatitis C infection. Her deteriorating condition 
prompted discussion regarding the possibility of living donation. Her sister was ABO 
compatible and was evaluated as a potential donor. Her medical, psychiatric and social 
evaluation revealed no contraindication for living donation. The donor operation took 3,5 hr. 
The LDLT was uneventful, as was the postoperative course in both donor and recipient. 
The second adult recipient of a right lobe LDL T was a 50-year-old female with Child's B 
cirrhosis and recurrent sepsis due to primary sclerosing cholangitis. Recurrent bouts of 
cholangitis led to consideration of living donor liver transplantation. Her 31-year-old son was 
ABO compatible and wished to donate. Both donor and recipient operation went well and 
even more important, both donors stated that they would make the decision to donate again 
(24). 
Marcos et al reported early results of right lobe liver transplantation. Twenty-five right 
lobe LDL T's were performed between adults, with no significant complications in the donors. 
Recipient and graft survival was 88%, with 3 recipient death due to uncontrolled sepsis in 
high-risk patients, all with functioning grafts. They stressed the value of the intra operative 
cholangiogram of the donor as it avoided unnecessary dissection near the common bile duct 
and defined the number of bile ducts draining the right lobe. Intra operative ultrasound was 
used to map the course of the middle hepatic vein and its relationship to the right hepatic 
vein. Accessory veins contributing to the outflow of the right lobe to the vena cava were 
identified and preserved (25). 
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As cadaveric liver donors are scarce in Hong Kong, Lo eta/. evaluated the use of living 
donors in high urgency patients. 49 patients in intensive care with acute or chronic liver 
failure were placed on the high urgency list for liver transplantation. Family members were 
not solicited for living donation and the initiation for living donation was based on the donor's 
voluntary intent. In 25 of 49 patients (51%) no family member volunteered as living donor, 23 
died awaiting donor organs, and 2 received a cadaveric organ. The other 24 patients had 36 
family members who volunteered as living donors. During the evaluation of the donors 
another 2 patients received a cadaver graft. LDL T was not performed in 9 patients because 
of recipient contraindications. Eight of these patients died and one received a cadaveric liver 
transplant. The remaining 13 (27%) patients received grafts from living donors. Eleven of 
these 13 (85%) who underwent LDLT survived. The authors concluded that emergency liver 
transplantation from living donors can be applied to high-urgency adult patients (26). 
The Kyoto group of Tanaka confirmed these initial experiences in 26 patients. Although 
6 patients died after transplantation only one was related to graft dysfunction due to an 
outflow block while the other death were due to poor pre-transplant condition (27). 
Meticulous surgical technique and attention to detail is all important in LDL T and much 
attention is given to this topic in the literature. With growing experience the results further 
improved (28-30). 
With the growing numbers there is real concern regarding the safety of the donor (31 ). 
Until now there are in the literature two donors who died after living liver donation but the 
real figure, after more than 1000 living donor liver transplantations is expected to be higher 
judged by experts (32,33). Transplant programs are reluctant to publish a donor death but 
the exact figures should be available to the clinician but above all the donor-to-be should be 
given detailed information regarding morbidity and mortality before his or her decision is 
made (34). 
CONCLUSION 
Since the first partial liver transplantation 15 years ago several initiatives have been 
undertaken to seek alternatives for conventional post-mortem liver transplantation. The post-
mortem reduced size liver transplantation for children was favourable for the paediatric 
waiting list but, as the major part of the liver was discarded, the procedure was in fact 
detrimental for adult patients waiting for an organ. The split liver technique in which the liver 
was ex-vivo divided in 2 transplantable hemi-livers solved part of this problem. Negative 
effects however were a longer cold ischaemia time due to difficult logistics resulting in more 
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post operative complications and, not unimportant, only a small percentage of donor livers 
were suitable for this procedure. After introduction of the in-situ technique, the donor 
procedure became longer but the results improved due to more surgical experience and to 
shorter cold ischaemia time. The in-situ technique opened the possibility of living donor liver 
transplantation. The first experience gained in paediatric patients who received a left lateral 
segment of, in most cases, mother or father and in selected cases from other family 
members or even unrelated donors. The excellent results in experienced centres led to the 
first right lobe living donor liver transplantation, a decision taken during the donation 
procedure because of surgical anatomical reasons. The procedure was quickly introduced 
for elective but also for acute adult liver transplantation. There is concern about safety of the 
living donor and a world wide registry of morbidity and mortality of living donors would give 
the key information needed to take a well informed decision regarding live donor donation. 
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Introduction 
Four decades ago, patients with acute hepatitis, chronic hepatitis and cirrhosis were treated 
conservatively. If cirrhosis progressed to end-stage liver failure, only supportive treatment 
could be provided. Accordingly, attention was focussed at the complications of end-stage 
liver disease like ascites, encephalopathy and variceal bleeding. The provision of a new 
liver, with or without removal of the diseased liver was considered the ultimate, yet 
impossible therapeutic step. 
In nearly forty years, liver transplantation has become an effective and successful 
therapeutic modality in the treatment of end-stage liver diseases with an one-year patient 
survival of more than 80%. Due to the success of liver transplantation however, new 
challenges are brought to optimise the existing procedures and expand the use of donor 
organs. 
Chapter 1 of this thesis is focussed on the current problems in experimental auxiliary 
liver transplantation and clinical non-auxiliary liver transplantation. The aims and outline of 
the thesis are described here. 
In chapter 2 the history and development of the auxiliary liver transplantation is 
described. Since the first experiments both introduction of an extra organ in the abdominal 
cavity and whole organ replacement have been studied. The idea of auxiliary transplantation 
of the liver was primarily born from the technical difficulties to remove the diseased liver in a 
safe way. Although experimental and clinical successes were reported, the consequences of 
increased abdominal mass caused complications to the donor liver. Increased abdominal 
pressure caused insufficient portal inflow and hepatic outflow with graft dysfunction as a 
common result. When resection of the cirrhotic liver became technical feasible with 
progression in surgical skill and the use of technical innovations like the venous bypass, the 
interest in auxiliary liver transplantation decreased. However, the concept of preserving part 
of the liver remained interesting for selected patients. With the possibility to devide post-
mortem livers into two pieces (1 ), transplantation of an auxiliary graft in an orthotopic 
position came into focus and interest for auxiliary transplantation is now growing again since 
the early nineties. 
Chapter 3 addresses the history of and improvements in surgical technique, patient 
monitoring, post-operative care and immunosuppressive management of the orthotopic liver 
transplantation procedure. 
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Optimisation of portal flow in experimental auxiliary liver transplantation 
In chapter 4 we analysed the technical requirements for long-term metabolic correction of 
an inborn error of hepatic metabolism provided by a heterotopically placed graft. 
It has become apparent from previous experiments that a liver graft should receive both 
arterial and portal blood flow to prevent atrophy. In case of an inborn error of metabolism, 
portal hypertension is mostly absent and finding a balance in portal blood distribution 
between native liver and graft is complicated. The effect of four different techniques to 
supply the graft with portal blood on the post-operative metabolic correction was studied in 
the Dalmatian coach dog, which has a metabolic defect leading to hyperuricosuria and 
hypoallantoinuria. Separate from the initial results of our study (2), no experimental studies 
have been published which investigate the requirements for long-term graft function in 
correction of an inborn error. 
Metabolic correction increased in all groups after transplantation, but remained 
significantly better in the split-flow and ligation groups. These results are in line with the 
findings of Lilly in 1971 and Ducerf in 1995, who described superior graft function after split 
portal inflow in a pig model without portal hypertension (3, 4). Interestingly, Lilly described 
graft atrophy when the graft was perfused with systemic venous blood, but regeneration if 
pancreatico-splanchnic portal blood was used. 
We found no impact of the source of the portal blood on the regeneration capacity of the 
liver graft during the experiment and this contradicts the hypothesis of need for 
hepatotrophic growth factors in pancreatico-duodenal venous blood. The native livers in the 
ligation groups, which were deprived of portal blood, did show significant atrophy compared 
to the native livers in the free-flow group, but there was no significant difference with the 
banding and split-flow group. This confirms the hypothesis of autoregulation towards a 
required functional hepatic mass of about 3% of the total body weight of the dog, which was 
described previously by Terpstra (5). 
ln chapter 5 the experiment was modified with the graft in the orthotopic position, after 
resection of the left lateral and medial segments of the recipient. In this experiment there 
were three groups of portal blood inflow: ligation of the portal vein to the native liver, banding 
of the porta\ vein to the native liver and a free-flow group. Separate portal blood inflow for 
the native liver and graft was technically impossible in this model, because the grafts were 
harvested as living donor grafts without large vascular pedicles from the donor. Portal and 
arterial flow was quantitated using Doppler ultrasonography before resection of the left 
lateral segments in the recipient, after reperfusion of the donor lateral segments and after 
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intervention in the portal blood flow. Until then, only one attempt was made to investigate the 
distribution of portal and arterial blood flow between graft and host liver after APOL T (6), but 
in this study no interventions in the portal flow pattern were made. 
After reperfusion the blood flow through the common portal vein decreased significantly 
to 73% of the initial portal flow, probably caused by the size of the graft, which comprised 
only 40% of the liver weight. Also a "small for size" phenomenon was present in the ligation 
group, where the inflow was resticted by the hepatic venous outflow. 
Without intervention in the portal blood distribution, inflow towards the graft remained 
marginal. Ligation of the portal vein to the native liver resulted in the best graft perfusion, but 
adverse effect was the development of portal hypertension with periportal haemorrage and 
necrosis. Banding of the right portal vein restored the flow in the left portal vein in terms of 
percentage of the total portal blood flow. 
We conclude that diversion of the portal flow is necessary for adequate graft perfusion in 
APOL T and that ultrasound-guided banding of the native portal vein is the preferable 
technique to achieve this. 
In chapter 6 the consequences of the intervention in the portal inflow on graft function 
were assessed. Significant metabolic correction was initially seen in the banding and free-
flow group, but not achieved in the ligation group. In this group, two dogs died of bleeding 
from the splenic area. Histo-pathology confirmed massive portal and sinusoidal congestion 
and focal hemorrhagic necrosis in these dogs. At autopsy no evidence could be found for 
stenosis in the hepatic vein anastomosis. We assume that the portal inflow exceeded the 
hepatic outflow in this group and resulted in a relative venous outflow obstruction. In an 
experimental study model without portal hypertension, Yabe et al. described a mortality of 
2/7 dogs before sacrifice at day 5 after acute ligation of the portal vein of the native liver. 
Histologic findings were however not given (7). An explanation for the difference with our 
own results in the heterotopic experiment may be that in the present study the total portal 
flow was forced into a liver graft comprising only about 40% of the total liver weight, where in 
the previous experiments a 70% liver graft was used. According to previous reports, we 
found no evidence that ligation of the native portal vein had detrimental effects on the native 
liver supplied by arterial flow only. 
In the free-flow group, allowing free distribution of portal inflow between graft and native 
liver resulted in loss of metabolic correction within 2 weeks. Hypo-perfusion of the graft led 
to portal thrombosis in 3 of the 7 dogs and mortality was high due to sepsis from necrotic 
grafts, in accordance with the results of our heterotopic experiment. 
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Banding of the native portal vein provided metabolic correction until the end of the 
experiment, although metabolic correction decreased in time, which was comparable to the 
results that we found in our heterotopic partial liver transplantation model. Loss of metabolic 
function during follow-up was accompanied by portal thrombosis 4 of the 11 dogs. It might 
be explained by increased vascular resistance in the graft secondary to infection and 
rejection. Regarding the problem of late portal thrombosis, a gradual occlusion of portal vein 
to the native liver, as proposed by Hirayama et al., may be an attractive solution (8). This 
assures optimal graft function without the risk of portal hypertension. 
In conclusion, an adequate portal flow to the graft is required for sustained graft function. 
Acute total ligation of the host portal vein led to portal hypertension with congestion of the 
parenchyma and early death in our model. Without intervention, the portal flow is 
preferentially to the native liver, leading to poor perfusion and early loss of metabolic 
function of the graft. Partial banding, aimed at restoration of the pre-transplantation flow 
distribution, gives the best metabolic correction. 
Optimisation of clinical orthotopic liver transplantation 
Since the introduction of liver transplantation, the one-year patient survival improved from 
approximately 30% to better than 80%. Although excellent results can be achieved, there 
are still some subjects that need to be elucidated. In part Ill of the thesis, three current 
problems in orthotopic liver transplantation are addressed. 
Primary graft dysfunction 
In chapter 7 we investigated the role of nitric oxide in the pathogenesis of primary graft 
dysfunction after liver transplantation (PGDF). Although nitric oxide has received much 
attention and became "molecule of the year" in 1992 (9), it's role in ischaemia/reperfusion 
injury remains unclear. The vasodilatation that results from produced nitric oxide may be 
beneficial in ischaemic parts of the liver, but recently also a direct toxic effect of nitric oxide 
derived radicals on the mitochondrial function has been reported. 
In this study we investigated the energy content in hepatocytes during preservation and 
reperfusion and assessed the role of the nitric oxide derived peroxynitrite radical in 
mitochondrial dysfunction. 
We found higher energy levels at the end of the cold preservation in patients with PGDF. 
After reperfusion, this pattern reversed and control patients showed ATP regeneration, 
whereas the ATP and TAN levels in patients with PGDF decreased. 
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Other investigators described lower or equal TAN and ATP levels in PGDF patients at the 
end of the cold ischaemic period, compared to their control patients. However, none of these 
studies did follow the course of the adenine nucleotides content during the warm ischemic 
period, which makes it difficult to interpret the results. 
We hypothesise that the high energy content in our PGDF patients is caused by poor 
perfusion of the donor liver during organ donation. Optimal rapid hypothermic perfusion 
leads to cessation of all metabolic processes and enzymatic activity, but poor perfusion 
gives the donor liver time to induce oxidative phosphorylation, glycogenolysis and glycolysis 
in a salvage attempt to preserve ATP levels for proton pumping and maintenance of 
membrane integrity. The induction of oxidative phosphorylation to form ATP and activation 
of glucose output in patients with PGDF also prevents the degradation of high energy 
phosphates to adenosine. As adenosine has a strong vasodilative effect, it may be beneficial 
at reperfusion of the donor liver and omission of this substance from preservation solutions 
has deleterious effects. 
Electron microscopy confirmed the functional impairment of the mitochondria as soon as 
1 hour after reperfusion in patients with PGDF. In the same biopsies, nitrotyrosine was used 
as an indicator of peroxynitrite mediated damage. The level of nitration of hepatocytes and 
bile duct endothelium was high already at the end of the cold ischemic period and remained 
at that high level during warm ischemia and after reperfusion. Staining for iNOS revealed 
hepatocytes as the main source of NO, which was also present at the end of the cold 
ischemic period. Since the necessary NO for tyrosine nitration can not be produced by iNOS 
during cold ischemia itself, this indicates that the cellular proteins of the donor liver have 
been nitrated before the donation procedure 
In conclusion, our study shows that PGDF related mitochondrial dysfunction does not 
originate from the cold or warm ischemic period, but probably is caused earlier, during the 
organ donation procedure. Apparently, the high TAN and ATP levels at the end of the cold 
ischemic period can be used as an early marker of primary graft dysfunction. Although 
experimental studies indicated that occurrence of nitration of mitochondria is detrimental, the 
lack of any difference in nitrotyrosine formation between patient with or without PGDF 
makes nitration of mitochondria a unlikely cause of clinical primary graft dysfunction. 
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Hyperfibrinolysis and blood loss 
In chapter 8 the problems of impaired coagulation and blood loss during the liver 
transplantation procedure were investigated. Patients with preceding liver disease often 
have profound disturbances in the haemostatic system, including a low platelet count, low 
levels of clotting factors and increased levels of fibrinogen degradation products due to 
dissiminated intravascular coagulation and subsequent fibrinolysis. The blood loss during 
the procedure has to be minimalised as recent publications indicate that perioperative blood 
loss still affects postoperative outcome. 
To minimise the risk of viral transmission during blood component substitution therapy, 
solvent/detergent (SO) virus-inactivated plasma (ESDEP) was introduced in 1996 in our 
hospital. Since it's introduction however, hyperfibrinolysis occurred more frequent in patients 
undergoing liver transplantation than before, when fresh frozen plasma (FFP) was used. 
SD treatment of fresh frozen plasma is an effective method to reduce lipid coated 
viruses, but it has been reported that because of the SO process the concentration of FVII!, 
protein S and a2-antiplasmin is reduced. To clarify this increased incidence, intraoperative 
plasma samples of patients treated with FFP or ESDEP were analysed in a retrospective 
observational study. 
Hyperfibrinolysis occurred about 3 times more in the anhepatic phase and after 
reperfusion in patients who received ESDEP than in patients treated with FFP. 
Determination of a2-antiplasmin concentrations in ESDEP showed decreased levels in 
accordance with the results presented in literature. In 47% of the patients treated with 
ESDEP hyperfibrinolytic episodes did reoccur, despite adequate treatment of the first 
hyperfibrinolytic episode, proven by normalisation of the thromboelastograph recordings. We 
think that this effect is caused by the large plasma exchanges in liver transplantation, which 
dilute the level of rx2-antiplasmin in the patient to the level of ESDEP itself. 
Our results are in contrast with the study of Freeman (1 0), who found no differences in 
coagulation parameters between patients receiving FFP or SO treated plasma during liver 
transplantation. a2-Antiplasmin levels were however not determined in their study and 
hyperfibrinolytic problems were not mentioned in the article. This may well be explained by 
the standard prophylactic use of anti-fibrinolytic drugs in the participating centers in the 
United Kingdom. 
In summary we feel that the use of solvent/detergent virus inactivated plasma is of 
increasing importance in the prevention of HIV and Hepatitis C virus transmission. Clinicians 
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should however be aware that infusion of solvent/detergent treated plasma in patients 
needing massive transfusion may lead to insufficient levels of a.:2-antiplasmin and secondary 
hyperfibrinolysis. This hyperfibrinolysis can not be corrected with infusion of more 
solvent/detergent plasma, but should be treated with antifibrinolytic drugs like aprotinine or 
tranexamic acid. Considering the significant higher blood loss in patients with 
hyperfibrinolysis in our study, routine administration of antifibrinolytic drugs using 
solvent/detergent virus-inactivated plasma in patients with massive transfusion requirements 
is advised (11 ). 
Piggyback technique 
In chapter 9 the technique of liver transplantation with preservation of the vena cava is 
described. Preservation of the vena cava obviates the use of a vena-venous bypass and 
reduces blood loss from the retroperitoneal cavity. It has been reported to reduce warm 
ischaemic period, blood loss and transfusion requirements. Since then, (modified) piggyback 
techniques have been compared to the conventional orthotopic liver transplantation 
technique by several authors, reporting reduced operative time, blood loss, transfusion need 
and hospitalisation. 
So far no survival benefit has been established, but in these retrospective studies 
patients were not matched for other variables affecting outcome. In a prospective, but not 
randomised study by Hosein Shokouk-Amiri (12), outcome in both groups was excellent and 
no differences could be established (13). A retrospective analysis was undertaken to 
evaluate the results of the implementation of this technique in our institute. 
In accordance with most previous studies we found a significant decrease in intra-
operative blood loss and transfusion requirements due to absence of retrocaval dissection 
and caval encirclement. We also found a survival benefit at 6 months after liver 
transplantation with the caval preserving technique. This benefit can be attributed to a 
reduction in severe infections, a shorter warm ischaemic period and decreased blood loss 
during the procedure, which was proven to be a important factor for graft and patient survival 
before (14, 15). 
In summary the modified piggyback technique can be used in all patients without use of 
a vena-venous bypass. In our series these factors improved patient and graft survival and 
the piggyback technique has become the preferred technique for liver transplantation in our 
transplant centre. 
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Strategies to overcome donor shortage 
There is a reverse to every medal and the success of liver transplantation caused an 
increasing number of patients, waiting for a donor organ. 
In the Netherlands the number of donor livers hat is retrieved is stable since 1994 with about 
one hundred per year. The number of patients entering the waiting list is however doubled 
from 85 in 1994 to 159 in 2000 (16). In the United States there are now three times more 
patients on the waiting list for a liver transplantation than there are livers transplanted per 
year. Especially in paediatric liver transplantation, there was an alarming shortage in 
suitable liver donors for the growing population of transplantable patients. 
In chapter 10 new solutions to solve the problem of donor shortage are described. In 
1989 the first liver from a non-heartbeating liver donor was used for transplantation after 
initial success with non-heartbeating kidney donation (17). Results of non-heartbeating liver 
transplantation were however inferior to those of post-mortem heartbeating donation (18, 
19). 
Therefore another solution was sought to solve the problem of donor shortage. With the 
introduction of the split liver transplantation procedure now 15 years ago, a variety of partial 
liver transplantations were developed to split the donor liver and transplant the parts into two 
recipiens. 
The earliest form consisted of a reduction of a whole liver graft to the left lateral segment 
or the left liver lobe, small enough to transplant to a young child. The rest of the liver was 
discarded. This method solved part of the great need of liver grafts for children but as the 
remaining part of the liver was lost for transplantation, the method was in fact detrimental for 
adults on the waiting list. Further surgical development resulted in splitting of the liver on the 
bench table into two transplantable partial grafts, the left part to a child and the right lobe to 
an adult. The procedure was successfully introduced but the complicated logistics resulted 
in prolonged cold ischaemia times of the grafts. In order to keep the cold ischaemia time as 
short as possible, Rogiers eta/. developed the in-situ split liver technique in which the liver 
was split in the post-mortem donor. 
Refinement of this operation led to results, which were superior to the bench table 
method. Moreover, it opened the gate to living donor liver transplantation. The first 
successful procedure was performed from a mother to a child who received the mothers left 
liver segment. The introduction resulted in a decrease over the years on the paediatric 
waiting Jist to almost zero. As the demand for organs increases every year and the numbers 
of donors are constant in western countries, the right lobe living donor liver transplantation 
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for adults was introduced. Introduction of all forms of partial liver transplantation has relieved 
the pressure on waiting lists, especially for children but also for adults. There is however 
serious concern of the well being in terms of morbidity and mortality of the living donor 
donation procedure. 
Conclusions of the thesis 
1. Long-term metabolic correction can be provided by an auxiliary placed liver graft, 
but intervention in the portal blood flow is essential for graft survival in both 
heterotopically and orthotopically placed auxiliary liver grafts in absence of portal 
hypertension (chapter 4, 5 and 6). 
2. Ligation of the portal vein to the native liver does not result in histological atrophy of 
the native liver, but only reduces the liver mass and is well tolerated if it does not 
produce portal hypertension (chapter 4 and 6). 
3. Division of the portal blood flow between the two livers by ultrasound guided 
banding of the native portal vein is an accurate possibility (chapter 5 and 6). 
Banding based on elevated portal pressure in the graft portal vein did not 
guarantee long-term metabolic correction (chapter 4). 
4. There is a striking difference in resistance to portal blood flow deprivation between 
the native liver and the liver graft. The native liver tolerates ligation of the portal 
vein well, while insufficient portal inflow of the graft immediately leads to necrosis of 
hepatocytes with fibrosis and atrophy (chapter 4 and 6). 
5. Mitochondrial dysfunction in grafts with primary graft dysfunction is already present 
during the cold ischaemic period and is not caused by nitrosylation of mitochondrial 
membrane by nitric oxide derived peroxinitrite (chapter 7). 
6. TNBP and Triton X-100 treated plasma (ESDEP®) is deficient for cx2-antiplasmin 
and standard antifibrinolytic medication should be administered when ESDEP is 
used for large plasma volume substitution to minimise the risk of hyperfibrinolysis 
(chapter 8). 
7. The implementation of a vena cava preserving technique for orthotopic liver 
transplantation decreased blood loss and transfusion requirements and increased 
6-month graft and patient survival. 
8. Partial liver transplantation succeeded in reducing the waiting list for paediatric liver 
transplantation to practically nil, but initially increased donor shortage for adult liver 
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transplantation. With split liver techniques two recipients can now be helped with 
one donor liver, without compromising one-year patient survival. 
Future perspectives 
The widening indications for .liver transplantation and more liberal patient selection result in 
an increasing shortage of donor organs. At this moment, patients with liver cancer, who 
should be transplanted early, die on the waiting list because of low urgency status caused 
by their good functioning liver. The emerging technique to overcome this problem in the near 
future is living (related) donor liver transplantation, which gives equal results to post-mortem 
liver transplantation because of careful planning and short ischaemia periods. In the near 
future there will be attempts to split the donor liver during a laparoscopic procedure to 
minimise the extent of the operation for the living donor. The first steps are recently taken 
with sucessfulllaparoscopic liver resection (20). 
As the use of partial grafts becomes more widespread, the interest for auxiliary liver 
grafting in selected indications will be renewed. 
Especially patients with inborn errors of metabolism and patients with acute liver failure will 
benefit from this development. In patients with inborn errors of metabolism the partial graft 
will provide metabolic correction, until gene therapy becomes available. If in the meanwhile 
the graft fails, it can electively be replaced with another graft. In these patients the portal 
flow has to be deviated away from the native liver to allow adequate portal blood inflow for 
the graft. The use of intra-operative ultrasound with Doppler sonography and computed 
resistive indices will allow accurate distribution of the portal flow between the two livers. 
Separate portal blood flow for liver graft and native liver seems to be the best guarantee for 
long-term metabolic correction. If separate blood flow is not possible and banding of the 
native portal vein is applied, the portal flow should be visualised non-invasively with 
ultrasound in the port-operative period to detect changes in the equilibrium due to infection 
or rejection. 
Patients with acute liver failure will be bridged to recovery with an auxiliary liver graft as 
the processes that promote liver regeneration will be better understood and regeneration 
can be predicted more accurately. With increasing safety of living donor liver transplantation 
it will become ethically acceptable to propose this therapeutic option in an early stage of liver 
failure, when the prognosis is substantially better and long-term admission to an intensive 
care unit can be prevented. 
When whole or partial livers are used for transplantation, the piggyback technique will 
become the standard procedure for vascular anastomosis. The piggyback technique allows 
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the use of vascular stapling devices, which are rapid, reliable and decrease anastomotic 
problems. Also the use of a lateral cavo-cavostomy obviates the use of a vena-venous 
bypass and even enables liver transplantation in haemodynamically instable patients. The 
standard use of antifibrinolytic therapy will decrease per-operative blood loss, while still 
allowing the use of virus safe plasma. The combination of the piggyback technique and 
routine antifibrinolytic therapy will decrease the impact of the liver transplantation and make 
it a less extraordinary surgical procedure. 
To reduce the incidence of primary graft dysfunction of post-mortem donor livers, 
intensive research should be directed at the donor liver before and during harvesting. Our 
results indicate that changes leading to dysfunction are already present during the cold 
ischaemic period and probably not only result from the quality of the liver, but also from the 
procurement procedure. Haemodynamic and hormonal instability of the brain-dead liver 
donor, hypoperfusion during harvesting of the liver due to technical imperfection or bad 
communication between the organ procurement teams probably determine the faith of the 
graft before transplantation is started. In the pathogenesis of graft dysfunction activation of 
the Kupffercell seems to plays a key role. Therefore the behaviour of Kupffer cells during 
organ procurement and reperfusion is currently studied in the Laboratory of Experimental 
Surgery of the Erasmus University Rotterdam in an attempt to down regulate the activation 
of Kupffer cells. 
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lntroductie 
Tot veertig jaar gel eden werden patienten met acute en chronische hepatitis en levercirrose 
conservatief behandeld. Wanneer levercirrose voortschreed naar leverinsuffici8ntie, kon 
slechts een ondersteunende behandeling worden gegeven. Daarom was de therapie gericht 
op de behandeling van complicaties van het eindstadium van leverinsufficientie, zoals 
ascites, encephalopatie en bloeding van slokdarmvarices. Transplantatie van de lever, met 
of zonder de verwijdering van de zieke lever werd gezien als de uiteindelijke, maar op dat 
moment onhaalbare therapeutische oplossing. 
Sindsdien is levertransplantatie in bijna veertig jaar echter een effectieve en 
succesvolle behandeling geworden van leverinsufficientie met een patient-overleving van 
meer dan 80% na een jaar. Het succes van de levertransplantatie heeft, door een 
toenemend tekort aan donororganen, echter tot nieuwe uitdagingen geleid. 
Dit proefschrift beschrijft de aanpak van enkele problemen bij experimentele en 
klinische lever transplantatie om de bestaande procedures en het gebruik van donororganen 
te optimaliseren. 
Hoofdstuk 1 van dit proefschrift is gericht op de thans bestaande problemen bij 
experimentele auxiliaire levertransplantatie en klinische niet-auxiliaire levertransplantatie. De 
doelstellingen en indeling van het proefschrift worden hier beschreven. 
In hoofdstuk 2 worden de geschiedenis en ontwikkeling van de auxiliaire 
levertransplantatie beschreven. Sinds de eerste experimenten zijn zowel de toevoeging van 
een extra lever in de buikholte (auxiliaire transplantatie) als totale vervanging van de lever 
bestudeerd. Het idee om een extra lever in de buik te plaatsen, in een niet-anatomische 
positie (heterotoop) kwam voort uit technische problemen om de zieke lever op een veilige 
manier te verwijderen. Hoewel experimentele en klinische resultaten werden gerapporteerd, 
veroorzaakte implantatie van een extra orgaan in de buik complicaties. Toegenomen druk in 
de buik veroorzaakte onvoldoende doorbloeding van de v. Portae (poortader) en afknikken 
van de levervenen met disfunctie van de donorlever als resultaat. Toen resectie van de 
cirrotische lever technisch mogelijk werd door verbeteringen in de chirurgische technieken 
en het gebruik van de veneuze bypass, verminderde de interesse voor de auxiliaire 
levertransplantatie. Tach blijft behoud van een deel van de lever interessant voor 
geselecteerde patienten. Met de mogelijkheid om een donorlever te scheiden in twee 
gedeelten, werd transplantatie van een auxiliaire donorlever in de anatomische (orthotope) 
positie mogelijk, na resectie van een deel van de zieke lever. Sinds de jaren negentig groeit 
daarmee opnieuw de interesse in auxiliaire lever transplantatie. 
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Hoofdstuk 3 beschrijft de geschiedenis van de orthotope levertransplantatie en de 
verbeteringen in de chirurgische technieken, postoperatieve zorg en immunosuppressie-
therapie. 
Optimalisering van de bloedstroom door de v. Portae in experimentele auxiliaire 
levertransplantatie 
In hoofdstuk 4 worden de technische voorwaarden voor een langdurige correctie van een 
aangeboren stofwisselingsziekte van de lever met een heterotoop geplaatste 
transplantatielever bestudeerd. Het is reeds Ianger bekend dat de donorlever zowel van 
arterieel bloed als van veneus bloed uit de v. Portae moet worden voorzien om atrofie te 
voorkomen. Bij aangeboren stofwisselingsziekten bestaat er meestal geen portale 
hypertensie en het is daarom moeilijk om het bloed uit de v. Portae zo te verdelen tussen de 
eigen lever en de donorlever, dat er geen atrofie van de donorlever optreedt. Het effect van 
4 verschillende technieken om de donorlever van bloed uit de v. Portae te voorzien werd 
daarom bestudeerd in een model met honden met een aangeboren stofwisselingsziekte. 
De beste metabole correctie werd gezien in de groep met een gescheiden 
bloedtoevoer voor de eigen lever en donorlever en in de groep, waar de v. Portae-tak naar 
de eigen lever werd onderbonden. zodat al het portale bloed ten gunste kwam aan de 
donorlever. In de groep, waarin de bloedstroom naar de eigen lever kunstmatig werd 
vernauwd, bestond metabole correctie gedurende het hele experiment, maar nam de hoogte 
van deze correctie af na 70 dagen. Dit ging gepaard met trombose van de v. Portae in 4 van 
de 6 honden in deze groep. Vrije verdeling van de bloedstroom in de v. Portae leidde tot 
competitie tussen de eigen lever en de donorlever met een totaal verlies van metabole 
correctie na 3 maanden. 
In onze studie werd geen aanwijzing gevonden dat de oorsprong van het veneuze 
bloed van belang is voor regeneratie van de donorlever. Dit pleit voor de hypothese die 
eerder door Terpstra werd geponeerd, dat er een autoregulatie bestaat naar een vereiste 
functionele levermassa van ongeveer 3% van het totale lichaamsgewicht van de hond. 
Donorlevers die meer dan 15% activiteit opnamen tijdens nucleair onderzoek, vertoonden 
totale correctie van de stofwisselingsziekte, hetgeen in overeenstemming is met eerdere 
publicaties, waarbij transplantatie van ongeveer 12% van de totale levermassa nodig was 
voor correctie van ongeconjugeerde hyperbilirubinemie. De resultaten van deze studie 
geven aan dat auxi\iaire heterotope levertransplantatie een goede langdurige correctie van 
een aangeboren stofwisselingsziekte kan verzorgen, wanneer een adequate 
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bloedvoorziening van de donorlever wordt gegarandeerd. De beste resultaten werden 
bereikt met een gescheiden bloedstroom voor de eigen lever en de donorlever. 
In hoofdstuk 5 werd dit experiment gemodificeerd herhaald met de donorlever in de 
orthotope positie, na resectie van de linker laterals en media!e segmenten van de 
ontvanger. Doordat het experiment werd uitgevoerd als levende-donor levertransplantatie 
was het technisch niet mogelijk om de groep met een separate bloedstroom voor de eigen 
!ever en de donorlever te bestuderen. De linker v. Portae-tak van de donorlever werd 
geanastomoseerd op de vaatstomp van de linker v. Portae-tak van de geresecteerde 
leversegmenten. T1jdens het experiment werd de bloedstroom door de a. Hepatica en v. 
Portae van de eigen lever en de donorlever gemeten met Doppler-echografie. 
Na reperfusie van de donorlever nam de doorbloeding van de gemeenschappelijke v. Portae 
af tot 73% van de initiele waarde v66r transplantatie, met name veroorzaakt door een 
afname in doorbloeding van v. Portae van de donorlever. Deze afname was opmerkelijk, 
aangezien de levende-donor procedure een optimale kwaliteit van de donorlever 
garandeert. Tijdens de levende-donor levertransplantatie kan slechts zo'n 40% van het 
totals levergewicht veilig worden afgestaan. De kleine afmeting van de donorlever die 
tijdens deze experimenten gebruikt werd kan daarom een beperkende factor zijn voor de 
doorbloeding. Oak kan de instroom gelimiteerd zijn door de beperkte uitstroom in de v. 
Hepatica, het zogenaamde "small for size" fenomeen. 
In de groep met vrije verdeling van de bloedstroom in de v. Portae tussen de eigen 
lever en de donorlever bleef de doorbloeding van de donorlever marginaal. Kunstmatige 
vernauwing van de v. Portae naar de eigen lever herstelde de doorbloeding naar de 
donorlever. Totale onderbinding van de v. Portae naar de eigen lever gaf de beste perfusie 
van de donorlever. Ongewenste bijwerking hiervan was echter een verhoging van de druk in 
de gezamenlijke v. Portae, met bloedingen in het darmpakket en in de miltregio tot gevolg. 
In deze studie werd aangetoond dat kunstmatige interventie bij APOL T in de bloedstroom in 
de v. Portae tijdens de operatie noodzakelijk is voor een adequate bloedvoorziening van de 
donorlever. 
In hoofdstuk 6 worden de consequenties van de peroperative interventie in de bloedstroom 
op de postoperatieve correctie van de stofwisselingsziekte beschreven. 
Significante metabole correctie werd initieel gezien in de groep met kunstmatige vernauwing 
van de v. Portae naar de eigen lever en in de groep met vrije distributie van bloed tussen 
eigen lever en donorlever. In de groep met totals onderbinding van de v. Portae naar de 
eigen lever overleden twee honden aan de gevolgen van de portals hypertensie met 
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bloeding uit de miltregio. Histologisch onderzoek bevestigde massale congestie van de lever 
met hemorragische necrose. Bij sectie konden geen aanwijzingen voor een stenose van de 
v. Hepatica-anastomose worden gevonden, zodat een "small for size" fenomeen met een 
overtollig aanbod ten opzichte van de afvloed de meest waarschijnlijke oorzaak van de 
hypertensie is. 
Dit verklaart oak het verschil met het experiment met de donorlever in de heterotope 
positie, waar ligatie van de v. Portae geen portale hypertensie gal. In het eerste experiment 
bedroeg de getransplanteerde massa ongeveer 70% van de totale lever, terwijl nu slechts 
40% van de lever werd getransplanteerd. In de groep met vrije distributie van de 
bloedstroom over de eigen lever en donorlever trad een verlies van metabole correctie op 
na twee weken. Trombose van de v. Portae naar de donorlever werd gezien in 3 van de 7 
honden in deze groep. 
Kunstmatige vernauwing van de v. Portae naar de eigen lever zorgde voor metabole 
correctie tot het einde van het experiment, hoewel de hoogte van de correctie met de tijd 
afnam. In 4 van de 11 honden trad op langere termijn een porta trombose van de donorlever 
op, waarschijnlijk ten gevolge van de verhoogde vasculaire weerstand in de donorlever door 
infectie en afstoting. 
Deze studie bevestigt de eerdere bevindingen, dat voor een langdurige metabole correctie 
kunstmatig ingrijpen in de portale bloedstroom vereist is. Met een kleine donorlever leidt 
totale ligatie van de v. Portae van de eigen lever tot het ontstaan van onacceptabele portale 
hypertensie. Zander interventie stroomt het portale bloed daarentegen preferentieel naar de 
eigen lever en gaat de donorlever te grande aan hypopelfusie. Partiele vernauwing van de 
v. Portae naar de eigen lever garandeert langdurige correctie van een aangeboren 
stofwisselingsziekte. 
Optimalisatie van de klinische orthotope levertransplantatie 
Sinds de introductie van de orthotope levertransplantatie is de 1-jaars patientenoverleving 
verbeterd van ongeveer 30% naar meer dan 80%. Hoewel zeer goede resultaten kunnen 
worden bereikt, is er tach een aantal punten waarop verbetering mogelijk is. In de 
hoofdstukken 7 tot 11 van dit proefschrift word! een viertal problemen besproken, die zich 
thans bij klinische orthotope levertransplantatie voordoen. 
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Primaire disfunctie van de donorfever na transplantatie 
In hoofdstuk 7 word! de rol van stikstof oxide (NO) in de pathogenese van primaire 
disfunctie van de donorlever (PGDF) onderzocht. De rol van NO in het ontstaan van PGDF 
is nag onduidelijk. De vasodilatatie die door NO veroorzaakt wordt kan gunstige effecten 
hebben op ischemische gebieden in de donorlever, maar recent werd oak een schadelijk 
effect van NO op de functie van mitochondria beschreven. 
In deze studie werden ATP- (adenosine tri-fosfaat) en TAN- (totaal adenine 
nucleotiden} gehaltes in hepatocyten tijdens de preservatieperiode en na reperfusie 
gemeten. De aanwezigheid van nftrotyrosine, een radicaalproduct van NO, dat grate schade 
aan mitochondria kan aanbrengen werd aan de energie-inhoud gerelateerd. Tevens werden 
elektronenmicroscopische foto's van de levers gemaakt om schade aan mitochondria te 
visualiseren. 
In patienten met PGDF werd een hogere ATP- en TAN-inhoud gemeten aan het einde 
van de koude ischemische periode, dan in centrale patienten. Na reperfusie van de 
donorlever namen zowel de TAN- als ATP-gehaltes in patienten met PGDF significant af, 
terwijl in controle-patienten deze waarden juist stegen na reperfusie. De hogere ATP- en 
TAN-waarden in patienten met PGDF werden niet eerder in de literatuur beschreven. De 
stijging in centrale patienten na reperfusie is conform enkele eerdere bevindingen, waarbij 
echter niet het beloop tijdens de gehele transplantatieprocedure werd gevolgd. De hoge 
energiewaarden in patienten met PGDF zijn waarschijnlijk te wijten aan een slechte koude 
perfusie van de donorlever. Hierdoor valt de biochemische activiteit niet direct stil en is er 
tijd voor inductie van oxidatieve fosforylatie, glycogenolyse en glycolyse, waarbij ATP 
gevormd wordt om de celmembraanpotentiaal in stand te houden. Tijdens dit proces wordt 
ATP niet afgebroken tot adenosine, dat een sterke vaatverwijdende eigenschap heeft en 
een gunstig effect kan hebben op de reperfusie van de donorlever. Nitrotyrosine werd 
gevonden in leverbiopten van patienten met PGDF, maar oak bij aile centrale patienten 
tijdens de koude en warme ischemische periodes en na reperfusie. 
Dit geeft aan dat de cellulaire eiwitten reeds tijdens de donorprocedure genitreerd zijn, 
omdat de voor deze reactie benodigde NO niet tijdens de koude ischemie door het enzym 
'inducible NO synthase' kan worden geproduceerd. 
In conclusie laat deze studie zien dat PGDF gerelateerde disfunctie van de 
mitochondria niet ontstaat tijdens de koude of warme ischemische periode en reperfusie, 
maar reeds eerder wordt veroorzaakt, waarschijnlijk tijdens de donorprocedure. De hoge 
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ATP- en TAN-waarden kunnen mogelijkerwijs als indicator voor het optreden van PGDF 
worden gebruikt. 
Het ontbreken van enig verschll in nitrotyrosine vorming tussen patienten met PGDF 
en controls patienten maakt nitratie van de mitochondria een onwaarschijnlijke oorzaak van 
PGDF. 
Hyperfibrinolyse en peroperatief bloedver/ies 
In hoofdsluk 8 wordt het probleem van hyperfibrinolyse en bloedverlies tijdens de 
levertransplantatieprocedure beschreven. Patienten met een leverziekte hebben 
voorafgaand aan de transplantatie reeds vaak een ernstige verstoring van de hemostase 
met een laag thrombocytenaantal, !age niveaus van stollingsfactoren en een 
gedissimineerde intravasa!e stalling met toegenomen fibrinolyse (voortijdig oplossen van 
stolsels). Tijdens de transp!antatieprocedure dient het bloedverlies geminimaliseerd te 
worden, omdat er een verband bestaat tussen het peroperatieve bloedverlies en de 
postoperatieve over!eving. 
Om het risico van virale transmissie tijdens bloed(componenten)transfusie te 
verkleinen werd in 1996 in het Academisch Ziekenhuis Rotterdam ESDEP® geYntroduceerd, 
een nieuw plasma-product waarin virussen door middel van solvent/detergent (SO) 
behandeling worden ge·lnactiveerd. Sinds de invoering van ESDEP nam echter de incidentie 
van hyperfibrinolyse bij patienten die een orthotope levertransplantatie ondergingen 
drievoudig toe. Om de oorzaak van deze stijging te achterhalen werd een groep patienten 
die met ESDEP behandeld was vergeleken met een groep patienten, die met het oude 
plasma (FFP) behandeld was. 
Er werden behoudens een toename in factor VIII geen verschillen gevonden in de 
individuele stollingsfactoren. Wei werden tijdens de anhepatische fase en na reperfusie van 
de donorlever significant hogere waarden gevonden van de fibrinogeenafbraakproducten en 
d-dimeren, samen met een toegenomen fibrinolyseactiviteit op de thrombo-elastograaf. Dit 
is bewijzend voor een toegenomen fibrinolyse. T evens bleek op deze tijdstippen de 
concentraties van het o::2-antiplasmine, de belangrijkste inhibitor van fibrinolyse in het bloed, 
verlaagd te zijn in patienten die met ESDEP waren behandeld. Oorzaak van deze lage 
concentraties is het ESDEP plasma zelf, dat ten gevolge van de SO behandeling slechts 
25% van de normals hoeveelheid cx2-antiplasmine bleek te bevatten. 
Het gebruik van virus-veilig plasma wordt steeds belangrijker in de preventie van HIV, 
hepatitis B en C infecties. ESDEP-gebruik in situaties van massale transfusie kan echter 
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leiden tot insufficiente concentraties van a.2-antiplasmine en secundaire fibrinolyse. Oeze 
fibrinolyse kan niet worden behandeld door infusie van meer ESDEP, maar moet met anti-
fibrinolytische medicatie (zoals aprotinine of cyclokapronzuur) worden bestreden. Het 
standaard gebruik van anti-fibrinolytische medicatie ter preventie van hyperfibrinolyse word! 
aangeraden bij gebruik van ESDEP bij massale transfusie behoefte. 
De v. Cava sparende transplantatietechniek 
In hoofdstuk 9 worden de resultaten van de levertransplantatietechniek beschreven, 
waarbij de v. Cava van de ontvanger word! behouden tijdens de transplantatie. Het niet 
afklemmen en niet vervangen van de v. Cava inferior tijdens de transplantatie staat toe dat 
het veneuze bloed uit het mesenteriale vaatbed en de onderste extremiteiten via de v. Cava 
inferior word! teruggevoerd naar het hart. Deze zogenaamde piggyback techniek maakt 
daardoor het gebruik van een veno-veneuze bypass overbodig en vermindert het 
bloedverlies uit de retroperitoneale weefsels. In klinische onderzoeken is bij gebruik van de 
piggyback techniek een verkorting van de warme ischemische periods en vermindering van 
het peroperatieve bloedverlies en transfusiebehoefte beschreven. Tot nu toe werd echter 
nag nooit een voordeel in patientenoverleving van de techniek aangetoond. 
In deze studie word! de overleving van patienten, die met de piggyback techniek 
geopereerd zijn retrospectief vergeleken met die van patienten die een standaard 
levertransplantatie ondergingen. In de beginfase van de piggyback techniek moest in 2 
patienten worden overgegaan tot de standaard transplantatieprocedure met vervanging van 
de v. Cava wegens technische problemen. Tijdens de studie kon de techniek in aile 45 
patienten worden toegepast. Er werd in de piggyback groep inderdaad een significante 
vermindering gezien van het peroperatieve bloedverlies en de transfusiebehoefte. 
Daarnaast was in de piggyback groep zowel het aantal ernstige infecties verminderd als de 
overleving van de donorlever en van de getransplanteerde patienten significant beter. 
De piggybacktechniek blijkt in aile patienten goed uitvoerbaar en leidt tot een 
vermindering van het peroperatieve bloedverlies en (bloed)transfusiebehoefte. Gezien de 
verbetering van de overleving na 6 maanden wordt de piggyback techniek als standaard 
techniek bij orthotope levertransplantaties gebruikt in het Erasmus Medisch Centrum 
Rotterdam. 
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Strategieen om het tekort aan donoren te overbruggen 
Het succes van de levertransplantatie heeft als keerzijde dat er een groeiend aantal 
patienten op de wachtlijst staat voor een donorlever. In hoofdstuk 10 wordt een overzicht 
gegeven van nieuwe strategieen beschreven om het tekort aan donorlevers te verminderen. 
In Nederland wordt sinds 1994 een stabiel aantal van ongeveer honderd donorlevers 
per jaar verkregen. Het aantal patienten dat jaarlijks op de wachtlijst wordt geplaatst voor 
een transplantatie is echter gegroeid van 85 in 1994 tot 159 in 2000. Dit leidt tot een 
toenemend tekort aan geschikte donorlevers voor de groeiende populatie transplantabele 
patienten. 
In een poging om het aantal voor transplantatie beschikbare donorlevers te vergroten, 
werd in 1989 in Japan voor het eerst een donorlever getransplanteerd van een patient met 
een circulatiestilstand. Enthousiastme voor deze techniek was ontstaan na eerdere 
bemoedigende resultaten van niertransplantatie van donoren met een circulatiestilstand. De 
resultaten van deze transplantatietechniek vor levertransplantatie bleven echter achter bij 
die van de gebruikelijke postmortale donatie van een hersendode donor zonder 
circulatiestilstand. Daarom werden andere oplossingen gezocht om het donortekort op te 
lessen. Met de opkomst van de gesplitste-lever transplantatieprocedure werden de 
afgelopen 15 jaar technieken ontwikkeld om een donorlever naar twee ontvangers te 
transplanteren. Aanvankelijk werd een donorlever van een volwassen donor gereduceerd tot 
linker laterale leverkwab, klein genoeg om naar een kind te transplanteren. Deze methode 
bracht verlichting in de wachttijd voor kindertransplantatie, maar had als ongewenste 
bijwerking dat de hoeveelheid beschikbare donororganen voor volwassenen afnam. 
Verbetering in de chirurgische technieken resulteerde in de mogelijkheid om de donorlever 
te splitsen buiten het lichaam en beide helften voor transplantatie te gebruiken: de linker 
leverkwab voor een kind en de rechter leverkwab voor een volwassene. Later werd de 
techniek verfijnd en kon de lever reeds in de orgaandonor gesplitst worden, waardoor de 
koude ischemische periode met enige uren werd bekort. De techniek maakt inmiddels een 
1-jaars patientenoverleving mogelijk, die minstens vergelijkbaar is met die van de 
conventionele levertransplantatie. 
Tevens opende dit de deuren naar de levende-donor levertransplantatie. De eerste 
succesvolle procedure werd in Australie uitgevoerd bij een meisje, dat de linkerleverkwab 
van haar moeder ontving. Door de bovengenoemde ontwikkelingen verdween in drie jaar tijd 
de wachtlijst voor kinderen bijna geheel. 
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De vraag naar donorlevers voor volwassenen nam echter elk jaar toe en recent werd 
levertransplantatie van de rechter leverkwab van een levende-donor ge"introduceerd. 
Ondanks de voordelen en gerapporteerde successen van de levende-donor 
levertransplantatie bestaat er zorg over de morbiditeit en mortaliteit van de gezonde 
leverdonor. 
Conclusies van dit proefschrift 
1. Langdurige metabole correctie kan door een auxiliair geplaatste transplantatielever 
worden verkregen, maar in afwezigheid van portale hypertensie is interventie in de 
bloedstroom van de v. Portae essentieel voor overleving van de donorlever, zowel bij 
heterotoop als bij orthotoop geplaatste donorlevers (hoofdstuk 4, 5 en 6). 
2. Totale onderbinding van de v. Portae van de eigen lever leidt niet tot histologisch 
bewezen atrofie van de eigen lever. Het vermindert slechts de levermassa en kan goed 
worden verdragen als het niet in portale hypertensie resulteert (hoofdstuk 4 en 6). 
3. Verdeling van de bloedstroom van de v. Portae tussen de donorlever en eigen lever op 
geleide van echogeleide banding is een accurate methode (hoofdstuk 4 en 6). Banding 
op geleide van de drukverhoging in de v. Portae van de donorlever kon metabole 
correctie op lange termijn niet garanderen (hoofdstuk 4). 
4. Er bestaat een opmerkelijk verschil in afhankelijkheid van bloedvoorziening via de v. 
Portae tussen de eigen lever en de donorlever. De eigen lever kan totale ligatie van de 
v. Portae goed verdragen, terwijl insufficiente portals doorbloeding van de donorlever 
onmiddellijk leidt tot necrose van de levercellen met fibrose en atrofre (hoofdstuk 4 en 
6). 
5. Disfunctie van de mitochondria in patienten met een primaire disfunctie van de 
donorlever (PGDF) bestaat reeds tijdens de koude ischemische periode. Het word! niet 
veroorzaakt door nitrosylering van de mitochnodriale structuren door peroxynitriet, 
gevormd uit stikstofmonoxide (hoofdstuk 7). 
6. Solvent/detergent behandeld plasma heeft een a2-antiplasmine deficientie. Anti-
fibrinolytische therapie zou dan oak standaard gegeven moeten worden, wanneer 
ESDEP gebruikt word! bij massale transfusie om het risico van hyperfibrinolyse te 
minimaliseren (hoofdstuk 8). 
7. Het gebruik van een v. Cava sparende operatietechniek bij de orthotope 
levertransplantatie leidde tot een afname van het peroperatieve bloedverlies en de 
transfusiebehoefte en verbeterde de 6-maands overleving van patienten (hoofdstuk 9). 
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8. Door partiBle levertransplantatie verdween de wachtlijst voor kinderlevertransplantatie 
bijna geheel, maar dit ging ten koste van donororganen voor volwassen patienten. Met 
de komst van technieken om de donorlever te splitsen in twee volwaardige 
transplantabele gedeelten, kunnen nu twee ontvangers met een donorlever worden 
geholpen, zonder de 1-jaars patientenoverleving in gevaar te brengen. 
Toekomstige ontwikkelingen 
Het toenemend aantal patienten dat in aanmerking komt voor levertransplantatie zal tot een 
toenemend tekort aan donororganen leiden. Op dit moment overlijden reeds pati8nten op de 
wachtlijst. De levende-donor levertransplantatie techniek is in opkomst en kan een bijdrage 
leveren aan de oplossing voor dit probleem. De resultaten van deze procedure zijn 
momenteel gelijk aan die van de standaard levertransplantatie. Recent werd de eerste 
succesvolle paging gemeld om de donorlever op laparoscopische wijze te splitsen en dit zal 
op den duur resulteren in een verdere afname van operatierisico's voor de leverdonor. 
Met de toename in ervaring met partiBle levertransplantatie zal oak de auxilaire parti81e 
orthotope levertransplantatie voor geselecteerde patienten meer in de belangstel!ing komen. 
Met name patienten met een aangeboren stofwisselingsziekte van de lever en pati8nten met 
acuut levetfalen zullen hiervan profiteren. In pati8nten met een metabole ziekte kan de 
parti81e donorlever de ziekte corrigeren, terwijl de eigen lever beschikbaar blijft voor 
toekomstige gentherapie. Als intussen de donorlever faalt, kan deze electief vervangen 
worden, terwijl de patient overleeft op de eigen lever. 
Een dee! van de patienten met acuut leverialen kan met een auxiliaire donorlever naar 
herstel van de eigen leveriunctie overbrugd worden, waarna de donorlever verwijderd kan 
worden en de anti-afstotingsmedicijnen kunnen worden gestaakt. Het proces van 
leverregeneratie moet echter nag beter begrepen en voorspelbaar worden, om te bepalen 
welke patienten baat zullen hebben bij een auxiliaire donorlever. Met toenemende veiligheid 
van levende-donor levertransplantatie zal het ethisch acceptabel worden om deze techniek 
aan te bieden in een vroeg stadium van de ziekte, wanneer zich nag geen complicaties van 
het leverialen hebben voorgedaan en de overlevingskansen aanzienlijk beter zijn. 
De combinatie van de piggyback transplantatie techniek en standaard anti-
fibrinolytische medicatie tijdens de orthotope levertransplantatie zal het peroperatieve 
bloedverlies doen dalen, de duur van de ingreep verkorten en het operatietrauma 
verminderen. 
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Om het rendement van de schaarse donororganen te verbeteren zal primaire disfunctie 
van de donorlever verder moeten worden teruggedrongen. Onze resultaten geven aan dat 
de oorzaken van deze disfunctie mogelijk al tijdens de orgaandonatie-procedure ontstaan. 
Activatie van de macrofagen in de lever (Kupffercellen) tijdens de perfusie van de 
donorlever lijkt een sleutelrol te spelen in het ontstaan van primaire disfunctie. Het gedrag 
van de Kupffercellen tijdens de orgaandonatie en preservatieperiode en mogelijke 
therapeutische interventies daarop wordt daarom momenteel bestudeerd in het Chirurgisch 
Laboratorium van het Erasmus Medisch Centrum Rotterdam. 
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Oil proefschrift is niet zonder slag of stool tot stand gekomen. Vele mensen hebben op enige 
wijze een bijdrage geleverd aan de verschillende onderzoeken, de begeleiding ervan of in de 
ondersteuning. Op he! gevaar af sommigen te vergeten wil ik loch een aantal mensen 
persoonlijk bedanken. 
Prof.dr. H. W. Til anus. Beste Huug, zonder jouw briefje met de tekst: "Enthousiaste 
student gevraag voor wetenschappelijk onderzoek bij nacht en ontij - financiele vergoeding: 
geen" op het prikbord in de faculteit was alles anders gelopen. Dank je voor je enorme inzet 
tijdens de experimenten in he! EDC. He! was je nooit te vee I om direct na de spaghetti aan een 
relaparotomie te beginnen. Ook dank ik je voor het in mij gestelde vertrouwen en je 
onvoorwaardelijke steun tijdens mijn klinische werk en sollicitatie voor de heelkunde. 
Prof.dr. J.F. Koster, uit een vreemde samenloop van omstandigheden word! meestal he! 
beste onderzoek geboren. Uw goede ideeen over ischemische schade in de lever en de 
aandacht voor de leverdonor hebben een essentiele bijdrage geleverd aan deze dissertatie. De 
vanzelfsprekende gastvrijheid om in uw laboratoria experimenten te verrichten was 
hartverwarmend. Graag wil ik oak Dr. Wim Sluiter bedanken voor de directe begeleiding en zijn 
zorgvuldige commentaar op de uitkomsten en interpretaties daarvan. Elly de Wit en Regina 
Kraak-Siee dank ik voor het geduld waarmee ze een chirurgisch onderzoeker de kneepjes van 
het biochemische vak bijbrachten. Jullie gezelligheid tijdens de eindeloze HPLC en 
immunohistochemie sessies maakte het allemaal wat minder erg. 
Prof.dr. H.J. Bonjer, u bent voor mij een groat voorbeeld van een heel-kundige klinicus, 
die eveneens chirurgisch onderzoek op hoog niveau stimuleert. lk ben blij dat ik onder uw 
begeleiding de opleiding tot chirurg in Rotterdam mag volgen en he! is een grate eer dat u 
zitting wilde nemen in de kleine commissie. 
Prof.dr. 0. T. Terpstra, grondlegger van de levertransplantatie in Rotterdam. He! eerste 
gedeelte van de dissertatie gaat met name over uw gedachtegoed en ik ben verheugd dat ik er 
met u van gedachten over mag wisselen. 
Prof.dr. J.C. Molenaar, uw advies en begeleiding maakte mijn eerste congres in het 
buitenland mogelijk. lk dank u voor de bereidheid het manuscript op zijn wetenschappelijke 
waarde te beoordelen. 
Prof.dr. MJ.H S/ooff, u wil ik graag bedanken voor de nuttige discussies die we voerden 
op de AST I ASTS in Chicago. Als hoofd van he! grootste levertransplantatiecentrum in 
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Nederland hecht ik veel waarde aan uw commentaar en dank ik u voor uw bereidheid om dee! 
uit te maken van de promotiecommissie. 
Dr. J.N.M. /Jzermans, beste Jan, jou wil ik bedanken voor je interesse in mijn onderzoek 
vanaf het begin. Ook als het minder ging was je altijd bereid mee te denken over oplossingen 
en je inzichten wierpen vaak een verhelderend Iicht op de materie. lk hoop dat ik straks van je 
- als plaatsvervangend opleider- net zoveel nuttige tips en opbouwend commentaar krijg op 
mijn klinische werk. 
Dr. H.J. Metselaar. Herold, rots in de branding. Jouw pep-talks waren vaak belangrijker 
dan je zelf kan vermoeden. Niet aileen was je coach tijdens congressen, oak in de aanloop 
naar de opleiding gaf je me wei eens een bruikbaar advies. lk heb heel vee! respect voor je 
klinische werk en je richtinggevende rol in het transplantatieteam. 
De anesthesiologen van het transplantatieteam: Drs. T.H.N. Groen/and, Drs. L.. Visser, 
Drs. R. T.M. van Gee/ en Drs. J. W. Kroon wil ik hartelijk dan ken voor de ruim 500 uur die ik hun 
midden mocht vertoeven. Jullie leerden me de eerste beginselen van de intensive care. 
Dagelijks val ik terug op jullie tricks and tactics. 
Aile overige !eden van het Rotterdamse levertransplantatieteam wil ik hartelijk danken 
voor hun inbreng in de verschillende onderzoeken en vanzelfsprekendheid waarmee ik in het 
team werd opgenomen. Door jullie motiverende gastvrijheid is inmidde!s een hele generatie 
studenten enthousiast geraakt voor het wetenschappelijk onderzoek. In de toekomst hoop ik 
jullie gelederen klinisch te komen versterken. 
Een groat gedeelte van het onderzoek werd verricht in het laboratorium van chirurgie. 
Dr. R.L. Marquet wil ik danken voor zijn rol aan de zijlijn. Richard, overleg over mijn onderzoek 
vervulde me altijd met enige vrees, omdat je analytische geest feilloos doorheeft waar de 
zwakke plekken zitten. Tach gal je altijd weer een handreiking in welke richting de oplossing te 
vinden was. Vooral je begeleiding bij de leverperfusie stel ik enorm op prijs. 
Dr. R. W.F. de Bruin wil ik hartelijk dan ken voor zijn interesse in mijn onderzoek en zijn 
begeleiding van de leverperfusie, die een vervolg is op de klinische experimenten. Ron, dank je 
voor al het nuttige en aangename, met name op de AST/ASTS. Meer dan eens heb je als 
bliksemafleider gefungeerd en ik wil onze samenwerking graag voortzetten en intensiveren. 
Janny de Kam dank ik voor haar inzet en kunde tijdens de transplantaties. Zander jouw hulp 
was het niets geworden. Nog steeds heb ik dagelijks profijt van al je lessen op de OK. Enno 
Collij en Henk Drank hebben de honden met grate precisie door de transplantaties geloodst. 
Het feit dat 'mars in tabula' niet voorkwam zegt wat over jullie deskundigheid en inzet. Roy 
Spruyt is de beste dierenverzorger van Rotterdam. Je betrokkenheid bij de honden en je inzet 
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om de experimenten te Iaten slagen zijn bewonderenswaardig. Pim van Schalkwijk en Ton 
Boijmans namen de verwerking van de monsters en laboratoriumtesten voor hun rekening. 
lr. PPM. Kooi, beste Peter. Hartelijke dank voor je bereidheid om de nucleaire HIDA-
scintigrafie8n te verrichten, vaak op ultra korte termijn en tussen je gewone werkzaamheden 
door. 
Een andere afdeling die aan het slagen van dit proefschrift heeft meegewerkt is het 
Hemostase-laboratorium van het academisch ziekenhuis Rotterdam. Dr. Jeanne Stibbe dank ik 
voor de mogelijkheid die zij bood om laboratoriumwerk te verrichten en de voor de diepgaande 
discussies over de uitslagen, die mijn inzicht in de stalling vormde. Jr. Huub H.D.M. van Vliet 
dank ik voor de overname van de begeleiding van het fibrinolyse onderzoek, toen het voor Dr. 
Stibbe niet meer mogelijk was. Jaques van Gee! en Constan van den Broek waren degenen 
die mij het stollingsonderzoek volgens GLP bijbrachten en altijd bereid waren extra monsters in 
de routine mee te draaien. Aile overige analisten wil ik danken voor de gastvrijheid die ik -dag 
of nacht- op jullie werkplek mocht genieten. 
Drs. Pieter E. Zondervan dank ik voor de veelvuldige beoordelingen van de levercoupes 
van honden en mensen. Wanneer het nodig was verzorgde jij afdrukken van aile belangrijke 
details binnen de kortste tijd. lk hoop bij toekomstig onderzoek weer veel langs te komen om bij 
de zelfgemaakte espresso de histologie te bekijken. Monica Seijbel is mijn steun en toeverlaat 
in aile zaken die de heelkunde en de pathologie met elkaar verbindt Monica: bedankt voor aile 
onmogelijke zaken die je voor me hebt geregeld. 
Carla Capel wil ik bedanken voor de vele gezellige momenten en de tijd die je altijd voor 
me wist te creeren in de agenda van de hooggeleerde. Scarlet van Belle is onmisbaar omdat 
ze alles regelt en altijd klaarstaat 
Aile studenten van het levertransplantatieteam die biopten hebben verzameld ben ik grate 
dank verschuldigd. Marijke Stegeman, Linetta Kopperl en Michie/ Warle wil ik met name 
noemen omdat ik hoop dat het onderzoek oak hen help\ om de opleiding die ze ambieren te 
verkrijgen. Marijke en Linetta, bedankt voor aile steun, scheldsessies op wetenschappelijk 
onderzoek en bazen en ongecompliceerde gezelligheid. Jullie tijd komt vast en zeker: go girls, 
go! 
Aile collega's en verpleegkundigen van 10 Zuid IC van he\ AZR dank ik hartelijk voor hun 
belangstelling voor het onderzoek en de mogelijkheden die ze me gaven om oak tijdens mijn 
klinische werkzaamheden het wetenschappelijke deel af te ron den. 
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Lieve familie, schoonfamilie, aanhang en vrienden. Dankzij jullie warme belangstelling en 
support was het mogelijk om samen op dezelfde datum te promoveren. Altijd stonden jullie 
klaar om ons bij te springen of juist aileen ontspanning te geven. We boffen metjullie! 
lngeborg van der Geest, Jolanda van der Pas en Frank Verhoeven: Paranimfen, ex-
huisgenoten, vrienden voor het Ieven. lk dank jullie voor de jaren van gezelligheid en de 
ondersteuning bij deze queeste. 
Pap en mam, jullie hebben mij de basis gegeven, waardoor dit alles mogelijk is geworden. 
Merijn, slechts gezekerd aan 18 em titaan in een bevroren waterval weet je op wie je 
blindelings kunt vertrouwen. lk denk dater zelden een hechter gezin is geweest. 
Annemarie, mijn liefste. Vanaf het allereerste begin tot aan de finale heb jij mij gesteund en 
geholpen bij het onderzoek en het schrijven van dit boekje. Zander jouw hulp was het er nu 
niet, of nooit meer van gekomen. Twee gelijktijdige promovendi onder een dak en tach nag 
altijd gezellig, dat lijkt me het beste bewijs dat we samen alles aankunnen. Nu gaan we weer 
genieten! 
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